documents incorporated reference portions proxy statement registrants annual meeting stockholders held may incorporated reference part iii annual report table contents part item business general bristolmyers squibb company may referred bristolmyers squibb bms company incorporated laws state delaware august name bristolmyers company successor new york business started bristolmyers company changed name bristolmyers squibb company result merger company divisions subsidiaries engaged discovery development licensing manufacturing marketing distribution sale pharmaceuticals health care related products acquisitions divestitures july company completed sale bufferin excedrin brands japan asia excluding china taiwan certain oceanic countries lion corporation japan million cash result transaction company recognized pretax gain million million net tax third quarter october company completed acquisition adnexus therapeutics inc adnexus developer new therapeutic class biologics called adnectins net purchase price million addition event certain future development regulatory milestones achieved company obligated terms agreement pay former stockholders adnexus additional million december company entered definitive agreement avista capital partners lp avista sale medical imaging business purchase price approximately million cash subject customary postclosing adjustments closing transaction completed january result transaction company expects recognize pretax gain approximately million million million million loss net tax first quarter subject postclosing adjustments bristolmyers squibb website companys internet website address wwwbmscom company makes available free charge website annual quarterly current reports including amendments reports soon reasonably practicable company electronically files material furnishes material us securities exchange commission sec information relating corporate governance bristolmyers squibb including companys standards business conduct ethics code ethics senior financial officers code business conduct ethics directors collectively codes corporate governance guidelines information concerning companys executive committee board directors including board committees committee charters transactions bristolmyers squibb securities directors executive officers available companys website wwwbmscom investorscorporate governance caption print stockholder upon request waivers codes directors executive officers material amendment code business conduct ethics directors code ethics senior financial officers posted promptly companys website information relating stockholder services including companys dividend reinvestment plan direct deposit dividends available companys website wwwbmscom investorsstockholder services caption company incorporates reference certain information parts proxy statement annual meeting stockholders sec allows company disclose important information referring manner please refer information companys proxy statement annual meeting stockholders annual report available companys website wwwbmscom investorssec filings caption march table contents business segments company three reportable segmentspharmaceuticals nutritionals convatec previously component health care operating segment january company completed sale medical imaging business avista results medical imaging business previously included former health care operating segment presented part companys results discontinued operations pharmaceuticals segment made global pharmaceutical international consumer medicines business pharmaceuticals segment accounted companys sales companys sales companys sales us pharmaceuticals sales accounted total pharmaceutical sales respectively international pharmaceutical sales accounted total pharmaceutical sales respectively two segments nutritionals convatec comprise companys health care group nutritionals segment consists mead johnson nutritionals mead johnson primarily infant formula childrens nutritionals business convatec segment consists ostomy wound skin care business health care group sales accounted companys sales companys sales companys sales us health care group sales accounted total health care group sales respectively international health care group sales accounted total health care group sales respectively additional information segments see item financial statementsnote segment information pharmaceuticals segment pharmaceuticals segment competes worldwide researchbased drug companies smaller research companies generic drug manufacturers products sold worldwide primarily wholesalers retail pharmacies hospitals government entities medical profession company manufactures products us puerto rico foreign countries us pharmaceuticals net sales accounted total pharmaceuticals net sales respectively pharmaceuticals net sales europe middle east africa accounted total pharmaceuticals net sales respectively pharmaceuticals net sales japan accounted total pharmaceuticals net sales companys key products include plavix clopidogrel bisulfate avaproavalide irbesartanirbesartanhydrochlorothiazide reyataz atazanavir sulfate abilify aripiprazole erbitux cetuximab sprycel dasatinib baraclude entecavir orencia abatacept sustiva franchise efavirenz ixempra ixabepilone composition matter patent plavix expires currently subject patent litigation us apotex inc apotex corp apotex generic companies well less significant jurisdictions previously disclosed august apotex launched generic clopidogrel bisulfate product competes plavix generic launch significant adverse impact plavix sales company estimates range million million billion billion estimated total us prescription demand clopidogrel bisulfate branded generic increased compared estimated total us prescription demand branded plavix increased period company believes supply generic clopidogrel bisulfate sold distribution channels following apotex atrisk launch august substantially depleted june us district court southern district new york district court upheld composition matter patent plavix enjoined apotex engaging activity infringes patent including marketing generic product us patent expires apotex appealed district courts decision apotex appeal date set march damages phase trial ongoing information pending plavix litigation well generic launch apotex see item financial statements note legal proceedings contingencies table contents products companys pharmaceutical revenues come products following therapeutic classes cardiovascular virology including human immunodeficiency virus hiv infection oncology affective psychiatric disorders immunoscience pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity market exclusivity based upon patent rights andor certain regulatory forms exclusivity us countries patent rights forms exclusivity expire generic versions medicine approved marketed often substantial rapid declines sales original innovative product companys business focused innovative pharmaceutical products company relies patent rights forms protection maintain market exclusivity products discussion patents rights regulatory forms exclusivity see intellectual property product exclusivity discussion impact generic competition companys business see generic competition increasing portion companys innovative pharmaceutical products biological products biologics currently generic versions biological products approved us law however law could change future even absence new legislation us food drug administration fda taking steps toward allowing generic versions certain biologics competitors seeking approval biological products must file safety efficacy data address challenges biologics manufacturing involves complex processes costly traditional pharmaceutical operations chart shows net sales key products pharmaceuticals segment together year basic exclusivity loss patent rights data exclusivity occurred currently estimated occur us european union eu japan company also sells pharmaceutical products countries however data provided countrybycountry basis individual country sales significant outside us eu japan many instances basic exclusivity loss date listed expiration date patent claims active ingredient drug method using drug approved indication instances basic exclusivity loss date listed chart expiration date data exclusivity period situations data exclusivity without patent protection competitor could seek regulatory approval submitting clinical trial data obtain marketing approval prior expiration data exclusivity company estimates market exclusivity period products casebycase basis purposes business planning length market exclusivity companys products impossible predict certainty complex interaction patent regulatory forms exclusivity inherent uncertainties regarding patent litigation although company provides estimates business planning purposes intended indication companys patents might fare particular patent litigation brought potential infringers assurance particular product enjoy market exclusivity full period time appears estimate exclusivity limited estimate table contents past currently past currently past currently estimated estimated estimated year year year us basic eu basic japanese basic pharmaceutical products exclusivity loss exclusivity loss exclusivity loss dollars millions cardiovascular plavix avaproavalide pravachol coumadin b b virology reyataz sustiva franchise total revenue c c baraclude oncology erbitux taxol paclitaxel sprycel e ixempra affective psychiatric disorders abilify total revenue f g immunoscience orencia h pharmaceuticals efferalgan na note currently estimated year basic exclusivity loss includes statutory extensions exclusivity earned speculative instances may laterexpiring patents cover particular forms compositions drug well methods manufacturing methods using drug patents may sometimes result favorable market position companys product product exclusivity predicted assured note also products filed biologics license application bla us year exclusivity listed year patent expiration even though currently regulatory pathway approval followon biologic products described detail intellectual property product exclusivity indicates brand names products registered trademarks owned company subsidiaries specific trademark ownership information found company currently market product jurisdiction indicated references eu throughout include following current member states austria belgium bulgaria cyprus czech republic denmark estonia finland france germany greece hungary ireland italy latvia lithuania luxembourg malta netherlands poland portugal romania slovakia slovenia spain sweden united kingdom uk basic patent applications filed current member states listed products instances date basic exclusivity loss different various eu member states instances earliest latest dates basic exclusivity loss listed eu countries basic patent obtained may data protection available b basic exclusivity expired bms acquired product c exclusivity period relates sustiva brand biologic product approved bla us currently regulatory approval path generic biologics e pending application eu patent application filed estonia latvia lithuania malta slovakia slovenia f companys rights commercialize aripiprazole us terminate g companys rights commercialize aripiprazole eu terminate h data exclusivity eu expires table contents summary indication intellectual property position licensing arrangements thirdparty manufacturing arrangements products us applicable eu japan cardiovascular plavix clopidogrel bisulfate platelet aggregation inhibitor approved protection fatal nonfatal heart attack stroke patients history heart attack stroke peripheral arterial disease acute coronary syndrome clopidogrel bisulfate codeveloped jointly marketed sanofiaventis sanofi worldwide alliance operates framework two geographic territories one americas australia companys primary territory europe asia sanofis primary territory composition matter patent us expires includes statutory patent term extension currently subject patent litigation us apotex generic companies well less significant jurisdictions district court upheld validity enforceability composition matter patent apotex appealed decision oral argument apotex appeal date set march possible time reasonably assess outcome appeal apotex andor timing renewed generic competition apotex potential additional generic competition generic pharmaceutical companies however apotex prevail appeal company would expect renewed generic competition promptly thereafter information litigation matters well generic launch apotex see item financial statementsnote legal proceedings contingencies eu regulatory data exclusivity expires july eu member countries key composition matter patent expires majority eu member countries company obtains bulk requirements clopidogrel bisulfate sanofi third party company sanofi finish product facilities information companys arrangements sanofi see strategic alliances item financial statementsnote alliances investments avaproavalide irbesartanirbesartanhydrochlorothiazide angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy irbesartan codeveloped jointly marketed sanofi worldwide alliance operates framework two geographic territories one americas australia companys primary territory europe asia sanofis primary territory september company elected terminate copromotion product sanofi ireland sweden norway finland denmark basic composition matter patent us expires including pediatric extension eu data exclusivity eu expires august avapro october avalide irbesartan manufactured company sanofi company manufactures bulk requirements irbesartan finishes avaproavalide facilities avalide company purchases bulk requirements hydrochlorothiazide third party information companys arrangements sanofi see strategic alliances item financial statementsnote alliances investments pravachol pravastatin sodium hmg coa reductase inhibitor indicated adjunct diet exercise patients primary hypercholesterolemia lowering risk first heart attack people without clinically evident coronary heart disease elevated cholesterol reducing risk heart attack stroke patients clinically evident coronary heart disease table contents company licensed patent covering pravastatin marketed company us pravachol sankyo company ltd sankyo japan key provisions agreement expiring exclusivity expires marketbymarket basis exclusivity us patent including pediatric extension expired april company entered distribution agreement watson pharmaceutical watson november authorizing watson distribute generic pravastatin sodium tablets us december lek dd lek slovenian generic company whollyowned novartis ag novartis filed suit company watson us district court eastern district texas marshall texas leks complaint alleges companys sale pravachol watsons sale authorized generic pravachol infringe two patents lek information litigation matter see item financial statementsnote legal proceedings contingencies composition matter patent expired countries eu company obtains bulk requirements pravastatin sankyo finishes product facilities coumadin warfarin sodium oral anticoagulant used predominantly patients atrial fibrillation deep venous thrombosispulmonary embolism market exclusivity expired us basic patent protection regulatory data protection expired company acquired coumadin company obtains bulk requirements warfarin third party produces majority finished goods facilities virology reyataz atazanavir sulfate protease inhibitor treatment hiv reyataz launched us july company developed atazanavir worldwide license novartis pays royalty based percentage net sales company entitled promote reyataz use combination norvir ritonavir nonexclusive license agreement abbott laboratories company dated july amended pays royalty based percentage net sales market exclusivity reyataz expected expire us major eu member countries japan data exclusivity eu expires company manufactures bulk requirements atazanavir finishes product facilities sustiva franchise efavirenz active ingredient sustiva nonnucleoside reverse transcriptase inhibitor nnrti treatment hiv sustiva franchise includes sustiva antiretroviral drug used treatment hiv well bulk efavirenz included combination therapy atripla sold joint venture gilead sciences inc gilead company gilead share responsibility commercializing atripla us gilead records atripla revenues consolidates results joint venture operating results company records revenue bulk efavirenz component atripla upon sales product gilead joint venture thirdparty customers companys revenue efavirenz component determined applying percentage atripla revenue approximates revenue sustiva brand europe company gilead share responsibility commercializing atripla throughout eu certain european countries gilead record revenues future net sales atripla countries europe company record revenues percentage relative contribution represented sustiva december european commission granted marketing authorization atripla information companys arrangement gilead see strategic alliances item financial statementsnote alliances investments table contents rights market efavirenz us canada uk france germany ireland italy spain licensed merck co inc royalty based percentage net sales market exclusivity sustiva expected expire us countries eu company another company market efavirenz japan company obtains bulk requirements efavirenz third parties produces finished goods facilities company provides bulk efavirenz gilead responsible producing atripla finished goods baraclude entecavir potent selective inhibitor hepatitis b virus approved fda march treatment chronic hepatitis b infection baraclude discovered developed internally also approved marketed countries outside us including china japan eu company learned china several companies filed clinical trial permission since company received approval company aware applications clinical trial permission china approved due uncertainty chinas exclusivity laws possible one companies could receive marketing authorization chinas health authority company composition matter patent expires us application patent term extension approved us extends patent expiration composition matter patent expires eu japan patent term extension approved japan extends patent expiration supplementary protection certificates requested eu approved eu countries extending exclusivity approved product company manufactures bulk requirements entecavir finishes product facilities oncology erbitux erbitux cetuximab igg monoclonal antibody designed exclusively target block epidermal growth factor receptor egfr expressed surface certain cancer cells multiple tumor types well normal cells erbitux biological product approved treatment combination irinotecan patients egfrexpressing metastatic colorectal cancer mcrc failed irinotecanbased regimen monotherapy patients intolerant irinotecan march fda approved erbitux use treatment squamous cell carcinoma head neck specifically erbitux approved use combination radiation therapy treatment locally regionally advanced squamous cell carcinoma head neck single agent treatment patients recurrent metastatic squamous cell carcinoma head neck prior platinumbased therapy failed also october company received fda approval supplemental biologics license application sbla filing update erbitux product labeling include overall survival data single agent egfrexpressing mcrc patients failure irinotecanbased oxaliplatinbased regimens erbitux marketed north america company distribution copromotion agreement imclone systems incorporated imclone company shares copromotion rights erbitux merck kgaa japan codevelopment cocommercialization agreement signed october among company imclone merck kgaa merck japan erbitux yet marketed japan although application submitted japanese pharmaceuticals medical devices agency pmda use erbitux treating patients advanced colorectal cancer description companys alliance imclone see strategic alliances item financial statementsnote alliances investments table contents july company imclone amended terms agreement codevelopment copromotion erbitux north america amendment companies jointly agreed expand investment ongoing clinical development plan erbitux several hundred million dollars development costs threshold value sole responsibility company costs excess threshold shared companies according predetermined ratio composition matter patent specifically claims erbitux erbitux approved fda health authorities monotherapy use patent use erbitux combination antineoplastic agent approved fda combination use claimed granted us patent expires inventorship use patent challenged three researchers yeda research development company ltd yeda september court granted yeda complete ownership patent imclone appealed courts decision also filed declaratory judgment action alleging yeda researchers remain sole inventors patent patent invalid pursuant settlement agreement executed announced december imclone sanofi yeda end worldwide litigation related use patent sanofi yeda granted imclone worldwide license use patent settlement agreement change imclones worldwide royalty rate erbitux sales commercial agreement imclone company pays royalty imclone sales erbitux impacted settlement agreement yeda also right license use patent others yedas license patent third parties could result product competition erbitux might otherwise occur early assess whether extent competitive impact occur quantify impact however yeda also granted amgen inc amgen license use patent amgen received fda approval market egfrproduct competes erbitux information litigation see item financial statementsnote legal proceedings contingencies european equivalent use patent opposed information biologics patents see intellectual property product exclusivity company obtains finished goods requirements cetuximab use north america imclone imclone manufactures bulk requirements cetuximab facilities finishing performed third party imclone description companys supply agreement imclone see manufacturing quality assurance taxol paclitaxel paclitaxel used treatment refractory ovarian cancer firstline treatment ovarian cancer combination cisplatin secondline treatment acquired immunodeficiency syndrome aidsrelated kaposis sarcoma treatment metastatic breast cancer failure combination chemotherapy adjuvant treatment nodepositive breast cancer treatment non small cell lung carcinoma cisplatin active ingredient taxol paclitaxel patent protection us eu japan regulatory protection form data exclusivity data exclusivity us expired initial approval us generic version paclitaxel granted revoked fda reinstated data exclusivity eu expired data exclusivity taxol paclitaxel japan expired patent claiming approved dosing administration schedule expires japan nullity action filed japanese patent office invalidated patent company appealed decision invalidation decision affirmed meanwhile generic paclitaxel launched japan paclitaxel developed collaborative research development agreement us government agreement company obtained rights us governments taxol paclitaxel data company manufactures bulk requirements paclitaxel finishes product facilities table contents sprycel dasatinib multitargeted tyrosine kinase inhibitor approved fda june treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including imatinib treatment adults philadelphia chromosomepositive acute lymphoblastic leukemia resistance intolerance prior therapy dasatinib approved eu november sprycel discovered developed internally basic composition matter patent protecting dasatinib us due expire april patent term extension requested upon grant would extend patent term june several eu countries patent pending upon grant would expire april excluding term extensions eu patent application filed cyprus estonia latvia lithuania malta netherlands slovakia slovenia us new chemical entity protection expires orphan drug exclusivity expires protects product generic applications currently approved orphan indications company manufactures bulk requirements dasatinib finishes product facilities ixempra ixempra ixabepilone microtubule inhibitor belonging class antineoplastic agents epothilones analogs october fda approved ixabepilone combination capecitabine treatment patients metastatic locally advanced breast cancer resistant treatment anthracycline taxane whose cancer taxane resistant anthracycline therapy contraindicated monotherapy treatment metastatic locally advanced breast cancer patients whose tumors resistant refractory anthracyclines taxanes capecitabine marketing authorization currently sought eu countries basic composition matter patent protecting ixabepilone us due expire may patent term extension requested upon grant would extend patent term september corresponding patent also granted eu countries due expire june excluding term extensions eu patent application filed malta us new chemical entity protection expires ixabepilone developed company subject license agreement helmholtz zentrum fur infektionsforschung gmbh hzi relating epothilone technologies agreement hzi entitled royalties net sales countries product sold company manufactures bulk requirements ixabepilone facilities including manufacture active ingredient drug product comprises pharmaceutical kit finished baxter oncology gmbh affective psychiatric disorders abilify aripiprazole atypical antipsychotic agent patients schizophrenia acute bipolar mania bipolar disorder aripiprazole copromoted us company otsuka pharmaceutical co ltd otsuka companys rights commercialize aripiprazole us terminate thereafter otsuka sole right commercialize aripiprazole us germany spain company copromotes otsuka affiliate uk france company currently acts distributor product copromotes otsuka affiliate european markets company acts exclusive distributor company exclusive licensee product rest world excluding japan certain countries us spain germany company records alliance revenue contractual share net sales records expenses related product alliance revenue recorded company net sales based upon third party customer net sales copromotion countries company recognizes alliance revenue abilify shipped risks rewards ownership transferred thirdparty customers uk france italy company currently records net sales related cost products sold countries company exclusive right sell abilify company also records net sales related cost products sold information companys arrangement otsuka see strategic alliances item financial statementsnote alliances investments table contents basic us composition matter patent abilify expires including granted patent term extension otsuka filed us patent trademark office uspto request reexamination us composition matter patent us patent patent covering abilify june uspto issued ex parte reexamination certificate patent confirming patentability original claims approving additional new claims otsuka received formal notices teva pharmaceuticals usa teva barr pharmaceuticals inc barr sandoz inc sandoz synthon laboratories inc synthon sun pharmaceuticals ltd sun apotex stating filed abbreviated new drug application anda fda various dosage forms aripiprazole company otsuka comarket us abilify notices states anda contains piv certification directed patent covers aripiprazole expires october addition notices purports provide otsuka respective piv certification certifications contain various allegations regarding enforceability patent andor validity andor infringement claims therein otsuka filed patent infringement actions based patent teva barr sandoz sun apotex us district court new jersey synthon us district court middle district north carolina otsuka sole rights enforce patent composition matter patent force germany uk france italy netherlands romania sweden switzerland spain denmark original expiration date extended grant supplemental protection certificate countries except romania denmark data exclusivity eu expires composition matter patent austria belgium finland greece ireland luxembourg portugal latvia hungary cyprus czech republic slovenia slovakia poland malta lithuania bulgaria estonia company obtains bulk requirements aripiprazole otsuka otsuka company finish product facilities immunoscience orencia abatacept biological product fusion protein novel immunosuppressive activity targeted initially adult patients moderate severe rheumatoid arthritis inadequate response certain currently available treatments abatacept approved fda december made commercially available us february orencia discovered developed internally company series patents covering abatacept method use latest composition matter patents expires us company submitted request patent term extension one composition matter patents expires could possibly extend term patent majority eu countries company patent covering abatacept expires data exclusivity eu expires january repligen corporation regents university michigan filed complaint company us district court eastern district texas marshall division alleging companys thenanticipated sales orencia infringe us patent august zymogenetics inc filed complaint company us district court district delaware complaint alleges companys manufacture sales orencia infringe us patents information litigations see item financial statementsnote legal proceedings contingencies company obtains bulk abatacept third party manufacturing facilities company finishes product facilities pharmaceuticals efferalgan efferalgan formulation acetaminophen first introduced distributed effervescent tablet indicated treatment fever mild moderate pain adults children marketed primarily europe composition matter patent europe efferalgan table contents addition products discussed companys pharmaceuticals segment also includes companys whollyowned upsa consumer medicines business europe includes efferalgan described well aspirine upsa dafalgan fervex europe overseas markets strategic alliances arrangements company enters strategic alliances arrangements third parties give company rights develop manufacture market andor sell pharmaceutical products rights owned third parties company also enters strategic alliances arrangements third parties give third parties rights develop manufacture market andor sell pharmaceutical products rights owned company alliances arrangements take many forms including licensing arrangements codevelopment comarketing agreements copromotion arrangements joint ventures alliances arrangements reduce risk incurring research development expenses lead revenuegenerating products however gross margins alliance products generally lower sometimes substantially gross margins companys products partnered profits alliance products shared companys alliance partners assurance new alliances formed company actively pursues arrangements views alliances important complement discovery development activities companys significant current alliances arrangements companys products sanofi plavix avaproavalide otsuka abilify imclone erbitux gilead atripla companys significant alliances arrangements investigational compounds development medarex inc medarex ipilimumab monoclonal antibody investigated anticancer treatment rights owned medarex astrazeneca plc astrazeneca saxagliptin oral compound discovered company potential treatment diabetes dppiv inhibitor dapagliflozin oral compound discovered company potential treatment diabetes sodiumglucose cotransporter sglt inhibitor pfizer inc pfizer apixaban anticoagulant discovered company studied prevention treatment broad range venous arterial thrombotic conditions significant alliances arrangements discussed detail additionally company licensing arrangements novartis reyataz hzi ixempra novel microtubulestabilizing agent treatment breast cancer general companys strategic alliances arrangements periods coextensive periods market exclusivity protection countryby country basis based companys current expectations respect expiration market exclusivity companys significant markets licensing arrangements novartis reyataz expected expire us eu japan hzi ixempra expected expire us th anniversary first commercial sale eu japan discussion market exclusivity protection including chart showing net sales key products together year basic exclusivity loss occurred expected occur us eu japan see products intellectual property product exclusivity companys strategic alliances arrangements third parties rights manufacture market andor sell pharmaceutical products contain customary early termination provisions typically found agreements kind generally based partys material breach bankruptcy voluntary involuntary product safety concerns amount notice required early termination generally ranges immediately upon notice days receipt notice termination immediately upon notice generally available party files voluntary bankruptcy petition material safety issue arises product medical riskbenefit incompatible welfare patients continue develop commercialize product termination upon days notice generally available involuntary bankruptcy petition filed dismissed material breach party occurred cured early termination due product safety concerns typically arises product determined create significant risk harm patients due concerns regarding products efficacy level toxicity companys strategic alliances arrangements typically otherwise contain provisions provide party right terminate alliance short notice general party companys strategic alliance arrangement continue exclusivity protection upon expiration termination alliance company retain rights product partys intellectual property loss rights one products marketed sold company pursuant strategic alliance arrangements third parties one countries territories could material companys results operations cash flows case plavix could material financial condition liquidity customary pharmaceutical industry terms companys strategic alliances arrangements generally coextensive exclusivity period discussed may vary countrybycountry basis discussed companys strategic alliance otsuka expires november us puerto rico prior expected expiration market exclusivity protection abilify us including granted patent term extension table contents current marketed products sanofi company agreements codevelopment cocommercialization avaproavalide angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy copromoted certain countries outside us tradename aprovelcoaprovel comarketed certain countries outside us company tradename karveakarvezide plavix platelet aggregation inhibitor copromoted certain countries outside us tradename plavix comarketed certain countries outside us company tradename iscover worldwide alliance operates framework two geographic regions one covering certain european asian countries defined territory one covering us puerto rico canada australia certain latin american countries defined territory b region covering us puerto rico canada australia certain latin american countries managed two separate territory agreements one us puerto rico avaproavalide second agreement us puerto rico plavix plus canada australia mexico brazil colombia argentina products within territory b territory partnership exists supply product countries within territory manage certain central expenses marketing research development royalties countries within territory b structured companys local affiliate sanofi either comarket separate brands eg affiliate operates independently sells competing brand copromote single brand within territory comarketing countries include germany spain italy irbesartan greece china clopidogrel bisulfate company sells iscover karveakarvezide sanofi sells plavix aprovelcoaprovel countries except china company retains right currently comarket iscover company sanofi copromote plavix aprovelcoaprovel france uk belgium netherlands switzerland portugal addition company sanofi copromote plavix austria italy ireland denmark finland norway sweden turkey taiwan korea singapore malaysia hong kong aprovelcoaprovel certain french export countries sanofi acts operating partner territory owns majority financial controlling interest territory companys ownership interest territory company accounts investment partnership entities territory equity method records share results equity net income affiliates consolidated statement earnings companys share net income partnership entities taxes million million million within territory b company sanofi copromote plavix us canada puerto rico avaproavalide canada territory b countries australia mexico brazil colombia clopidogrel bisulfate argentina comarketing countries company sanofi modified previous exclusive license company avaproavalide us puerto rico form copromotion joint venture part company contributed avaproavalide intellectual property sanofi agreed pay company million million company accounts payments sale interest license defers amortizes total amount million income expected useful life license approximately years date formation copromotion joint venture company acts operating partner territory b uspuerto rico avaproavalide territory owns majority controlling interest territories company consolidates partnership results territories records sanofis share results minority interest expense net taxes million million million company recorded sales territory b uspuerto rico avaproavalide territory territory comarketing countries million million million september company opted copromotion rights sanofi aprovelcoaprovel ireland sweden denmark finland norway company also opted comarketing copromotion arrangements number countries prior company receives royalty payment sanofi based percentage sanofis net sales optout countries territory partnerships governed series committees enumerated functions powers responsibilities territory two senior committees senior committees final decision making authority respect territory enumerated functions powers responsibilities within jurisdiction agreements sanofi expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patents exclusivity rights applicable territory alliance arrangements may terminated company sanofi either whole affected country territory depending circumstances event voluntary involuntary bankruptcy insolvency case involuntary bankruptcy continues days order decree approving continues unstayed effect days ii table contents material breach obligation major alliance agreement remains uncured days following notice breach except commencement diligent prosecution cure occurred within days notice iii deadlocks one senior committees render continued commercialization product impossible given country territory case avaproavalide us respect advertising promotion spending levels amount sales force commitment iv increase combined cost goods royalty exceeds specified percentage net selling price product v good faith determination terminating party commercialization product terminated reasons patient safety case termination rights agreements include provisions termination relevant alliance respect applicable product applicable country territory case termination due bankruptcy insolvency material breach products applicable territory termination procedures slightly different however events company could lose rights either products applicable relevant country territory even case bankruptcy insolvency material breach company defaulting party discussion companys strategic alliance sanofi see item financial statementsnote alliances investments otsuka company entered worldwide commercialization agreement otsuka codevelop copromote abilify treatment schizophrenia related psychiatric disorders except japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt company began copromoting product otsuka us puerto rico november june company received marketing approval european commission product currently copromoted otsuka uk germany france spain us germany spain product invoiced thirdparty customers company behalf otsuka company records alliance revenue contractual share thirdparty net sales records expenses related product company recognizes alliance revenue abilify shipped risks rewards ownership transferred thirdparty customers uk france italy company presently exclusive distributor product company records net sales related cost products sold expenses company also exclusive right sell abilify countries europe americas number countries asia countries company records net sales related cost products sold terms agreement company purchases product otsuka performs finish manufacturing sale company otsuka thirdparty customers agreement expires november us entire eu agreement expires june country company exclusive right sell abilify agreement expires later th anniversary first commercial sale country expiration applicable patent country early termination available based partys voluntary involuntary bankruptcy failure make minimum payments failure commence first commercial sale within three months receipt necessary approvals material breach amount notice required early termination strategic alliance immediately upon notice case voluntary bankruptcy ii minimum payments made otsuka iii first commercial sale occurred within three months receipt necessary approvals days material breach occurred cured commencement cure occurred within days notice material breach days case involuntary bankruptcy petition filed dismissed addition termination available otsuka upon days notice event company challenge otsukas patent rights marketbymarket basis company market product direct competition abilify upon termination expiration alliance company retain rights abilify company recorded total revenue abilify million million million total milestone payments made otsuka agreement million million expensed acquired inprocess research development remaining million capitalized intangible assets amortized cost products sold remaining life agreement us ranging years company amortized cost products sold million unamortized capitalized payment balance million million december respectively discussion companys strategic alliance otsuka see item financial statementsnote alliances investments imclone company purchased million shares imclone per share million represented approximately imclone shares outstanding prior companys commencement public tender offer imclone shares imclone biopharmaceutical company focused developing targeted cancer treatments include growth factor blockers cancer vaccines antiangiogenesis therapeutics equity investment imclone part strategic agreement company imclone also included commercialization arrangement expiring september codevelopment copromotion erbitux series payments originally totaling billion company table contents paid imclone milestone payment million agreement imclone revised reduce total payments million billion accordance agreement company paid imclone million million million million first quarter payment made upon approval fda bla erbitux use combination irinotecan treatment patients egfr expressing mcrc refractory irinotecanbased chemotherapy use single agent treatment patients egfrexpressing mcrc intolerant irinotecanbased chemotherapy milestone payment made upon fda approval erbitux use treatment squamous cell carcinoma head neck combination radiation monotherapy company also codevelopment copromotion rights canada japan extent product commercialized countries agreement covering north america imclone receives distribution fee based flat rate net sales north america company purchases commercial requirements bulk erbitux imclone price equal imclones manufacturing cost plus july company imclone amended terms agreement codevelopment copromotion erbitux north america amendment companies jointly agreed expand investment ongoing clinical development plan erbitux several hundred million dollars development costs threshold value sole responsibility company costs excess threshold shared companies according predetermined ratio company shares copromotion rights erbitux merck kgaa japan codevelopment cocommercialization agreement signed october among bms bmkk er squibb sons llc imclone merck kgaa merck japan erbitux yet marketed japan although company imclone submitted february application pmda use erbitux treating patients advanced colorectal cancer company accounts million total approval milestones paid license acquisitions amortizes payments cost products sold remaining term agreement ends company amortized cost products sold million million million respectively unamortized portion approval payments recorded intangible assets net consolidated balance sheet million million december respectively company determines equity share imclones net income loss eliminating imclones results milestone revenue imclone recognized million preapproval milestone payments made company company recorded net income million million respectively net loss million share imclones results operations company records share results equity net income affiliates consolidated statement earnings company recorded net sales erbitux million million million companys recorded investment market value holdings imclone common stock million approximately million december respectively million approximately million december respectively company holds million shares imclone stock representing approximately imclones shares outstanding december per share basis carrying value imclone investment closing market price imclone shares december respectively compared respectively december early termination available based material breach effective days notice material breach material breach cured commencement cure occurred upon six months notice company exists significant concern regarding regulatory patient safety issue would seriously impact longterm viability product upon termination expiration alliance company retain rights erbitux may mckesson corporation mckesson one companys wholesalers provided warehousing packing shipping services erbitux mckesson held erbitux inventory consignment companys revenue recognition policy company recognized revenue inventory shipped mckesson endusers mckesson also held inventories erbitux account upon divestiture oncology therapeutics network may company discontinued consignment arrangement mckesson mckesson longer held inventories account thereafter company sold erbitux intermediaries wholesalers specialty oncology distributors shipped erbitux directly endusers product customers intermediaries beginning third quarter company began expanding distribution model include wholesalers distributors hold erbitux inventory company recognizes revenue upon shipment consistent revenue recognition policy discussion companys strategic alliance imclone see item financial statementsnote alliances investments table contents gilead company gilead entered joint venture develop commercialize fixeddose combination companys sustiva gileads truvada emtricitabine tenofovir disoproxil fumarate us july fda granted approval atripla first complete highly active antiretroviral therapy treatment product hiv available us fixeddose combination taken daily fixeddose combinations contain multiple medicines formulated together may help simplify hiv therapy patients providers guidelines issued us department health human services list combination emtricitabine tenofovir disoproxil fumarate efavirenz one preferred nonnnrtibased treatments use appropriate patients never taken antihiv medicines september companies amended agreements commercialize atripla canada atripla approved health canada october european commission december commercialization countries eu well norway iceland company gilead share responsibility commercializing atripla us canada throughout eu certain european countries provide funding fieldbased sales representatives support promotional efforts atripla gilead records atripla revenues us canada countries europe company records revenue bulk efavirenz component atripla upon sales product joint venture gilead thirdparty customers companys revenue efavirenz component determined applying percentage atripla revenue approximates revenue sustiva brand company recorded efavirenz revenues million million related atripla sales gilead consolidates results joint venture operating results company accounts participation joint venture equity method accounting records share joint venture results equity net income affiliates consolidated statement earnings company recorded equity loss joint venture gilead million million million joint venture company gilead continue terminated mutual agreement parties otherwise described event material breach one party nonbreaching party may terminate joint venture parties agree desirable practicable withdraw combination product markets commercialized time one generic versions sustiva appear market us gilead right terminate joint venture thereby acquire rights combination product us canada however company continue three years receive percentage net sales based contribution bulk efavirenz atripla otherwise retains rights sustiva discussion companys strategic alliance gilead see item financial statementsnote alliances investments investigational compounds development medarex company entered worldwide collaboration share purchase agreement medarex codevelop copromote ipilimumab fully human antibody currently phase iii development treatment metastatic melanoma agreement became effective january companies received certain governmental clearances approvals receipt consent us public health service sublicense company medarexs rights mdx gp vaccine developed combination ipilimumab fda granted fast track status ipilimumab combination mdx treatment patients late stage unresectable metastatic melanoma failed intolerant firstline therapy january terms agreement company made cash payment million medarex expensed research development additional million equity investment medarex milestone payments expected made upon successful achievement various regulatory salesrelated stages company medarex also share future development commercialization costs medarex could receive million regulatory milestones met million salesrelated milestones medarex option copromote receive profits company us company receive exclusive license outside us pay royalties medarexthe agreement medarex expire unless one following events occurs company voluntarily terminates agreement entirety countrybycountry basis providing medarex six months prior written notice company voluntarily terminates agreement productbyproduct basis second product glp toxicology studies later countrybycountry basis providing medarex six months prior written notice depending circumstances company terminates medarexs copromotion option rights us days written notice end second calendar year event medarex provides less percent certain performance obligations two three consecutive calendar years termination right exercised respect indications medarex failed meet performance obligation upon termination company via scenarios medarex longer right share profits losses product terminated indications instead company pay medarex royalties net sales product medarex terminates agreement respect products days written notice company provides less percent certain performance obligations two three consecutive calendar years generally upon termination company assign rights product medarex receive royalty thereafter intellectual property licensed company medarex medarex may also elect copromote product one indications us event receive royalty sales product indication material breach manufacturing party party shall limited termination partys manufacturing rights table contents astrazeneca january company entered two worldwide except japan codevelopment cocommercialization agreements astrazeneca one codevelopment cocommercialization saxagliptin dppiv inhibitor saxagliptin agreement one codevelopment cocommercialization dapagliflozin sglt inhibitor sglt agreement compounds studied treatment diabetes discovered company terms agreements company received astrazeneca upfront payment million january deferred recognized life agreements income company amortized income million unamortized portion upfront payment million december milestone payments expected received company upon successful achievement various development regulatory events well salesrelated milestones saxagliptin agreement company could receive million development regulatory milestones met additional million salesbased milestones met sglt agreement company could receive million development regulatory milestones met additional million salesbased milestones met agreement company astrazeneca also share future development commercialization costs majority development costs initial development plans paid astrazeneca additional development costs generally shared equally company records research development expenses saxagliptin dapagliflozin development costs net alliance partners share agreement two companies jointly develop clinical marketing strategy share commercialization expenses profitslosses equally global basis excluding japan company manufacture products certain limited exceptions record net sales pfizer april company pfizer entered worldwide codevelopment cocommercialization agreement apixaban anticoagulant discovered company studied prevention treatment broad range venous arterial thrombotic conditions accordance terms agreement pfizer made upfront payment million company may deferred recognized life agreement income december company pfizer agreed include japan worldwide agreement pfizer made upfront payment million december deferred recognized life agreement income company amortized income million unamortized portion upfront payments million december pfizer fund development costs effective january going forward company fund company records research development expenses apixaban development costs net alliance partners share company may also receive additional payments million pfizer based development regulatory milestones companies jointly develop clinical marketing strategy apixaban share commercialization expenses profitslosses equally global basis information alliances relating products development drug discovery see research development health care group nutritionals segment nutritionals segment mead johnson manufactures markets distributes sells infant formulas nutritional products including entire line enfamil products enfamil lipil product first infant formula us contain nutrients docosahexaenoic acid dha arachidonic acid ara also naturally found breast milk dha ara believed support infant brain eye development company obtains nutrients sole provider pursuant nonexclusive worldwide license supply agreement supply agreement force least provides firm guarantee supply pricing subject change pursuant pricing formula license expires beginning countrybycountry basis years company commenced sales country companys nutritionals products generally sold wholesalers retailers promoted primarily health care professionals company also promotes nutritionals products directly consumers worldwide advertising company manufactures products us five foreign countries nutritionals sales accounted companys sales companys sales companys sales us nutritionals sales accounted total nutritionals sales respectively international nutritionals sales accounted total nutritionals sales respectively approximately onehalf us gross sales infant formula subject rebates issued women infants children wic program sales subject wic rebates much lower margins nonwic program sales table contents key nutritionals product lines sales follows dollars millions infant formulas enfamil toddlerchildrens nutritionals enfagrow convatec segment convatec segment manufactures distributes sells ostomy modern wound skin care products principal brands convatec include natura surfit esteem aquacel duoderm flexiseal products marketed worldwide primarily hospitals medical professions medical suppliers company mainly relies internal sales force sales made various distributors around world company manufactures products us uk dominican republic convatec sales accounted approximately companys sales companys sales companys sales us convatec sales accounted total convatec sales respectively international convatec sales accounted total convatec sales respectively convatec sales business key products follows dollars millions convatec ostomy wound therapeutics productivity transformation initiative company undertook broad range actions fourth quarter part previously announced threeyear productivity transformation initiative pti reducing costs streamlining operations rationalizing global manufacturing initiative track achieve billion annual cost savings cost avoidance pretax basis central companys strategy become nimble flexible next generation biopharmaceutical enterprise key productivity initiatives include reducing general administrative operations simplifying standardizing outsourcing appropriate processes services rationalizing companys mature brands portfolio consolidating global manufacturing network eliminating complexity enhancing profitability simplifying geographic footprint implementing efficient gotomarket model specific productivity goals include reducing number brands companys mature products portfolio percent reducing number manufacturing facilities percent end reducing total headcount approximately percent positions eliminated although substantial majority positions eliminated company announced impending closure several manufacturing facilities including barceloneta puerto rico mayaguez puerto rico costs associated implementation pti estimated billion billion pretax basis million incurred approximately million expected incurred ultimate timing recording charges predicted certainty affected occurrence triggering events expense recognition us generally accepted accounting principles gaap among factors table contents sources availability raw materials general company purchases raw materials medical devices supplies required production companys products open market products company purchases raw materials medical devices supplies single source certain circumstances specified companys product registrations thereby requiring company obtain raw materials supplies particular source company attempts possible mitigate raw material supply risks company inventory management alternative sourcing strategies discussion sourcing see manufacturing quality assurance discussions particular products manufacturing quality assurance meet expected product demand company operates manages manufacturing network including thirdparty contract manufacturers inventory related thereto manner permits company improve efficiency maintaining flexibility ability reallocate manufacturing capacity pharmaceutical production processes complex highly regulated vary widely product product given shifting adding manufacturing capacity lengthy process requiring significant capital outofpocket expenditures regulatory approvals company maintains operates flexible manufacturing network consisting internal external resources minimizes unnecessary product transfers inefficient uses manufacturing capacity discussion regulatory impact companys manufacturing see government regulation price constraints pharmaceutical manufacturing facilities require significant ongoing capital investment maintenance compliance increasing regulatory requirements addition company adds product line realigns focus next several years company expects modify existing manufacturing network meet complex processing standards may required newly introduced products including biologics biologics manufacturing involves complex processes traditional pharmaceutical operations although company capacity manufacture biologics clinical trials commercial launch capacity manufacture larger commercial volumes limited biologics become important companys product portfolio company may continue make arrangements thirdparty manufacturers addition expects make substantial investments increase internal capacity produce biologics commercial scale board directors approved capital expenditures approximately million bulk biologics manufacturing facility us february company completed land purchase acre site locate large scale multiproduct bulk biologics manufacturing facility devens massachusetts construction devens massachusetts facility began early facility projected operationally complete company expects submit site regulatory approval commercial production biologic compounds anticipated begin company relies third parties manufacture supply active ingredients necessary manufacture certain products including plavix abilify erbitux sustiva franchise orencia pravachol coumadin taxol paclitaxel maintain stable supply products company takes variety actions designed provide reasonable level ingredients held thirdparty supplier company companys manufacturing operations interrupted additional protection cases company takes steps maintain approved backup source available example company rely combined capacity devens massachusetts syracuse new york manati puerto rico facilities capacity available thirdparty contract manufacturers manufacture orencia commercial quantities companys investigational compounds latestage development compounds receive regulatory approval company thirdparty manufacturer company relies existing future products unable maintain stable supply products operate sufficient capacity meet order requirements comply government regulations manufacturing pharmaceuticals meet heightened processing requirements biologics companys business performance prospects could negatively impacted additionally company thirdparty suppliers experience extended plant shutdowns substantial unplanned increases demand suspension manufacturing regulatory reasons company could experience interruption supply certain products product shortages production could resumed expanded connection divestitures licensing arrangements distribution agreements certain companys products certain circumstances company entered agreements company agreed supply products third parties addition liabilities could arise companys failure supply products agreements arrangements could require company invest facilities production non strategic products result additional regulatory filings obligations cause interruption manufacturing products companys success depends great measure upon customer confidence quality products integrity data support safety effectiveness product quality arises total commitment quality parts companys operations including research development purchasing facilities planning manufacturing distribution company maintains qualityassurance procedures relating quality integrity technical information production processes table contents control production processes involves detailed specifications ingredients equipment facilities manufacturing methods processes packaging materials labeling company performs tests various stages production processes final product ensure product meets regulatory requirements companys standards tests may involve chemical physical chemical analyses microbiological testing combination along analyses quality control provided business unitsite quality assurance groups monitor existing manufacturing procedures systems used company subsidiaries thirdparty suppliers intellectual property product exclusivity company owns licenses number patents us foreign countries primarily covering products company also developed many brand names trademarks products areas company considers overall protection patent trademark license intellectual property rights material value acts protect rights infringement pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity us countries market exclusivity expires generic versions product approved marketed often substantial rapid declines products sales rate decline varies country therapeutic category discussion generic versions product impact products sales see generic competition products market exclusivity generally determined two forms intellectual property patent rights held innovator company regulatory forms exclusivity innovative drug entitled patents key determinant market exclusivity branded pharmaceuticals patents provide innovator right exclude others practicing invention related medicine patents may cover among things active ingredients various uses drug product pharmaceutical formulations drug delivery mechanisms processes intermediates useful manufacture products protection individual products extends varying periods accordance expiration dates patents various countries protection afforded may also vary country country depends upon type patent scope coverage availability meaningful legal remedies country market exclusivity also sometimes influenced regulatory intellectual property rights many developed countries provide certain nonpatent incentives development medicines example us eu japan provide minimum period time approval new drug regulatory agency may rely upon innovators data approve competitors generic copy regulatory intellectual property rights also available certain markets incentives research new indications orphan drugs medicines useful treating pediatric patients regulatory intellectual property rights independent patent rights company may possess particularly important drug lacks broad patent protection however regulatory forms exclusivity prevent competitor gaining regulatory approval prior expiration regulatory data exclusivity basis competitors safety efficacy data drug even drug identical marketed innovator company estimates likely market exclusivity period products casebycase basis possible predict length market exclusivity companys products certainty complex interaction patent regulatory forms exclusivity inherent uncertainties concerning patent litigation assurance particular product enjoy market exclusivity full period time company currently estimates exclusivity limited estimate discussion market exclusivity see pharmaceuticals segment addition patents regulatory forms exclusivity company also holds intellectual property form trademarks products enfamil trademarks effect market exclusivity product considered marketing value worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely specific aspects law governing market exclusivity pharmaceuticals vary country country following summarizes key exclusivity rules markets representing significant company sales united states company seeking market innovative pharmaceutical us must file complete set safety efficacy data fda type application filed depends whether drug chemical small molecule biological product large molecule innovative pharmaceutical chemical company files new drug application nda medicine biological product bla filed type application filed affects regulatory exclusivity rights table contents competitor seeking launch generic substitute chemical innovative drug us must file anda fda anda generic manufacturer needs demonstrate bioequivalence generic substitute approved nda drug anda relies upon safety efficacy data previously filed innovator nda medicines approved nda receive several types regulatory data protection innovative chemical pharmaceutical also known new chemical entity entitled five years regulatory data protection us anda filed fda innovators patent challenged described generic manufacturer may file anda fourth year fiveyear data protection period pharmaceutical drug product contains active ingredient previously approved nda approved new formulation new indication basis new clinical trials receives three years data protection finally nda designated orphan drug drug gains indication treatment condition occurs rarely us receive seven years exclusivity orphan indication time period neither ndas andas drug product approved orphan use significant portion patent life lost time takes obtain regulatory approval innovator extend one patent compensate innovator lost patent term least part specifically innovator may identify one patent claims product approved method use depending number factors may extend expiration date patent two limits extensions first maximum term patent extended five years second extension cause patent effect years date nda approval company may also earn six months additional exclusivity drug specific clinical trials conducted written request fda study use medicine treat pediatric patients submission fda made prior loss basic exclusivity sixmonth period extends forms exclusivity patent regulatory listed fda time studies completed submitted fda products already finally approved currently generic versions biological products approved us law however law could change future even absence new legislation fda taking steps toward allowing generic versions certain biologics competitors seeking approval biological products must file safety efficacy data address challenges biologics manufacturing involves complex processes costly traditional pharmaceutical operations many innovative drugs also covered patents held nda sponsor beyond minimum period regulatory exclusivity provided us law innovator company required list certain patents covering medicine fda commonly known orange book absent successful patent challenge fda approve anda innovators listed patents expire however innovator marketed product four years generic manufacturer may file anda allege one patents listed orange book innovators nda either invalid infringed allegation commonly known paragraph iv certification innovator must decide whether file patent infringement suit generic manufacturer one ndalisted patents successfully challenged innovator chooses sue first filer paragraph iv certification first filers one generic qualifies may entitled day period market exclusivity generic manufacturers time time andas including paragraph iv certifications filed respect certain companys products company evaluates andas casebycase basis warranted files suit generic manufacturer protect patent rights us increased likelihood generic challenges innovators intellectual property increased risk loss innovators market exclusivity first generic companies increasingly sought challenge innovators basic patents covering major pharmaceutical products discussion one litigation related patent challenges generic companies see item financial statementsnote legal proceedings contingenciesplavix litigation intellectual property litigation second statutory regulatory provisions us limit ability innovator company prevent generic drugs approved launched patent litigation ongoing third fda actively considering ways expand use regulatory mechanism allows regulatory approval drugs similar generic copies innovative drugs basis less extensive data required full nda result developments possible predict length market exclusivity particular company product certainty based solely expiration relevant patents current forms regulatory exclusivity information new legislation see government regulation price constraints table contents european union recent pharmaceutical legislation eu impact procedures authorization pharmaceutical products eu centralized mutual recognition procedures particular legislation contains new data protection provisions products regardless whether approved centralized mutual recognition procedures subject regime eight years innovator received first community authorization medicinal product generic company may file marketing authorization application product health authorities however generic company may commercialize product either years elapsed initial marketing authorization granted innovator possible oneyear extension available innovator first eight years marketing authorization obtains additional indication significant clinical benefit comparison existing treatments transitional provision new data protection requirements provisions apply new marketing authorization applications submitted new legislation products continue covered old law year period data protection centralized procedures period either six years mutual recognition procedure depending member state regardless procedure used obtain marketing authorization approval company must obtain pricing reimbursement pharmaceutical product typically subject member state law pricing reimbursement procedure take months sometimes years obtain patents pharmaceutical products generally enforceable eu however contrast us patents listed regulatory authorities generic copies approved data protection expires regardless whether innovator holds patents covering drug thus possible innovator may seeking enforce patents generic competitor already marketing product also european patent system opposition procedure generic manufacturers may challenge validity patents covering innovator products within nine months grant us patents eu may extended compensate patent term lost regulatory review process extensions granted countrybycountry basis general eu law treats chemicallysynthesized drugs biologicallyderived drugs respect intellectual property market exclusivity european medicines evaluation agency emea issued guideline outlines additional information provided biosimilar products also known generic biologics order emea review application marketing approval japan japan medicines new chemical entities generally afforded eight years previously six years data exclusivity approved indications dosage patents pharmaceutical products enforceable generic copies receive regulatory approval data exclusivity patent expirations us patents japan may extended compensate patent term lost regulatory review process general japanese law treats chemicallysynthesized biologicallyderived drugs respect intellectual property market exclusivity rest world countries outside us eu japan wide variety legal systems respect intellectual property market exclusivity pharmaceuticals developed countries utilize systems similar either us eg canada eu eg switzerland among developing countries adopted patent laws andor regulatory exclusivity laws others developing countries formally adopted laws order comply world trade organization wto commitments taken steps implement laws meaningful way enforcement wto obligations long process assurance outcome thus assessing likely future market exclusivity companys innovative drugs developing countries company takes account formal legal rights political factors well marketing distribution customers company promotes products medical journals directly health care providers doctors nurse practitioners physician assistants pharmacists technologists hospitals pharmacy benefit managers pbms managed care organizations mcos government agencies company also markets directly consumers us directtoconsumer print radio television advertising addition company sponsors general advertising educate public innovative medical research discussion regulation promotion marketing pharmaceuticals see government regulation price constraints companys sales marketing organizations company explains approved uses advantages products medical professionals company works gain access health authority pbm mco formularies lists recommended approved medicines products including medicare part plans reimbursement lists demonstrating table contents qualities treatment benefits products marketing prescription pharmaceuticals limited approved uses particular product company continues develop information products provides information response unsolicited inquiries doctors medical professionals drugs must complete clinical trials required regulatory authorities show safe effective treating one medical problems manufacturer may choose however undertake additional studies including comparative clinical trials competitive products demonstrate additional advantages compound studies costly take years complete results uncertain balancing considerations makes difficult decide whether undertake additional studies successful studies major impact approved marketing claims strategies companys operations include several pharmaceutical marketing sales organizations organization markets distinct group products supported sales force typically based particular therapeutic areas physician groups sales forces often focus selling new products introduced promotion physicians increasingly targeted specialists high value primary care physicians companys prescription pharmaceutical products sold principally wholesalers company also sells directly distributors retailers hospitals clinics government agencies pharmacies sales three pharmaceutical wholesalers us mckesson cardinal health inc cardinal amerisourcebergen corporation amerisourcebergen accounted approximately respectively companys total net sales sales mckesson cardinal amerisourcebergen accounted approximately respectively companys total net sales sales mckesson cardinal amerisourcebergen accounted approximately respectively companys total net sales sales us wholesalers concentrated pharmaceuticals segment companys us pharmaceuticals business inventory management agreements imas arrangements substantially direct wholesaler distributor customers allow company monitor us wholesaler inventory levels require wholesalers maintain inventory levels one month demand imas twoyear term december subject certain termination provisions company sells erbitux intermediaries wholesalers specialty oncology distributors ships erbitux directly end users product customers intermediaries company also sells erbitux us wholesalers distributors hold erbitux inventory company recognizes revenue upon shipment consistent revenue recognition policy information sales marketing nutritionals convatec products see nutritionals segment convatec segment competition markets company competes generally broadbased highly competitive principal means competition vary among product categories business groups companys pharmaceuticals segment competes worldwide researchbased drug companies many smaller research companies limited therapeutic focus generic drug manufacturers important competitive factors include product efficacy safety ease use price demonstrated cost effectiveness marketing effectiveness product labeling service research development new products processes sales companys products impacted new studies indicate competitors product greater efficacy treating disease particular form disease one companys products companys sales also impacted additional labeling requirements relating safety convenience may imposed products fda similar regulatory agencies different countries competitors introduce new products processes therapeutic cost advantages companys products subject progressive price reductions decreased volume sales successfully compete business mcos pbms company must often demonstrate products offer medical benefits also cost advantages compared forms care new products company introduces must compete products already market products later developed competitors manufacturers generic pharmaceuticals typically invest far less research development research based pharmaceutical companies therefore price products significantly lower branded products accordingly branded product loses market exclusivity normally faces intense price competition generic forms product certain countries outside us patent protection weak nonexistent company must compete generic versions shortly launches innovative product addition generic pharmaceutical companies may introduce generic product exclusivity expired resolution related patent litigation discussion generic launch clopidogrel bisulfate product competes plavix see item financial statementsnote legal proceedings contingenciesplavix litigation table contents many companies large small manufacture sell one products similar marketed companys nutritionals convatec segments sources competitive advantage include patents trademarks product quality efficacy brand identity advertising promotion product innovation broad distribution capabilities customer satisfaction price significant expenditures advertising promotion marketing generally required achieve consumer trade acceptance products company believes longterm competitive position depends upon success discovering developing innovative costeffective products serve unmet medical need together ability manufacture products efficiently market effectively highly competitive environment assurance companys research development efforts result commercially successful products products processes become outmoded time time result products processes developed competitors managed care organizations growth mcos us major factor competitive makeup health care marketplace half us population participates version managed care size patient population covered mcos marketing prescription drugs pbms serve many organizations become important companys business mcos include medical insurance companies medical plan administrators healthmaintenance organizations medicare part formularies alliances hospitals physicians physician organizations organizations consolidating fewer even larger entities enhancing purchasing strength importance company major objective mcos contain possible reduce health care expenditures typically use formularies volume purchases longterm contracts negotiate discounts pharmaceutical providers mcos pbms typically develop formularies reduce cost medications formularies based prices therapeutic benefits available products due generally lower cost generic medicines often favored breadth products covered formularies vary considerably one mco another many formularies include alternative competitive products treatment particular medical problems mcos use variety means encourage patients use products listed formularies exclusion product formulary lead sharply reduced usage mco patient population consequently pharmaceutical companies compete aggressively products included possible companies compete inclusion based upon unique features products greater efficacy better patient ease use fewer side effects lower overall cost therapy also important factor products demonstrate fewer therapeutic advantages must compete inclusion based primarily price company generally although universally successful major products included mco formularies generic competition one biggest competitive challenges company faces us lesser extent internationally generic pharmaceutical manufacturers upon expiration loss market exclusivity product company lose major portion sales product short period time us fda approval process exempts generics costly timeconsuming clinical trials demonstrate safety efficacy allows generic manufacturers rely safety efficacy innovator product therefore generic competitors operate without companys large research development expenses costs conveying medical information product medical community information market exclusivity see intellectual property product exclusivity rate sales decline product expiration exclusivity varies country general decline us market rapid developed countries also declines developed countries tend rapid developing countries rate sales decline expiration exclusivity also historically influenced product characteristics example drugs used large patient population eg prescribed primary care physicians tend experience rapid declines drugs specialized areas medicine eg oncology drugs complex manufacture eg sterile injectable products usually experience slower decline simpler manufacture noted mcos focus primarily immediate cost drugs often favor generics brandname drugs many governments also encourage use generics alternatives brandname drugs health care programs laws us generally allow many cases require pharmacists substitute generic drugs rated government procedures therapeutically equivalent brandname drug substitution must made unless prescribing physician expressly forbids laws policies provide added incentive generic manufacturers seek marketing approval automatic substitution removes need generic manufacturers incur many sales marketing costs innovators must incur table contents research development company invests heavily research development believes critical longterm competitiveness bristolmyers squibb pharmaceutical research development major facilities princeton hopewell new brunswick new jersey wallingford connecticut pharmaceutical research development also carried various facilities us belgium canada uk india management continues emphasize leadership innovation productivity quality strategies success bristolmyers squibb pharmaceutical research development company spent million million million companysponsored research development activities companysponsored pharmaceutical research development spending includes certain payments thirdparty collaborations contracts end company employed approximately people research development throughout company including substantial number physicians scientists holding graduate postgraduate degrees higherskilled technical personnel company concentrates pharmaceutical research development efforts following disease areas significant unmet medical need affective psychiatric disorders alzheimersdementia atherosclerosisthrombosis diabetes hepatitis hivaids obesity oncology rheumatoid arthritis related diseases solid organ transplant however company continues analyze may selectively pursue promising leads areas addition discovering developing new molecular entities company looks ways expand value existing products new uses formulations provide additional benefits patients supplement companys internal efforts company collaborates independent research organizations including educational institutions researchbased pharmaceutical biotechnology companies contracts others performance research facilities companys drug discovery program includes many alliances collaborative agreements agreements bring new products pipeline help company remain cutting edge technology search novel medicines drug development company engages services physicians hospitals medical schools research organizations worldwide conduct clinical trials establish safety effectiveness new products drug development time consuming expensive risky development human health products industry practice government regulations us foreign countries provide determination effectiveness safety new molecular entities preclinical tests controlled clinical evaluation new drug may marketed us recorded data preclinical clinical experience included nda bla fda required approval development certain products also subject government regulations covering safety efficacy us many foreign countries assurance compound developed result program obtain regulatory approvals necessary marketed particular disease indication average one chemical compounds discovered pharmaceutical industry researchers proves medically effective safe enough become approved medicine process discovery regulatory approval typically takes years longer drug candidates fail stage process even latestage product candidates sometimes fail receive regulatory approval company believes investments research internally collaboration others rewarded number new pharmaceutical compounds indications stages development listed several investigational compounds company later stages development compounds phase iii clinical trials whether investigational compounds ultimately becomes one companys marketed products depends results preclinical clinical studies competitive landscape potential products market manufacturing processes necessary produce potential product commercial scale among factors however noted assurance company seek regulatory approval compounds approval sought obtained stage development company determine intellectual property issues patent protection may may available investigational compounds patent coverage highlighted include potential patent term extensions apixaban apixaban oral factor xa inhibitor developed internally recently entered phase iii clinical trials prevention thromboembolic disorders april company entered worldwide agreement pfizer codevelopment cocommercialization apixaban company owns issued us patent covering composition matter method use apixaban expires september extended february via patent term adjustment saxagliptin saxagliptin oral compound potential treatment diabetes discovered internally currently phase iii clinical trials january company entered saxagliptin agreement astrazeneca codevelopment cocommercialization saxagliptin patent application covering composition matter issued expire us table contents ipilimumab ipilimumab codeveloped medarex currently phase iii clinical trials monoclonal antibody investigated anticancer treatment novel class agents intended potentiate elements immunologic response company owns composition matter patent expires us rights method use patents owned medarex expire us company also rights medarex composition matter patent expires extended via patent term adjustment pending medarex patent applications covering composition matter method use ipilimumab belatacept belatacept biological product developed internally phase iii clinical trials fusion protein novel immunosuppressive activity targeted prevention solid organ transplant rejection company composition matter patent expires us dapagliflozin dapagliflozin oral compound potential treatment diabetes discovered internally currently phase iii clinical trials january company entered sglt agreement astrazeneca codevelopment cocommercialization dapagliflozin patent application covering composition matter issued expire us november company pierre fabre medicament sa announced termination license agreement development vinflunine chemotherapy agent investigation treatment advanced metastatic bladder cancer tumor types company sometimes enters agreements respect investigational compounds order share costs risks development cases facilitate commercialization agreements take many forms including codevelopment comarketing copromotion andor joint venture arrangements companys competitors also devote substantial funds resources research development addition consolidation occurred pharmaceutical industry created companies substantial research development resources extent companys competitors successful research could result erosion sales products unanticipated product obsolescence government regulation price constraints pharmaceutical industry subject extensive global regulation regional country state local agencies federal food drug cosmetic act fdc act federal statutes regulations various state statutes regulations laws regulations foreign governments govern varying degrees testing approval production labeling distribution postmarket surveillance advertising dissemination information promotion companys products lengthy process laboratory clinical testing data analysis manufacturing development regulatory review necessary required governmental approvals extremely costly significantly delay product introductions given market promotion marketing manufacturing distribution pharmaceutical products extensively regulated major world markets addition companys operations subject complex federal state local foreign environmental occupational safety laws regulations company anticipates laws regulations affecting manufacture sale current products introduction new products continue require substantial scientific technical effort time expense significant capital investment particular importance fda us jurisdiction virtually companys businesses imposes requirements covering testing safety effectiveness manufacturing labeling marketing advertising postmarketing surveillance companys pharmaceutical products fda also regulates companys nutritionals convatec products many cases fdas requirements increased amount time money necessary develop new products bring market us companys pharmaceutical products well medical device products sells convatec business subject premarket approval requirements us new drugs approved subject fdc act related regulations biological drugs subject fdc act public health service act phs act related regulations biological drugs licensed phs act medical devices subject fdc act including medical device amendments companys nutritionals products regulated fda primarily infant formula act amendmentsthe fda mandates drugs manufactured packaged labeled conformity current good manufacturing practices cgmp established fda complying cgmp regulations manufacturers must continue expend time money effort production record keeping quality control ensure product meets applicable specifications requirements ensure product safety efficacy fda periodically inspects drug manufacturing facilities ensure compliance applicable cgmp requirements failure comply statutory regulatory requirements subjects manufacturer possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experiences use products must reported fda could result imposition market restrictions labeling changes product removal product approvals may withdrawn compliance regulatory requirements maintained problems concerning safety efficacy product occur following approval table contents federal government extensive enforcement powers activities pharmaceutical medical device manufacturers including authority withdraw product approvals commence actions seize prohibit sale unapproved noncomplying products halt manufacturing operations compliance cgmps impose seek injunctions voluntary recalls civil monetary criminal penalties restriction prohibition sales withdrawal approval products marketed company could materially adversely affect business financial condition results operations cash flows federal government similar powers respect manufacturing operations nutritionals business marketing authorization companys products subject revocation applicable governmental agencies addition modifications enhancements approved products changes manufacturing locations many circumstances subject additional fda approvals may may received may subject lengthy application process distribution pharmaceutical products subject prescription drug marketing act pdma part fdc act regulates activities federal state level pdma implementing regulations states permitted require registration manufacturers distributors provide pharmaceuticals even manufacturers distributors place business within state states also permitted adopt regulations limiting distribution product samples licensed practitioners pdma also imposes extensive licensing personnel recordkeeping packaging quantity labeling product handling facility storage security requirements intended prevent sale pharmaceutical product samples diversions discussion recent settlement certain investigations drug pricing sales marketing activities see item financial statementsnote legal proceedings contingencies fda amendments act imposed additional obligations pharmaceutical companies delegated enforcement authority fda area drug safety key elements legislation give fda new authority require companies conduct postmarketing safety studies drugs impose certain drug labeling changes relating safety mandate risk mitigation measures education healthcare providers restricted distribution medicines require companies publicly disclose data clinical trials prereview television advertisements marketing practices us pharmaceutical manufacturers subject federal state health care laws used protect integrity government health care programs office inspector general us department health human services oig oversees compliance applicable federal laws connection payment products government funded programs primarily medicaid medicare laws include federal anti kickback statute criminalizes offering something value induce recommendation order purchase products services reimbursed government health care program oig issued series guidances segments health care industry including compliance program guidance pharmaceutical manufacturers oig guidance includes recommendation pharmaceutical manufacturers minimum adhere phrma code voluntary industry code marketing practices company subscribes phrma code implemented compliance program address requirements set forth oig guidance companys compliance health care laws failure comply health care laws could subject company administrative legal proceedings including actions state federal government agencies actions could result imposition civil criminal sanctions may include fines penalties injunctive remedies impact could materially adversely affect companys business financial condition results operations cash flows company also subject jurisdiction various federal state regulatory enforcement departments agencies federal trade commission department justice department health human services us company also licensed us drug enforcement agency procure produce controlled substances company therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include fines penalties injunctive administrative remedies companys activities outside us also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing companys products regulatory requirements vary country country eu two ways company obtain marketing authorization pharmaceutical product first route centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products second route obtain marketing authorization eu mutual recognition procedure applications made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states set forth pricing reimbursement product continues subject member state law table contents whether fda approval approval emea obtained product approval product comparable regulatory authorities countries outside us eu case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required us approval one country assure product approved another country many markets outside us company operates environment governmentmandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs andor enacted acrosstheboard price cuts methods cost control european countries provide market pricing new medicines except uk germany pricing freedom limited uk operation profit control plan germany operation reference price system companies also face significant delays mainly france spain italy belgium market access new products two years elapse new medicines become available national markets additionally member states eu regularly imposed new additional cost containment measures pharmaceuticals recent years italy example imposed mandatory price decreases existence price differentials within europe due different national pricing reimbursement laws leads significant parallel trade flows recent years congress state legislatures considered number proposals enacted laws could effect major changes health care system either nationally state level driven part budget concerns medicaid access reimbursement restrictions implemented states proposed many others similar cost containment issues exist many foreign countries company business federal state governments also pursued direct methods reduce cost drugs pay company participates state governmentmanaged medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities rebates medicaid related state programs reduced revenues million million million decrease compared primarily due exclusivity loss pravachol lower plavix sales shift patient enrollment medicaid medicare medicare part also resulted decrease medicaid rebates partially offset corresponding increase companys managed health care rebates company also participates prime vendor programs government entities significant us department defense us department veterans affairs entities receive minimum discounts based defined nonfederal average manufacturer price purchases prime vendor programs company participates provide discounts outpatient medicines purchased certain public health service entities hospitals meeting certain criteria company recorded discounts related prime vendor programs million million million us governmental cost containment efforts extended federally funded special supplemental nutrition program wic states participate wic program sought obtained rebates manufacturers infant formula whose products used program states conducted competitive bidding infant formula contracts require use specific infant formula products state wic program unless physician requests noncontract formula wic customer states participating wic program required engage competitive bidding use cost containment measures yield savings equal greater savings generated competitive bidding system mead johnson participates program approximately half gross us sales subject rebates wic program rebates wic program reduced revenues million million million discussion rebates programs see item managements discussion analysis financial condition results operations results operations environmental regulation companys facilities operations subject extensive us foreign laws regulations relating environmental protection human health safety including governing discharges pollutants air water use management disposal hazardous radioactive biological materials wastes cleanup contamination pollution controls permits required many companys operations permits subject modification renewal revocation issuing authorities environment health safety group within company monitors operations around world providing company overview regulatory requirements overseeing implementation company standards compliance company also incurs operating capital costs matters ongoing basis company expended approximately million million million capital environmental projects undertaken specifically meet environmental requirements respectively expects spend approximately million although company believes table contents substantial compliance applicable environmental health safety requirements permits required operations company nevertheless could incur additional costs including civil criminal fines penalties cleanup costs thirdparty claims property damage personal injury violations liabilities laws many companys current former facilities operation many years time company operators facilities generated used stored disposed substances wastes considered hazardous federal state foreign environmental laws including us comprehensive environmental response compensation liability act cercla result soil groundwater certain facilities may contaminated company may required make significant expenditures investigate control remediate contamination cases provide compensation andor restoration damages natural resources currently company involved investigation remediation current former company facilities company also identified potentially responsible party prp applicable laws environmental conditions approximately former waste disposal reprocessing facilities operated third parties investigation andor remediation activities ongoing company may face liability cercla federal state foreign laws entire cost investigation remediation contaminated sites natural resource damages regardless fault ownership time disposal release addition certain sites company bears remediation responsibility pursuant contract obligations generally thirdparty operator sites involving multiple prps liability expected apportioned based nature amount hazardous substances disposed party site number financially viable prps additional information matters see item financial statementsnote legal proceedings contingencies employees company employed approximately people december late company undertook broad range actions part previously announced threeyear pti part multiyear pti company implementing comprehensive cost reduction program includes workforce reductions areas rationalization facilities specific productivity goals include reducing total headcount approximately percent positions eliminated although substantial majority positions eliminated company recorded pretax charges million relating termination benefits related costs workforce reductions approximately manufacturing selling administrative personnel across geographic regions discussion initiative restructuring activities see productivity transformation initiative item financial statementsnote restructuring foreign operations company significant operations outside us conducted companys subsidiaries distributors involve three business segments companys us operations pharmaceuticals nutritionals convatec revenues operations outside us billion accounted companys total revenues revenues exceeded million france canada spain japan italy mexico germany revenues exceeded million france japan canada spain italy mexico revenues exceeded million france japan spain canada italy germany single country outside us contributed companys total revenues geographic breakdown net sales see table captioned geographic areas item financial statementsnote segment information discussion companys sales geographic area see item managements discussion analysis financial condition results operationsgeographic areas international operations subject certain risks inherent conducting business abroad including limited currency fluctuations possible nationalization expropriation price exchange controls counterfeit limitations foreign participation local enterprises restrictive governmental actions companys international businesses also subject governmentimposed constraints including laws pricing reimbursement use productsdepending direction change relative us dollar foreign currency values increase reduce reported dollar value companys net assets results operations change foreign exchange rates net favorable impact growth rate revenues company predict certainty future changes foreign exchange rates effect company attempts mitigate impact operational means using various financial instruments see discussions item quantitative qualitative disclosures market risk item financial statementsnote financial instruments table contents item risk factors factors described could significantly negatively affect companys business prospects financial condition operating results credit ratings could cause trading price companys common stock decline additional risks uncertainties presently known company risks company currently considers immaterial may also impair companys operations company faces competition pharmaceutical manufacturers including lowerpriced generic products possible company may lose market exclusivity product earlier expected competition manufacturers competing products including lowerpriced generic versions companys products major challenge within united states us internationally competition may include new products developed competitors lower prices superior performance features otherwise competitive companys current products ii technological advances patents attained competitors iii results clinical studies related companys products competitors products iv problems licensors suppliers distributors v business combinations among companys competitors major customers pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity us countries market exclusivity expires generic versions product approved marketed often substantial rapid declines products sales rate decline varies country therapeutic category market exclusivity companys products based upon patent rights andor certain regulatory forms exclusivity scope companys patent rights may vary country country countries including certain european union member states basic patent protection companys products may exist historically certain countries offer right obtain certain types patents andor company licensors file markets absent relevant patent protection product data exclusivity period expires generic versions product approved marketed addition prior expiration data exclusivity competitor could seek regulatory approval submitting clinical trial data obtain marketing approval manufacturers generic products also increasingly seeking challenge patents expire may cases launch generic product expiration applicable patents andor final resolution patent litigation length market exclusivity companys products impossible predict certainty assurance particular product enjoy market exclusivity full period time appears estimates disclosed discussion generic versions product impact products sales see item businesscompetitiongeneric competition information market exclusivity see item businessproducts item businessintellectual property product exclusivity patent infringement lawsuit apotex inc apotex corp apotex involving plavix ongoing risk generic competition apotex generic pharmaceutical companies although previously disclosed us district court southern district new york district court issued opinion order upholding validity enforceability us patent relating plavix ruled apotexs generic clopidogrel bisulfate product infringed patent enjoined apotex engaging activity infringes patent plavix patent infringement lawsuit still ongoing risk company could face generic competition apotex generic pharmaceutical companies apotex filed notice appeal us court appeals federal circuit apotex prevail appeal district courts decision company could face renewed generic competition plavix apotex promptly thereafter loss market exclusivity plavix andor sustained generic competition would material companys results operations cash flows could material financial condition liquidity possible time reasonably assess outcomes appeal apotex district courts decision plavix patent litigations timing renewed generic competition plavix apotex additional generic competition plavix thirdparty generic pharmaceutical companies company recorded deferred tax assets related us foreign tax credit research tax credit charitable contribution carryforwards charitable contribution carryforwards expire varying amounts beginning foreign tax credit research tax credit carryforwards expire varying amounts beginning realization foreign tax credit research tax credit charitable contribution carryforwards dependent generating sufficient domestic taxable income prior expiration although realization assured management believes likely deferred tax assets realized amount foreign tax credit research tax credit charitable contribution carryforwards considered realizable however could reduced near term plavix subject either renewed additional generic competition events occur company may need record additional valuation allowances us federal deferred tax assets discussion plavix related matters see item financial statementsnote legal proceedings contingencies company may adversely impacted economic factors beyond control may incur additional impairment charges investment portfolio december company million principal invested auction rate securities ars representing interests collateralized debt obligations supported pools residential commercial mortgages credit cards insurance securitizations structured credits including corporate bonds underlying collateral ars held company consists subprime mortgages estimated market value companys ars holdings december million reflects million adjustment principal value million although ars continue pay interest according stated terms based valuation models analysis otherthantemporary impairment factors company recorded impairment charge million fourth quarter reflecting portion ars holdings company concluded otherthantemporary decline value addition company recorded unrealized pretax loss million comprehensive income reduction shareholders equity reflecting million adjustments ars holdings million marketable securities company concluded temporary decline value credit capital markets continued deteriorate uncertainties markets continue markets deteriorate company experiences additional ratings downgrades investments portfolio including ars company may incur additional impairments investment portfolio could negatively affect companys financial condition cash flow reported earnings table contents company also significant operations outside us revenue operations outside us accounted companys revenues company exposed changes fluctuation foreign currency exchange rates information companys foreign currency exchange exposure see item quantitative qualitative disclosures market risk company also significant borrowings exposed changes interest rates december company shortterm borrowings longterm debt billion information companys interest rate exposure see item quantitative qualitative disclosures market risk company also exposed economic factors company control company may experience difficulties delays manufacturing sale products company may experience difficulties delays inherent manufacturing sale seizure recalls pharmaceutical products forced closings manufacturing plants ii failure obtain imposition limitations use loss patent intellectual property rights iii failure company vendors suppliers comply current good manufacturing practices application regulations quality assurance guidelines could lead temporary manufacturing shutdowns product shortages delays product manufacturing iv construction delays related construction new facilities expansion existing facilities including intended support future demand companys biologics products v manufacturing distribution problems including changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced biologics physical limitations could impact continuous supply company may experience difficulties delays development commercialization new products company may experience difficulties delays development commercialization new products including inherent risks uncertainties associated product development compounds products may appear promising development fail reach market within expected optimal timeframe fail ever reach market approved additional indications number reasons including efficacy safety concerns delay denial necessary regulatory approvals difficulty excessive cost manufacture ii failure enter successfully implement optimal alliances appropriate discovery andor commercialization products otherwise maintain consistent scope variety promising latestage products iii failure one companys products achieve maintain commercial viability legal matters adverse outcomes could negatively affect companys business company currently involved various lawsuits claims proceedings government investigations preclude delay commercialization products adversely affect operations profitability liquidity financial condition including intellectual property disputes ii sales marketing practices us internationally iii adverse decisions litigation including product liability commercial cases iv recalls withdrawals pharmaceutical products forced closings manufacturing plants v failure fulfill obligations supply contracts government customers may result liability vi product pricing promotion matters vii lawsuits claims asserting violations securities antitrust federal state pricing laws viii environmental health safety matters ix tax liabilities assurance increase scope matters additional lawsuits claims proceedings investigations future assurance matters material adverse impact company us foreign regulations may negatively affect companys sales profit margins company could become subject new government laws regulations health care reform initiatives us state federal level countries ii changes us food drug administration fda foreign regulatory approval processes may cause delays approving preventing approval new products iii tax changes phasing tax benefits heretofore available us certain foreign countries iv new laws regulations judicial governmental decisions affecting pricing marketing within across jurisdictions v changes intellectual property law vi matters compulsory licenses could alter protections afforded one products company faces increased pricing pressure us abroad managed care organizations institutional purchasers government agencies programs could negatively affect companys sales profit margins pharmaceutical products subject increasing price pressures restrictions us worldwide including rules practices managed care groups institutional governmental purchasers ii judicial decisions governmental laws regulations related medicare medicaid healthcare reform including medicare prescription drug improvement modernization act iii potential impact importation restrictions legislative andor regulatory changes pharmaceutical reimbursement medicare part formularies product pricing general iv developments technology andor industry practices could directly indirectly impact reimbursement policies practices third party payers table contents company relies third parties meet contractual regulatory obligations company relies vendors partners including alliances pharmaceutical companies development commercialization products third parties meet contractual regulatory obligations relation arrangements company failure parties meet obligations andor development significant disagreements factors materially disrupt ongoing commercial relationship prevent optimal alignment partners activities could material adverse impact company failure execute companys business strategy could adversely impact growth profitability part strategy company currently implementing comprehensive cost reduction program includes workforce reductions areas rationalization facilities company expects incur restructuring charges connection program range billion billion pretax basis next three years million charges incurred fourth quarter approximately million charges expected incurred company may able fully execute strategic transformation business attain new period sustainable revenue earnings growth company continues invest key products pipeline part focus addressing areas significant unmet medical need failure realize expected cost savings achieve maintain competitive cost base successfully transition product portfolio however could materially adversely affect companys results operations addition companys failure hire retain personnel right expertise experience operations critical business functions could adversely impact execution business strategy changes companys structure operations revenues costs efficiency resulting acquisitions divestitures mergers alliances restructurings strategic initiatives could result greater expected costs difficulties including need regulatory approvals appropriate company increasingly dependent information technology outsourcing arrangements company increasingly dependent information technology systems significant breakdown invasion destruction interruption systems could negatively impact operations company also increasing dependence thirdparty providers certain services including information technology systems failure service providers meet obligations andor development significant disagreements factors materially disrupt companys ongoing relationship providers could negatively affect operations table contents item b unresolved staff comments none item properties companys world headquarters located park avenue new york ny leases approximately square feet floor space approximately square feet sublet others company manufactures products major worldwide locations aggregate floor space approximately million square feet facilities owned company following table illustrates geographic location companys significant manufacturing facilities business segment total company pharmaceuticals nutritionals convatec united states europe middle east africa western hemisphere pacific total portions facilities facilities owned leased company us elsewhere used research administration storage distribution information companys facilities see item businessmanufacturing quality assurance item legal proceedings information pertaining legal proceedings found item financial statementsnote legal proceedings contingencies incorporated reference herein item submission matters vote security holders matters submitted vote security holders fourth quarter year ended december table contents part ia executive officers registrant listed information executive officers company february executive officers elected board directors initial term continues first board meeting following next annual meeting stockholders thereafter elected oneyear term successors elected executive officers serve pleasure board directors name current position age employment history past years james cornelius chief executive officer chairman board guidant chairman board chief executive officer corporation member management council interim chief executive officer chairman board guidant corporation interim chief executive officer director company chief executive officer director company present chairman board chief executive officer company lamberto andreotti senior vice president president international executive vice president president worldwide medicines group division company worldwide pharmaceuticals present executive vice president president worldwide member management council pharmaceuticals division company stephen e bear present senior vice president human resources corporate staff senior vice president human resources company corporate staff member management council andrew r j bonfield present chief financial officer corporate staff company executive vice president chief financial officer corporate staff member management council joseph c caldarella vice president finance pharmaceutical research institute vice president corporate controller division company corporate staff present vice president corporate controller corporate staff company john e celentano president latin america canada worldwide medicines president health care group group division company member management council present president health care group division company anthony c hooper president europe middle east africa worldwide president us pharmaceuticals medicines group division company member management council present president us pharmaceuticals worldwide medicines group division company sandra leung vice president corporate secretary corporate staff senior vice president general counsel company corporate staff vice president corporate secretary acting general member management council counsel corporate staff company present senior vice president general counsel corporate staff company table contents elliott sigal md phd senior vice president global clinical pharmaceutical executive vice president chief scientific officer development pharmaceutical research institute division president pharmaceutical research development company member management council present chief scientific officer president pharmaceutical research development division company robert zito executive vice president communications new york stock senior vice president corporate business exchange communications chief communications officer present senior vice president corporate affairs corporate staff member management council company table contents part ii item market registrants common stock stockholder matters market prices bristolmyers squibb common preferred stocks traded new york stock exchange nyse traded nyse arca inc formerly pacific exchange inc symbols bmy bmypr december company voluntarily withdrew securities listing nyse arca inc quarterly summary high low market prices presented common high low high low first quarter second quarter third quarter fourth quarter preferred high low high low first quarter second quarter third quarter fourth quarter second quarter trades companys preferred stock preferred stock pays quarterly dividend per share holders common stock number record holders common stock december number record holders based upon actual number holders registered books company date include holders shares street names persons partnerships associations corporations entities identified security position listings maintained depository trust companies voting securities principal holders reference made proxy statement filed march respect voting securities principal holders incorporated herein reference made part hereof response information required item table contents dividends board directors company declared following dividends per share paid quarters indicated common preferred first quarter second quarter third quarter fourth quarter december board directors company declared quarterly dividend per share common stock company per share preferred stock company paid february shareholders record january unregistered sales equity securities use proceeds following table summarizes surrenders companys equity securities connection stock option restricted stock programs month period ended december total number approximate dollar total number shares purchased value shares average price part publicly may yet shares paid per announced plans purchased period purchaseda sharea programsb plans programsb dollars millions except per share data january february march three months ended march april may june three months ended june july august september three months ended september october november december three months ended december twelve months ended december reflects following transactions months ended december surrender company shares common stock pay exercise price satisfy tax withholding obligations connection exercise employee stock options ii surrender company shares common stock satisfy tax withholding obligations connection vesting restricted stock issued employees b june company announced board directors authorized purchase billion company common stock months ended december shares repurchased pursuant program purchases shares program expected table contents performance graph following performance graph compares performance bristolmyers squibb periods indicated performance standard poors stock index sp average performance group consisting peer corporations lineofbusiness basis corporations making peer companies group abbott laboratories astrazeneca plc eli lilly company glaxosmithkline plc johnson johnson merck co inc novartis ag pfizer inc sanofiaventis including performance aventis prior merger sanofi scheringplough corporation wyeth total return indices reflect reinvested dividends weighted using beginningperiod market capitalization reported time periods measured performance group proxy statement comparison fiveyear cumulative total return bristolmyers squibb sp index peer group assumes invested bristolmyers squibb common stock sp index peer companies group index values december specified year assuming dividends reinvested table contents item selected financial data fiveyear financial summary amounts millions except per share data income statement data net sales earning continuing operations minority interest income taxes net earnings continuing operations net earnings continuing operations per common share basic diluted average common shares outstanding basic diluted dividends paid common preferred stock dividends declared per common share financial position data december total assets cash cash equivalents marketable securities longterm debt stockholders equity company recorded items affected comparability results discussion items years see item managements discussion analysis financial condition results operationsexpenses item financial statementsnote alliances investments note restructuring note acquisitions divestitures note discontinued operations assets held sale note cash cash equivalents marketable securities note shortterm borrowings longterm debt note legal proceedings contingencies excludes discontinued operations medical imaging years oncology therapeutics network years million weightedaverage shares issuable well million million respectively interest expense net tax assumed conversion convertible debt included diluted earnings per share calculation antidilutive includes impact adoption statement financial accounting standard sfas employers accounting defined benefit pension postretirement plansan amendment fasb statements r discussion sfas see item financial statementsnote pension postretirement benefits includes medical imaging assets classified held sale table contents item managements discussion analysis financial condition results operations executive summary company bristolmyers squibb company bms company bristolmyers squibb global biopharmaceutical related health care products company whose mission extend enhance human life providing highest quality pharmaceutical related health care products company engaged discovery development licensing manufacturing marketing distribution sale pharmaceuticals related health care products company three reportable segmentspharmaceuticals nutritionals convatec pharmaceuticals segment consists global pharmaceuticalbiotechnology international consumer medicines business accounted approximately companys net sales nutritionals segment consists mead johnson nutritionals mead johnson primarily infant formula childrens nutritionals business accounted approximately companys net sales convatec segment consists ostomy wound skin care business accounted approximately companys net sales previously included health care operating segment january company completed sale medical imaging business avista capital partners lp avista results medical imaging business previously included former health care operating segment presented part companys results discontinued operations financial highlights worldwide net sales continuing operations increased billion compared plavix clopidogrel bisulfate sales grew primarily reflecting adverse impact generic competition august mid well strong underlying sales growth key products within companys pharmaceuticals segment including avaproavalide irbesartanirbesartanhydrochlorothiazide reyataz atazanavir sulfate sustiva efavirenz franchise abilify aripiprazole experienced double digit sales growth year sales companys newer specialty biologics medicines baraclude entecavir orencia abatacept sprycel dasatinib continue strong addition company launched ixempra ixabepilone treatment metastatic locally advanced breast cancer overall worldwide sales growth however moderated significant decline pravachol pravastatin sodium sales due generic competition net earnings continuing operations billion compared billion results include million charge acquired inprocess research development related purchase adnexus therapeutics inc adnexus million charge connection companys threeyear productivity transformation initiative pti million impairment charge companys investment certain auction rate securities ars results include million increase reserves pricing sales litigation settlement million early debt retirement costs additionally company also recorded gains sale product assets properties million million respectively december company announced board directors board declared percent dividend increase first increase since dividend increase result quarterly dividend thirtyone cents per share companys common stock indicative dividend full year per share subject normal quarterly review board business environment company conducts business primarily within pharmaceuticalbiotechnology industry highly competitive subject numerous government regulations many competitive factors may significantly affect companys sales products including product efficacy safety price cost effectiveness marketing effectiveness product labeling quality control quality assurance manufacturing operations research development new products successfully compete business health care industry company must demonstrate products offer medical benefits well cost advantages currently companys new product introductions compete products already market therapeutic category addition potential competition new products competitors may introduce future company manufactures branded products priced higher generic products generic competition one companys leading challenges globally pharmaceuticalbiotechnology industry majority innovative products commercial value usually realized period product market exclusivity product loses exclusivity longer protected patent table contents subject new competing products form generic brands upon exclusivity loss company lose major portion products sales short period time currently generic versions biological products approved us law however law could change future even absence new legislation us food drug administration fda taking steps toward allowing generic versions certain biologics competitors seeking approval biological products must file safety efficacy data address challenges biologics manufacturing involves complex processes costly traditional pharmaceutical operations us internationally health care industry subject various governmentimposed regulations authorize prices price controls continue impact companys sales us congress state legislatures considered number proposals enacted laws could effect major changes health care system either nationally state level driven part budget concerns medicaid access reimbursement restrictions implemented states proposed many others addition medicare prescription drug improvement modernization act provides outpatient prescription drug coverage senior citizens us legislation modest favorable impact company result increase number seniors drug coverage continues potential negative impact us pharmaceutical business could result pricing pressures controls many markets outside us company operates environments governmentmandated costcontainment programs regulatory bodies groups exert downward pressure pricing pricing freedom limited united kingdom uk instance operation profit control plan germany operation reference price system companies also face significant delays market access new products two years elapse drug approval new medicines become available national markets growth managed care organizations mcos us played large role competition surrounds health care industry mcos seek reduce health care expenditures participants making volume purchases entering longterm contracts negotiate discounts various pharmaceutical providers market potential created large pool participants marketing prescription drugs mcos become important part companys strategy companies compete inclusion mco formulary company generally successful major products included company believes developments managed care industry including continued consolidation continue generally downward pressure prices pharmaceuticalbiotechnology production processes complex highly regulated vary widely product product shifting adding manufacturing capacity lengthy process requiring significant capital expenditures regulatory approvals biologics manufacturing involves complex processes traditional pharmaceutical operations biologics become important companys product portfolio company continue make arrangements thirdparty manufacturers make substantial investments increase internal capacity produce biologics commercial scale one investment building new stateoftheart manufacturing facility production biologics devens massachusetts construction began may company maintained competitive position market strives uphold position dependent success discovering developing innovative costeffective products serve unmet medical need recently several companys competitors announced cost reduction programs effort reduce respective cost bases increase productivity competitiveness company also announced threeyear pti reduce costs streamline operations rationalize global manufacturing part efforts become productive competitive biopharmaceutical company company subsidiaries subject number significant pending lawsuits claims proceedings investigations possible time reasonably assess final outcome investigations litigations additional discussion legal matters see item financial statementsnote legal proceedings contingencies strategy december company outlined multiyear strategy designed transform company nextgeneration biopharmaceutical company strategy encompasses aspects geographies business yield substantial cost savings cost avoidance increase companys financial flexibility take advantage attractive market opportunities may arise company develops nextgeneration biopharmaceutical company continue invest key growth products including specialty biologic medicines cardiovascular metabolic drugs company continues execute ongoing strategy longterm growth scale back assets profitable though declining mature brands increased focus table contents key new growth products include plavix abilify avaproavalide reyataz sustiva franchise erbitux cetuximab orencia baraclude sprycel ixempra company experienced last series major anticipated exclusivity losses expect significant new exclusivity losses next several years order support production specialty products pharmaceutical portfolio including biologics company completed land purchase acre site locate new largescale expandable multiproject bulk biologics manufacturing facility devens massachusetts company committed million fund construction facility began may facility projected operationally complete company plans submit site regulatory approval commercial production biologic compounds anticipated begin addition company expanded manati puerto rico facility expansion targeted startup new stateoftheart facility well expanded manati puerto rico facility support filling finishing companys sterile products biologic compounds including orencia companys first internally discovered developed biologic medicine commercial quantities compounds currently development compounds receive regulatory approval keeping strategy company invested billion research development representing growth rate research development dedicated pharmaceutical products including milestone payments inlicensing development programs billion compared billion consistent companys objective maximize value nonpharmaceutical businesses january company completed sale medical imaging business avista company continue seek opportunities maximize value remaining health care group businesses transitions nextgeneration biopharmaceutical company company seeks reallocate resources enable strategic acquisitions acquisition adnexus october well pursue partnerships collaborative arrangements worldwide alliance astrazeneca plc astrazeneca discover develop commercialize saxagliptin dapagliflozin two separate agreements pfizer inc pfizer research development commercialization pfizer discovery program development commercialization apixaban productivity transformation initiative company undertook broad range actions fourth quarter part previously announced threeyear pti reducing costs streamlining operations rationalizing global manufacturing initiative track achieve billion annual cost savings cost avoidance pretax basis central companys strategy become nimble flexible next generation biopharmaceutical enterprise key productivity initiatives include reducing general administrative operations simplifying standardizing outsourcing appropriate processes services rationalizing companys mature brands portfolio consolidating global manufacturing network eliminating complexity enhancing profitability simplifying geographic footprint implementing efficient gotomarket model specific productivity goals include reducing number brands companys mature products portfolio percent reducing number manufacturing facilities percent end reducing total headcount approximately percent positions eliminated although substantial majority positions eliminated among many productivity activities across entire organization fourth quarter impending closure several manufacturing facilities including mayaguez puerto rico barceloneta puerto rico costs associated implementation pti estimated billion billion pretax basis million incurred approximately million expected incurred ultimate timing recording charges predicted certainty affected occurrence triggering events expense recognition us generally accepted accounting principles gaap among factors table contents new product pipeline developments december company medarex inc medarex announced topline data three registrational trials constitute monotherapy program ipilimumab patients metastatic melanoma results study conducted special protocol assessment meet primary endpoint rule best objective response rate less percent however totality data registrational program included clear dose response effect observed study best objective response rates across three studies ranging midsingle digits midteens determined independent radiology review receipt additional data ongoing clinical trials companies plan meet fda discuss regulatory pathway goal submitting regulatory filing middle supported data november company pierre fabre medicament sa pierre fabre announced termination license agreement development vinflunine chemotherapy agent investigation treatment advanced metastatic bladder cancer tumor types november abilify approved fda adjunctive addon treatment antidepressant therapy adults major depressive disorder mdd abilify first medication approved fda addon treatment mdd fda also approved abilify treatment schizophrenia adolescent patients ages accepted priority review supplemental new drug application snda treatment pediatric patients ages bipolar disorder update sprycel label include lower recommended starting dose mg daily mg twice daily starting dose patients chronicphase chronic myeloid leukemia resistant intolerant imatinib approved fda november european commission august first quarter sprycel received approval andor reimbursement additional european markets including ireland norway sweden greece also approved canada new zealand october atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg approved canada first oncedaily singletablet regimen treatment human immunodeficiency virus infection adults december european commission granted marketing authorization atripla formally approving commercialization countries european union eu well norway iceland atripla launched uk germany austria october company launched ixempra treatment patients metastatic locally advanced breast cancer us addition japanese new drug application ixabepilone submitted december marketing authorization application ixabepilone review european medicines evaluation agency emea following submission september october company acquired privatelyheld adnexus developer new therapeutic class biologics called adnectins adnectins proprietary class targeted biologics based naturally occurring protein found human serum october company imclone systems incorporated imclone announced fda approved update erbitux product labeling include overall survival data single agent epidermal growth factor inhibitor egfrexpressing metastatic colorectal cancer mcrc patients failure irinotecan oxaliplatinbased regiments september company imclone announced phase iii study erbitux combination platinumbased chemotherapy conducted merck kgaa met primary endpoint increasing overall survival compared chemotherapy alone patients advanced nonsmall cell lung cancer previously disclosed earlier study conducted imclone company evaluating use erbitux combination different platinumbased therapy meet primary endpoint increasing progressionfree survival patients advanced nonsmall cell lung cancer key secondary endpoints study however statistically significant favored erbituxcontaining arm september fda approved snda single mg tablet plavix mg loading dose proven effective broad acute coronary syndrome patient population mg tablet clopidogrel bisulfate launched us december currently emea reviewin august company pfizer finalized collaborative agreement research development commercialization pfizer discovery program includes advanced preclinical compounds potential applications treatment metabolic disorders including obesity diabetes company recorded upfront charge million accordance terms agreement pfizer responsible research earlystage development activities metabolic disorders program companies jointly conduct phase iii development commercialization activities companies share development commercialization expenses along profitslosses basis pfizer assuming larger share expenses profitslosses table contents august fda accepted filing review supplemental biologics license application orencia treatment pediatric patients juvenile idiopathic arthritis orencia approved european commission may received approval andor reimbursement several european markets including uk germany austria sweden netherlands denmark april fda approved update orencia product labeling regarding progression structural joint damage important measure treatment rheumatoid arthritis ra indication strengthened slowing inhibiting progression structural damage adult patients moderately severely active ra inadequate response one diseasemodifying antirheumatic drugs methotrexate tumor necrosis factor antagonists july company imclone amended terms agreement codevelopment copromotion erbitux north america amendment companies jointly agreed expand investment ongoing clinical development plan erbitux development costs threshold value sole responsibility company costs excess threshold shared companies according predetermined ratio additional funding companies intend explore use erbitux additional tumor types including brain breast bladder gastric lung pancreas prostate may company isis pharmaceuticals inc isis entered collaborative agreement discover develop commercialize novel antisense drugs targeting proprotein convertase subtilisin kexin prevention treatment cardiovascular disease company made upfront payment million isis part agreement provide isis least million research funding period three years april company pfizer entered worldwide collaboration develop commercialize apixaban anticoagulant discovered company studied prevention treatment broad range venous arterial thrombotic conditions accordance terms agreement pfizer made upfront payments million million company may december respectively pfizer fund development costs effective january going forward company fund company may also receive additional payments million pfizer based development regulatory milestones companies jointly develop clinical marketing strategy apixaban share commercialization expenses profitslosses equally global basis february baraclude added american association study liver disease treatment guidelines hepatitis b firstline treatment option baraclude also received approval andor reimbursement additional european markets including italy throughout first quarter january company entered two worldwide except japan codevelopment cocommercialization agreements astrazeneca develop commercialize two investigational compounds studied treatment type diabetes company received upfront payments million astrazeneca addition company receive milestone payments astrazeneca upon successful achievement various regulatory sales related stages companies agreed upon initial development plans two compounds majority development costs paid astrazeneca subsequent development costs generally shared equally july companies decided move investigational compound dapagliflozin selective inhibitor sodiumglucose transporter studied treatment diabetes phase iii testing based results phase ii clinical trials december company entered collaboration agreement exelixis pharmaceuticals inc exelixis discover develop commercialize novel targeted therapies treatment cancer agreement became effective january accordance terms agreement company made upfront payment million exelixis january company exercised option develop commercialize compounds targeting one therapeutic target paid exelixis million february exelixis also eligible receive million two additional investigational drug candidates selected company option exelixis companies share equally development costs along commercial profits us otherwise company responsible development pay development milestones royalties exelixis table contents results operations following discussions companys results continuing operations exclude results related medical imaging business previously presented component former health care operating segment prior divestiture january oncology therapeutics network otn business previously presented separate operating segment prior divestiture businesses segregated continuing operations reflected discontinued operations periods presented see discontinued operations companys results operations follows change dollars millions vs vs net sales earnings continuing operations minority interest income taxes net sales provision income taxes effective tax rate net earnings continuing operations net sales net sales net sales continuing operations increased billion including favorable foreign exchange impact compared us net sales increased billion compared international net sales increased billion compared including favorable foreign exchange impact net sales continuing operations decreased billion compared us net sales decreased billion compared international net sales decreased billion compared composition change net sales follows analysis change total change volume price foreign exchange vs vs general companys business seasonal information us pharmaceutical prescriber demand reference made table within business segments pharmaceuticals section sets forth comparison changes net sales estimated total prescription growth retail mail order customers certain companys key pharmaceutical products new products sold us pharmaceuticals business company operates three reportable segmentspharmaceuticals nutritionals convatec previously component health care operating segment january company completed sale avista medical imaging business previously presented component health care operating segment may company completed sale otn previously presented separate operating segment results operations medical imaging otn presented part companys results discontinued operations accordance statement financial standards sfas accounting impairment disposal longlived assets accordingly medical imaging otn results operations prior periods reclassified discontinued operations conform current year presentations table contents companys net sales segment follows net sales change dollars millions vs vs pharmaceuticals net sales nutritionals net sales convatec net sales health care group total company recognizes revenue net various sales adjustments arrive net sales reported consolidated statement earnings adjustments referred grosstonet sales adjustments described critical accounting policies reconciliations companys gross sales net sales significant category grosstonet sales adjustments follows years ended december dollars millions gross sales grosstonet sales adjustments prime vendor chargebacks women infants children wic rebates managed health care rebates contract discounts medicaid rebates cash discounts sales returns adjustments total grosstonet sales adjustments net sales slight decrease grosstonet sales adjustments compared affected number factors sales returns decreased primarily due higher accruals cardiovascular nonexclusive brands discontinued commercialization tequin gatifloxacin decrease prime vendor chargebacks primarily due lower sales taxol paclitaxel result loss exclusivity partially offset increases managed health care rebates contract discounts primarily result higher plavix sales reversal reserves related tricare retail pharmacy refund program partially offset lower sales pravachol due loss exclusivity additionally increase cash discounts primarily due higher plavix sales volumes decrease grosstonet sales adjustments compared affected number factors including changes customer mix portfolio shift case towards products required lower rebates well changes contract status decrease prime vendor chargebacks primarily result lower plavix net sales volume erosion highlyrebated paraplatin carboplatin taxol paclitaxel due generic competition well impact discontinued commercialization tequin managed health care rebates contract discounts decreased primarily result reversal reserves related tricare retail pharmacy refund program well exclusivity loss pravachol also reduced medicaid rebates addition lower plavix net sales shift patient enrollment medicaid medicare medicare part resulted decrease medicaid rebates partially offset corresponding increase managed health care rebates decrease cash discounts primarily due lower sales pravachol due loss exclusivity lower plavix sales volumes increase sales returns primarily due higher returns trends nonexclusive brands well discontinued commercialization tequin table contents activities ending balances significant category grosstonet sales adjustments follows managed health care women rebates infants prime vendor children contract medicaid cash sales dollars millions chargebacks wic rebates discounts rebates discounts returns adjustments total balance january provision related sales made current period provision related sales made prior periods returns payments impact foreign currency translation discontinued operations balance december provision related sales made current period provision related sales made prior periods returns payments impact foreign currency translation discontinued operations balance december company recorded grosstonet sales adjustments related sales made prior periods significant items included charges sales returns million primarily related higher expected returns certain nonexclusive products company recorded grosstonet sales adjustments related sales made prior periods significant items included charges sales returns million primarily related higher expected return trends certain nonexclusive products well discontinued commercialization tequin credits contract discounts million primarily due reversal reserves related tricare retail pharmacy refund program significant revisions made estimates grosstonet sales adjustments pharmaceuticals composition change pharmaceutical sales follows analysis change foreign total change volume price exchange vs vs worldwide pharmaceuticals sales increased million including favorable foreign exchange impact compared period us pharmaceuticals sales increased million million primarily due increased plavix sales reflecting adverse impact generic competition august mid well strong underlying sales growth sales growth also attributed increased sales abilify sustiva franchise reyataz avaproavalide erbitux sales newer products sprycel orencia baraclude ixempra increase partially offset increased generic competition pravachol international pharmaceuticals sales increased including favorable foreign exchange impact million million excluding impact foreign exchange decrease sales primarily due increased generic competition pravachol taxol paclitaxel partially offset sales growth abilify reyataz plavix avaproavalide newer products baraclude sprycel worldwide pharmaceuticals sales decreased million us pharmaceuticals sales decreased million million primarily due lower sales plavix resulting launch generic clopidogrel bisulfate august loss exclusivity pravachol partially offset continued growth abilify erbitux reyataz sustiva franchise avaproavalide sales newer products including orencia table contents baraclude sprycel international pharmaceuticals sales decreased million million primarily due decline pravachol taxol paclitaxel sales resulting increased generic competition europe partially offset increased sales newer products including reyataz abilify baraclude key pharmaceutical products sales representing total pharmaceutical sales respectively follows change dollars millions vs vs cardiovascular plavix avaproavalide pravachol coumadin virology reyataz sustiva franchise total revenue baraclude oncology erbitux taxol paclitaxel sprycel ixempra affective psychiatric disorders abilify total revenue immunoscience orencia pharmaceuticals efferalgan change excess sales plavix platelet aggregation inhibitor part companys alliance sanofi increased including favorable foreign exchange impact million million us sales increased million million company estimates adverse effect generic clopidogrel bisulfate launched august range billion billion company estimates negative impact generic clopidogrel bisulfate range million million inventory generic clopidogrel bisulfate distribution channels substantially depleted june estimated total us prescription demand clopidogrel bisulfate branded generic increased approximately compared estimated total us prescription demand branded plavix increased period sales decreased million million us sales decreased million million market exclusivity plavix expected expire us major european markets composition matter patent plavix subject litigation data exclusivity plavix expires july eu key composition matter patent expires majority eu member countries additional information plavix litigations see item financial statementsnote legal proceedings contingencies sales avaproavalide angiotensin ii receptor blocker treatment hypertension also part sanofi alliance increased including favorable foreign exchange impact million million us sales increased million million primarily due higher average net selling prices estimated total us prescription demand decreased approximately compared international sales increased including favorable foreign exchange impact million million sales increased including favorable foreign exchange impact million million us sales increased million million international sales increased including favorable foreign exchange impact million million market exclusivity avaproavalide known eu aprovelkarvea expected expire including pediatric extension us countries eu company others market avaproavalide japan sales pravachol hmg coa reductase inhibitor decreased including favorable foreign exchange impact million million due increased generic competition us key european markets estimated total us prescription demand decreased approximately compared sales decreased table contents million million due market exclusivity expiration april resulting generic competition strengths us generic competition key european markets market exclusivity eu ended exception sweden expiration occurred march italy expiration occurred january france generic competition authorized company commenced july previously disclosed company authorized watson pharmaceutical distribute pravastatin sodium tablets us sales coumadin oral anticoagulant used predominantly patients atrial fibrillation deep venous thrombosispulmonary embolism decreased including favorable foreign exchange impact million million primarily due lower demand driven continued competition partially offset higher average net selling prices estimated total us prescription demand decreased approximately compared sales increased million million primarily due higher average net selling prices partially offset lower demand driven continued competition market exclusivity coumadin expired us sales reyataz protease inhibitor treatment hiv increased including favorable foreign exchange impact million million primarily due increased demand majority markets us sales increased million million primarily due higher demand estimated total us prescription demand increased approximately compared international sales increased including favorable foreign exchange impact million million sales increased million million primarily due increased demand us europe latin america market exclusivity reyataz expected expire us countries eu japan data exclusivity eu expires total revenue sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv increased including favorable foreign exchange impact million million us sales increased million million primarily due higher demand resulting successful launch atripla july estimated total us prescription demand sustiva franchise increased approximately compared international sales increased including favorable foreign exchange impact million million primarily due higher demand across markets july company gilead sciences inc gilead launched atripla oncedaily single tablet threedrug regimen hiv intended standalone therapy combination antiretrovirals total revenue sustiva franchise includes sales sustiva well revenue bulk efavirenz included combination therapy atripla company records revenue bulk efavirenz component atripla upon sales atripla joint venture gilead thirdparty customers sales increased million million due higher demand launch atripla third quarter market exclusivity sustiva expected expire us countries eu company others market sustiva japan additional information revenue recognition sustiva franchise see item financial statementsnote alliances investments sales baraclude oral antiviral agent treatment chronic hepatitis b increased million million due continued growth across markets including us china japan korea sales increased million million baraclude launched us april china february uk germany july france japan september company composition matter patent expires us eu japan previously disclosed uncertainty chinas exclusivity laws due uncertainty possible one companies china could receive marketing authorization chinas health authority sales erbitux sold company almost exclusively us increased million million primarily due increased demand usage treatment head neck cancer transition broader distribution model sales increased million million erbitux marketed company distribution copromotion agreement imclone use patent relating combination therapy cytotoxic treatments expires patent covering monotherapy currently generic versions biological products approved us law however law could change future even absence new legislation fda taking steps toward allowing generic versions certain biologics competitors seeking approval biological products must file safety efficacy data address challenges biologics manufacturing involves complex processes costly traditional pharmaceutical operations companys right market erbitux north america japan agreement imclone expires september company others market erbitux countries eu previously disclosed imclone yeda research development company ltd yeda litigation ownership use patent combination therapy cytotoxic treatments relating erbitux september district court granted yeda complete ownership patent pursuant settlement agreement executed imclone sanofi yeda announced december end worldwide litigation related use patent settlement agreement change imclones worldwide royalty rate erbitux sales commercial agreement imclone company pays royalty imclone sales erbitux impacted settlement agreement information pertaining legal proceedings involving erbitux see item financial statementsnote legal proceedings contingencies note alliances investments table contents sales taxol paclitaxel anticancer agent sold almost exclusively nonus markets decreased including favorable foreign exchange impact million million primarily due increased generic competition europe japan sales decreased including unfavorable foreign exchange impact million million primarily due increased generic competition europe generic entry japan third quarter market exclusivity protection taxol paclitaxel expired us countries eu two generic paclitaxel products received regulatory approval japan entered market sales sprycel oral inhibitor multiple tyrosine kinases treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib meslylate increased million million sprycel launched us july certain european markets beginning fourth quarter market exclusivity sprycel expected expire us several eu countries patent pending granted would expire sales ixempra microtubule inhibitor treatment patients metastatic locally advanced breast cancer million ixempra launched us october company composition matter patent us corresponding patent eu countries expiring company submitted request patent term extension composition matter patent us could possibly extent term patent corresponding patent eu countries may eligible patent term restoration could possibly extend term patent eu countries total revenue abilify antipsychotic agent treatment schizophrenia acute bipolar mania bipolar disorder increased including favorable foreign exchange impact million million us sales increased million million primarily due higher demand higher average net selling prices estimated total us prescription demand increased approximately compared sales increased million million primarily due higher demand higher average net selling prices total revenue abilify primarily consists alliance revenue representing companys share net sales countries copromotes otsuka pharmaceutical co ltd otsuka product sold otsuka affiliate distributor otsukas market exclusivity protection abilify expected expire us including granted patent term extension information patent litigations relating abilify see item financial statementsnote legal proceedings contingencies company also right copromote abilify several european countries uk france germany spain act exclusive distributor product rest eu composition matter patent force germany uk france italy netherlands romania sweden switzerland spain denmark original expiration date extended grant supplemental protection certificate countries except romania denmark data exclusivity eu expires companys contractual right market abilify expires november us puerto rico countries eu company exclusive right market abilify june additional information revenue recognition abilify see item financial statementsnote alliances investments sales orencia fusion protein indicated adult patients moderate severe ra inadequate response one currently available treatments methotrexate antitumor necrosis factor therapy increased including favorable foreign exchange impact million million primarily due demand substantially sales orencia currently us launched february orencia launched europe may company submitted request patent term extension one composition matter patents expires could possibly extend term patent noted generic versions biological products approved us law law could change future sales efferalgan paracetamol formulation acetaminophen pain relief sold principally europe increased including favorable foreign exchange impact million million primarily due severe flu season sales decreased million million primarily due change government reimbursement instances basic exclusivity loss date indicated expiration date patent claims active ingredient drug method using drug approved indication instances basic exclusivity loss date indicated expiration date data exclusivity period situations data exclusivity without patent protection competitor could seek regulatory approval prior expiration data exclusivity period submitting clinical trial data obtain marketing approval company assesses market exclusivity period products case bycase basis length market exclusivity companys products difficult predict certainty complex interaction patent regulatory forms exclusivity factors assurance table contents particular product enjoy market exclusivity full period time company currently anticipates estimates market exclusivities reported business planning purposes intended reflect companys legal opinion regarding strength weakness particular patent legal position estimated us prescription change data provided includes information retail mail order channels reflect information channels hospitals institutions longterm care among others estimated prescription data based nextgeneration prescription service ngps version provided ims health ims supplier market research pharmaceutical industry described company calculated estimated total us prescription change based ngps version data weightedaverage basis reflect fact mail order prescriptions include greater volume product supplied compared retail prescriptions mail order prescriptions typically reflect day prescription whereas retail prescriptions typically reflect day prescription calculation derived multiplying ngps mail order prescription data factor approximates three adding ngps retail prescriptions company believes calculation estimated total us prescription change based weightedaverage approach respect retail mail order channels provides superior estimate total prescription demand company uses methodology internal demand forecasts table contents estimated enduser demand following tables set forth companys key pharmaceutical products sold us pharmaceuticals business years ended december total us net sales period ii change reported us net sales period iii estimated total us prescription change retail mail order channels calculated company based ngps version weightedaverage basis iv months inventory hand distribution channel prior year prescription data adjusted conform ngps version data year ended december december change us change us months dollars millions total us net sales net salesa total prescriptions b hand plavix avaproavalide pravachol coumadin reyataz sustiva franchise c total revenue baraclude erbitux e na sprycel f ixemprae g na abilify total revenue orencia e h na year ended december december change us change us months dollars millions total us net sales net sales total prescriptions b hand plavix avaproavalide pravachol coumadin reyataz sustiva franchise c total revenue baraclude erbitux e na sprycel f ixemprae g na abilify total revenue orencia e h na table contents year ended december december total us change us change us months dollars millions net sales net sales total prescriptions b hand plavix avaproavalide pravachol coumadin reyataz sustiva franchise c total revenue baraclude erbitux e na sprycel f ixemprae g na abilify total revenue orencia e h na reflects percentage change net sales dollar terms including change average selling prices wholesaler buying patterns b derived multiplying ngps mail order prescription data factor approximates three adding ngps retail prescriptions c beginning third quarter sustiva franchise total revenue includes sales sustiva well revenue bulk efavirenz included combination therapy atripla change us total prescriptions growth sustiva franchise includes branded sustiva atripla prescription units baraclude launched us april e erbitux orencia ixempra parenterally administered products prescriptionlevel data physicians write prescriptions products f sprycel launched us july g ixempra launched us october h orencia launched us february change excess estimated prescription change data reported throughout annual report include information retail mail order channels reflect information channels hospitals institutions longterm care among others data provided ims product ims recordkeeping processes estimates based ims sampling procedures subject inherent limitations estimates based sampling margin error company continuously seeks improve quality estimates prescription change amounts ultimate patientconsumer demand review methodologies processes calculation estimates review analysis third parties data used calculations company expects continue review refine methodologies processes calculation estimates continue review analyze third parties data used calculations pursuant us securities exchange commission sec consent order described sec consent order company monitors level inventory hand us wholesaler distribution channel outside us direct customer distribution channel company obligated disclose products levels inventory excess one month hand expected demand subject de minimis exception following products estimated levels inventory distribution channel excess one month hand case companys us pharmaceuticals products december case companys international pharmaceuticals nutritionals convatec products december andor september december kenalog approximately months inventory hand us wholesaler distribution channel estimated value kenalog inventory us wholesaler distribution channel one month hand approximately million december increased level inventory hand december due volatile demand product fourth quarter result temporary product supply shortage company expects work wholesaler inventory levels one month hand less first quarter table contents december dafalgan analgesic product sold principally europe approximately months inventory hand direct customers compared approximately months inventory hand september increased level inventory hand due primarily private pharmacists purchasing dafalgan approximately every eight weeks seasonality product december monopril cardiovascular product approximately months inventory hand direct customers compared months inventory hand september increased level inventory hand december due primarily initial stocking new exclusive distributor poland stocking support launch monopril poland december videxvidex ec antiviral product approximately months inventory hand direct customers compared months inventory hand september increased level inventory hand due primarily government purchasing patterns brazil company contractually obligated provide videxvidex ec brazilian government upon placement order product government terms contract company control inventory levels relating orders december ostomy business approximately months inventory hand direct customers compared months inventory hand september increased level inventory due primarily increased purchases significant wholesaler anticipation price increase us products sold exclusively wholesalers distributors company determines months hand estimates using information respect inventory levels product hand amount outmovement products provided companys three largest wholesalers accounted approximately total gross sales us pharmaceuticals products provided companys distributors factors may influence companys estimates include generic competition seasonality products wholesaler purchases light increases wholesaler list prices new product launches new warehouse openings wholesalers new customer stockings wholesalers addition estimates calculated using thirdparty data represent recordkeeping processes may also reflect estimates pharmaceutical products us sold exclusively wholesalers distributors companys pharmaceuticals business outside us nutritionals convatec business units around world company significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely cases direct customer product level inventory ultimate patientconsumer demand outmovement data exist otherwise available company developed variety methodologies calculate estimates data including using factors historical sales made direct customers thirdparty market research data related prescription trends enduser demand accordingly company relies variety methods estimate direct customer product level inventory calculate months hand business units factors may affect companys estimates include generic competition seasonality products direct customer purchases light price increases new product product presentation launches new warehouse openings direct customers new customer stockings direct customers expected direct customer purchases governmental bidding situations health care group health care group consists nutritionals convatec operating segments nutritionals operating segment consists mead johnson nutritionals primarily infant formula childrens nutritionals business convatec operating segment consists ostomy wound skin care business following discussions exclude sales related medical imaging business discontinued operation previously included component former health care segment combined revenues health care group increased million combined revenues health care group increased million million table contents nutritionals composition change nutritionals sales follows analysis change total change volume price foreign exchange vs vs key nutritionals product lines sales representing total nutritional sales respectively follows change dollars millions vs vs infant formulas enfamil toddlerchildrens nutritionals enfagrow worldwide nutritionals sales increased including favorable foreign exchange impact million worldwide nutritionals sales million increase including favorable foreign exchange impact million international nutritionals sales increased including favorable foreign exchange impact million primarily due increased sales toddler childrens nutritional products enfamil companys best selling infant formula international nutritionals sales increased including favorable foreign exchange impact million million primarily due increased sales childrens nutritional products us nutritionals sales million million million respectively increase sales increase sales primarily due increased sales enfamil convatec composition change convatec sales follows analysis change total change volume price foreign exchange vs vs convatec sales business key products sales years ended december follows change dollars millions vs vs convatec ostomy wound therapeutics worldwide convatec sales increased including favorable foreign exchange impact million ostomy sales increased million including favorable foreign exchange impact sales wound therapeutic products increased including favorable foreign exchange impact million primarily due continued growth aquacel franchise worldwide convatec sales increased including favorable foreign exchange impact million million primarily due sales flexiseal aquacel international convatec sales increased including favorable foreign exchange impact million primarily due continued growth aquacel international convatec sales increased including favorable foreign exchange impact million primarily due growth aquacel us convatec sales increased million primarily due flexiseal continued growth aquacel brand us convatec sales increased million primarily due flexiseal continued growth aquacel brand table contents geographic areas general companys products available countries world largest markets us france canada spain japan italy mexico germany companys sales geographic areas follows change dollars millions vs vs united states total europe middle east africa total western hemisphere total pacific total total sales us increased primarily due increased plavix sales continued growth abilify sustiva franchise erbitux avaproavalide reyataz well sales newer products baraclude orencia sprycel partially offset increased generic competition pravachol sales us decreased primarily result lower sales plavix loss exclusivity pravachol april partially offset growth remaining pharmaceutical products including recently launched products sales europe middle east africa increased including favorable foreign exchange impact excluding impact foreign exchange decrease sales primarily due increased generic competition pravachol taxol paclitaxel partially offset sales growth major european markets sprycel reyataz sustiva franchise abilify sales decreased result sales decline pravachol taxol paclitaxel due increased generic competition decrease sales partially offset increased sales major european markets reyataz avaproavalide sales western hemisphere countries increased including favorable foreign exchange impact primarily due increased sales plavix canada mexico key nutritional products avaproavalide canada partially offset discontinued commercialization tequin sales increased including favorable foreign exchange impact excluding impact foreign exchange decrease sales primarily due decreased sales tequin pharmaceutical products partially offset increased sales avaproavalide canada key nutritional products sales pacific region increased including favorable foreign exchange impact primarily due increased sales baraclude china japan korea key nutritional products partially offset decreased sales taxol paclitaxel pravachol due increased generic competition sales remained consistent compared table contents expenses change dollars millions vs vs cost products sold net sales marketing selling administrative net sales advertising product promotion net sales research development net sales acquired inprocess research development net sales provision restructuring net net sales litigation expense net net sales gain sale product assets businesses net sales equity net income affiliates net sales expense net net sales total expenses net net sales change excess cost products sold percentage sales decreased compared margin improvement primarily due sales growth higher margin products including increased sales plavix cost products sold percentage sales respectively company included million percentage sales certain costs cost products sold reported marketing selling administrative expenses prior year results addition reclassification increase primarily due unfavorable impact pharmaceutical net sales mix including lower sales plavix impairment charges tequin emsam related assets well manufacturing facility marketing selling administrative expenses increased million compared primarily due unfavorable impact foreign exchange higher marketing expenses partially offset lower sales force expenses marketing selling administrative expenses decreased million million primarily due abovementioned reclassification lower sales force expenses resulting previously announced restructuring us primary care sales organization became effective march lower expenses pravachol partially offset impact adoption stock option expensing marketing selling administrative expenses percentage sales compared included decrease reclassification respectively advertising product promotion expenditures increased million compared primarily driven increased spending directto customer advertising plavix abilify orencia investments support launch ixempra higher spending newer products europe unfavorable impact foreign exchange advertising product promotion expenditures decreased million compared million primarily driven divestiture consumer medicines business lower spending mature brands partially offset increased investments new products including orencia sprycel companys investment research development million increase investment research development million represented increase million increases reflect companys strategy continued investments latestage compounds developing pipeline disease areas address significant unmet medical need increase partially offset sharing codevelopment costs alliance partners astrazeneca pfizer research development costs also included table contents charges million upfront milestone payments exelixis pfizer adnexus isis research development costs also included charges million million respectively consisting primarily upfront milestone payments exelixis solvay global medarex pierre fabre research development spending dedicated pharmaceutical products pharmaceutical sales compared respectively acquired inprocess research development charge million connection purchase adnexus fourth quarter additional information acquisition see item financial statementsnote acquisitions divestitures restructuring programs including pti began late well implemented realign streamline operations order increase productivity reduce operating expenses rationalize companys manufacturing network research facilities sales marketing organizations pti expected generate approximately billion cost reductions cost avoidance additional information restructuring see item financial statementsnote restructuring additional information pti see productivity transformation initiative litigation expense net settlement income insurance recoveries million million million million expense related reserves recorded proposed settlement certain pharmaceutical pricing sales litigations million net expense consisted increase reserves million settlement principle certain pricing sales investigations partially offset insurance recoveries million unrelated matter million income settlement litigation matter million net expense consisted increases reserves million liabilities primarily related private litigations governmental investigations partially offset insurance recoveries million additional information litigation see item financial statementsnote legal proceedings contingencies gain sale product assets million million net tax sale bufferin excedrin brands japan well certain assets related dermatology products gain sale product assets million million net tax sale inventory patent intellectual property rights related dovonex gain sale businesses million million net tax related sale consumer medicines business related assets additional information transactions see item financial statementsnote acquisitions divestitures equity net income affiliates million compared million million respectively equity net income affiliates principally related companys joint venture sanofi investment imclone million increase equity net income affiliates primarily due increased net income sanofi joint venture partially offset decreased net income equity investment imclone million increase equity net income affiliates primarily due increased net income joint venture sanofi income equity investment imclone compared loss additional information equity net income affiliates see item financial statements note alliances investments expense net million million million respectively expense net includes net interest expense foreign exchange gains losses income thirdparty contract manufacturing royalty income expense debt retirement costs impairment marketable securities gains losses disposal property plant equipment gains losses sale marketable securities insurance recoveries deferred income recognized certain litigation matters million increase expense net primarily due impairment charge million companys investment ars net unfavorability foreign exchange partially offset lower net interest expense debt retirement costs incurred million increase expense net primarily due higher debt retirement costs connection repurchase billion notes due compared repurchase billion notes due well million non recurring income resulting termination muraglitazar collaborative agreement partially offset lower net foreign exchange losses additional information see item financial statementsnote expense net note cash cash equivalents marketable securities note shortterm borrowing longterm debt stockbased compensation expense recognized sfas revised sharebased payment sfas r years ended december million million respectively expenses recorded cost product sold marketing selling administrative expenses research development expenses stockbased compensation expense recognized accounting principles board apb year ended december million expenses recorded marketing selling administrative expenses table contents years ended december company recorded several expenseincome items affected comparability results periods presented herein set forth following table discussion items see item financial statementsnote alliances investments note restructuring items note acquisitions divestitures note income taxes note cash cash equivalents marketable securities note shortterm borrowings longterm debt note legal proceedings contingencies gain marketing acquired provision sale cost selling research inprocess litigation product products research restructuring expense assets expense year ended december sold administrative development development net net businesses net total dollars millions productivity transformation initiative downsizing streamlining worldwide operations accelerated depreciation asset impairment process standardization implementation costs litigation settlement insurance recovery product liability upfront milestone payments acquired inprocess research development auction rate securities impairment downsizing streamlining worldwide operations accelerated depreciation asset impairment contract termination gain sale properties product assets income taxes items change estimate taxes prior year item increasedecrease net earnings c ontinuing perations gain sale cost marketing research provision litigation product products selling restructuring expense assets expense year ended december sold administrative development net net businesses net total dollars millions litigation matters pharmaceutical pricing sales litigation product liability claim damages commercial litigations insurance recovery debt retirement costs accelerated depreciation asset impairment contract termination upfront milestone payments downsizing streamlining worldwide operations gain sale product asset income taxes items change estimate taxes prior year items increasedecrease net earnings con inuing oper tions table contents gain provision sale cost research litigation product products restructuring expense assets expense year ended december sold development net net businesses net total dollars millions litigation matters private litigation governmental investigations erisa liability matters pharmaceutical pricing sales litigation insurance recoveries accelerated depreciation asset impairment debt retirement costs downsizing streamlining worldwide operations upfront milestone payments loss sale fixed assets gain sale equity investment termination muraglitazar agreement gain sale consumer medicines businesses income taxes items adjustment taxes repatriation foreign earnings increasedecrease net earnings continuing operations earnings continuing operations minority interest income taxes earnings continuing operations minority interest income taxes change dollars millions vs vs pharmaceuticals nutritionals convatec health care group total segments corporateother total earnings continuing operations minority interest income taxes increased million million increase primarily driven increased plavix sales strong sales growth key products improved gross margins increase equity net income affiliates partially offset net impact items affect comparability results discussed investment advertising product promotion research development earnings continuing operations minority interest income taxes decreased million million decrease primarily driven net impact items affected comparability results discussed lower net sales pharmaceutical products resulting lower plavix net sales loss exclusivity pravachol increased spending research development partially offset increase equity net income affiliates lower advertising promotion expensespharmaceuticals earnings continuing operations minority interest income taxes increased million increase primarily due increased plavix sales strong sales growth key products improved gross margins increase equity net income affiliates partially offset acquired inprocess research development charge continued investment research development including upfront milestone payments investment advertising product promotion earnings continuing operations minority interest income taxes decreased million million primarily due lower net sales result lower plavix sales loss exclusivity pravachol investment research development continued investment key products new products table contents nutritionals earnings continuing operations minority interest income taxes increased million primarily due growth key products partially offset lower gross margins primarily due higher dairy costs increased investment advertising product promotion establishment allowance doubtful account earnings continuing operations minority interest income taxes increased million million primarily due sales growth childrens nutritional products partially offset increased investments advertising expense research development programs convatec earnings continuing operations minority interest income taxes increased million primarily due increased growth key products improved gross margins partially offset increased investment research development programs product promotion earnings continuing operations minority interest income taxes increased million million primarily driven increased sales corporateother loss continuing operations minority interest income taxes decreased million results included gains sale product assets million million respectively additional difference primarily due debt retirement costs increases reserves pricing sales litigation settlement lower net interest expense partially offset impairments certain ars properties higher restructuring charges loss continuing operations minority interest income taxes increased million million primarily due lower gain sale product asset compared gain sale consumer medicines business higher debt retirement costs compared million income item resulting termination muraglitazar collaborative agreement well lower insurance recoveries compared partially offset lower litigation charges compared income taxes effective income tax rate earnings continuing operations minority interest income taxes compared tax rate unfavorably impacted impairment companys investment certain ars tax benefit non deductible writeoff acquired inprocess research development expenses related acquisition adnexus partially offset tax benefit million first quarter due favorable resolution certain tax matters us internal revenues service irs related deductibility litigation settlement expenses impact foreign tax credits effective tax rate unfavorably impacted elimination tax benefits section internal revenue code treatment provisions portion certain litigation reserves nondeductible partially offset favorable us tax legislation enacted related tax treatment certain intercompany transactions amongst companys foreign subsidiaries implementation tax planning strategies related utilization certain charitable contributions increase effective tax rate primarily due aforementioned section benefit elimination treatment provisions portion certain litigation reserves nondeductible tax benefits associated settlement irs examination favorable adjustment taxes special dividends american jobs creation act partially offset favorable us tax legislation enacted related tax treatment certain intercompany transactions amongst companys foreign subsidiaries implementation tax planning strategies related utilization certain charitable contributions company recorded significant deferred tax assets december related us foreign tax credit carryforwards approximately million us research tax credit carryforwards approximately million charitable contribution carryforwards million charitable contribution carryforwards expire varying amounts beginning foreign tax credit research tax credit carryforwards expire varying amounts beginning foreign tax credit research tax credit reduced due derecognition fin realization credits charitable contribution carryforwards dependent generating sufficient domestic taxable income prior expiration although realization assured management believes likely deferred tax assets realized company anticipates increasing level domestic profitability time undertaking actions pti increasing biologics manufacturing capacity us implementing tax planning strategies increasing domestic profitability likely cause companys effective tax rate increase also enhance companys ability utilize foreign tax credit research tax credit charitable contribution carryforwards table contents minority interest minority interest net taxes increased million primarily due higher earnings companys partnership sanofi territory covering americas minority interest net taxes decreased million million primarily due lower earnings companys partnership sanofi territory covering americas changes three years reflect negative impact generic clopidogrel bisulfate august mid discontinued operations december company entered definitive agreement avista sale medical imaging business purchase price approximately million cash subject customary postclosing adjustments closing transaction completed january result transaction company expects recognize pretax gain approximately million million million million loss net tax first quarter subject postclosing adjustments medical imaging previously included former health care operating segment may company completed sale otn one equity partners llc cash proceeds million including impact preliminary working capital adjustment company recorded pretax gain million million net tax presented gain sale discontinued operations consolidated statement earnings otn previously presented separate segment following summarized financial information related medical imaging otn businesses segregated continuing operations reported discontinued operations date disposition reflect costs certain services provided medical imaging otn costs allocated company medical imaging otn services included legal counsel insurance external audit fees payroll processing certain human resource services information technology systems support year ended december dollars millions net sales earningsloss incomes taxes provision income taxes net earningsloss discontinued operations financial position liquidity capital resources cash cash equivalents marketable securities approximately billion december compared billion december company continues maintain sufficient level working capital approximately billion december decreasing billion december future periods company expects cash generated us operations together existing cash cash equivalents marketable securities borrowings capital markets sufficient cover cash needs working capital capital expenditures company expects include substantial investments facilities increase maintain companys capacity provide biologics commercial scale milestone payments dividends paid us cash cash equivalents marketable securities conversion workingcapital items borrowings expected fund near term operations outside us december company approximately billion undistributed earnings foreign subsidiaries taxes provided company invested expects invest undistributed earnings permanently offshore future earnings repatriated us company determines earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided cash cash equivalents december primarily consisted bank deposits time deposits money market funds cash equivalents primarily highly liquid investments original maturities three months less time purchase recorded cost approximates fair value company maintains cash cash equivalent balances us dollars foreign currencies subject currency rate risk january company converted substantial portion cash equivalents money market funds us treasury bills similar investmentsmarketable securities december consisted us dollardenominated floating rate securities frs primarily aaaaaa rated frs longterm debt securities coupons reset periodically benchmark interest rate underlying assets companys frs consist primarily investment grade corporate bonds loans carrying value frs reduced million million million december reflecting change fair market value company assessed decline fair market value temporary recorded pretax million reduction million net tax shareholders equity accumulated comprehensive income oci table contents previously disclosed september company sanofi posted million towards million bond us district court southern district new york district court collateral support preliminary injunction issued august collateral reported marketable securities companys consolidated balance sheet december result outcome plavix patent litigation noted june district court ordered release million bond release issuer bond liability connection bond companys obligations collateral arrangements respect bond effectively terminated addition december company million principal invested ars ars held company private placement securities longterm nominal maturities interest rates reset dutch auction month monthly auctions historically provided liquid market securities companys investments ars represent interests collateralized debt obligations supported pools residential commercial mortgages credit cards insurance securitizations structured credits including corporate bonds underlying collateral ars held company consists subprime mortgages consistent companys investment policy guidelines ars investments held company aaaaaa credit ratings time purchase liquidity issues experienced global credit capital markets ars held company december experienced multiple failed auctions amount securities submitted sale exceeded amount purchase orders addition fourth quarter million principal invested ars held company downgraded others placed credit watch securities retained least one aaa rating december estimated market value companys ars holdings december million reflects million adjustment principal value million although ars continue pay interest according stated terms based valuation models analysis otherthantemporary impairment factors company recorded pretax impairment charge million fourth quarter reflecting portion ars holdings company concluded otherthantemporary decline value addition company recorded unrealized loss million pretax net tax accumulated oci reduction shareholders equity reflecting adjustments ars holdings company concluded temporary decline value million impairment charge material impact companys liquidity financial flexibility historically given liquidity created auctions ars presented current assets marketable securities given failed auctions companys ars illiquid successful auction accordingly entire amount remaining ars reclassified marketable securities noncurrent assets credit capital markets continued deteriorate uncertainties credit capital markets continue markets deteriorate company experiences additional ratings downgrades investments portfolio including ars company may incur additional impairments investment portfolio could negatively affect companys financial condition cash flow reported earnings company believes based companys current cash cash equivalents marketable securities balances billion december expected operating cash flows current lack liquidity credit capital markets material impact companys liquidity cash flow financial flexibility ability fund operations including dividend february company completed sale leaseback administrative facility paris france approximately million company expects record gain majority deferred reduce future lease rental costs lease period december company completed sale leaseback several administrative facilities new jersey million resulted pretax gain transaction million million deferred reduce future lease rental costs lease periods ranging years shortterm borrowings end billion million respectively company maintains cash balances shortterm investments excess shortterm borrowings million yen notes due million yen notes due million notes due associated unamortized discount interest rate swap valuation billion floating rate convertible debentures due putcall reclassified longterm debt shortterm borrowings longterm debt billion december compared billion december billion reduction primarily due reclassification shortterm borrowings noted september repayment remaining billion balance floating rate bank term facility due fourth quarter company restructured longterm debt retiring outstanding billion principal amount notes due cash tender offer subsequent redemption issuing million aggregate principal notes due million aggregate principal notes due well billion aggregate principal notes due company incurred aggregate pretax expense approximately million table contents connection early redemption notes termination related interest rate swaps included writeoff related unamortized discount issuance costs deferred loss interest rate lock addition company repaid billion billion floating rate bank term facility due december company replaced prior billion revolving credit facility new billion fiveyear revolving credit facility syndicate lenders extendable anniversary date consent lenders facility contains customary terms conditions substantially similar prior facility including financial covenant whereby ratio consolidated debt consolidated capital exceed end quarter company compliance covenant since inception facility borrowings outstanding revolving credit facility december second quarter company repurchased outstanding billion aggregate principal amount notes due incurred aggregate pretax loss approximately million connection early redemption notes termination related interest rate swaps majority companys debt fixed rate company however entered fixed floating interest rate swaps billion billion billion december longterm debt pretax interest expense net interest swap gains million million million respectively decrease interest expense primarily due effects debt restructuring increase interest expense primarily due higher interest rates moodys investors service moodys longterm shortterm credit ratings company currently prime respectively moodys long term credit rating remains stable outlook standard poors sp longterm shortterm credit ratings company currently respectively second quarter sp revised longterm credit rating outlook stable negative fitch ratings fitch longterm shortterm credit ratings company currently f respectively third quarter fitch revised longterm credit rating outlook stable negative working capital years ended december follows december dollars millions working capital decrease working capital billion december december impacted decrease marketable securities due reduction carrying value floating rate securities certain ars fair market value subsequent reclassifications remaining value ars noncurrent assets increase shortterm borrowings longterm debt due reclassifications noted increase accrued royalties resulting increased plavix sales increase receivables primarily due increased plavix sales us reclassification medical imaging assets liabilities held sale reclassification certain tax contingencies current us foreign income taxes payable noncurrent upon adoption fin january following discussions companys cash flow activities include discontinued operations companys cash flow activities years ended december follows year ended december dollars millions cash flow provided byused operating activities investing activities financing activities net cash provided operating activities billion billion million increase compared attributable higher net earnings million higher net changes adjustments net earnings million higher net changes operating assets liabilities million table contents net positive changes adjustments net earnings compared million mainly included million negative cash flow variance due lower litigation settlement expenses million positive cash flow variance resulting impairment charges asset writeoffs mainly reduction carrying value ars fair value impending closure manufacturing facilities positive cash flow variance acquired inprocess research development related acquisition adnexus million negative cash flow variance deferred income tax benefit adjustments included deferred tax benefits restructuring companys international operations upfront cash receipts alliance partners resolution audit issue irs partially offset litigation payments adjustments included net deferred tax charge payment litigation settlements offset deferred tax benefit additional litigation accruals accrual additional foreign tax credits deferred tax benefit equitybased compensation million positive cash flow variance due higher provision restructuring connection pti net positive changes operating assets liabilities compared million mainly included million positive cash flow variance accounts payable accrued expenses primarily due increase accrued royalties resulting increased plavix sales higher purchases raw materials significant paydown payables early resulting lower payment invoices december reduction accrued rebates returns first quarter primarily resulting lower sales volume million negative cash flow variance receivables primarily due increased plavix sales lower collection resulting lower pravachol sales million positive cash flow variance deferred income liabilities mainly due upfront cash receipts alliance partners million negative cash flow variance inventories primarily due increase inventories anticipation new product launches strategic builds existing products reduction inventories resulting pravachol exclusivity loss million negative cash flow variance income taxes payable primarily related payments settle various tax issues irs audit net cash used investing activities million net cash provided investing activities million million negative cash flow variance primarily attributable million negative cash flow variance acquisition adnexus million negative cash flow variance proceeds disposal properties connection sales leaseback transaction million positive cash flow variance licensing milestone payments imclone somerset pharmaceuticals inc net cash used financing activities million million million positive cash flow variance mainly attributable million positive cash flow variance mainly higher cash proceeds exercise stock options compared net cash provided operating activities billion billion million increase compared mainly attributable significant changes adjustments net earnings million net changes operating assets liabilities million offset lower net earnings million significant positive changes adjustments net earnings compared million mainly included million positive cash flow variance deferred income tax benefit due lower level increase deferred tax benefit compared increase deferred tax benefits associated us research development foreign tax credits increase litigation reserves increase deferred tax benefits associated reversal tax liability related repatriation special dividends ajca million positive cash flow variance due lower gain sale product asset compared sale business million positive cash flow variance deferred income recognized related termination muraglitazar collaborative agreement table contents net positive changes operating assets liabilities compared million mainly included million negative cash flow variance receivables increase cash flow driven increases receivables due alliance partners partially offset lower trade receivable volume increase cash flow driven collection foreign withholding taxes alliance partners million positive cash flow variance inventories primarily due increase inventories resulting growth newer products anticipation new product launches reduction inventories resulting pravachol exclusivity loss million negative cash flow variance litigation primarily due settlement payments million dpa vanlev litigation partially offset unrelated insurance recoveries million million positive cash flow variance income taxes payable primarily related payments settlement examinations irs years repatriation special dividends ajca net cash provided investing activities million compared net cash provided million million negative cash flow variance primarily attributable million negative cash flow variance mainly sale marketable securities million negative cash flow variance lower proceeds sale product asset compared sale consumer medicines otn businesses million negative cash flow variance milestone payments primarily related imclone million positive cash flow variance proceeds disposal properties connection sale leaseback transaction net cash used financing activities million compared million million positive cash flow variance mainly attributable million positive cash flow variance repayment shortterm borrowings negative cash flow variance retirement longterm debt company repaid debt million retired notes due million company retired notes due million cash provided operations borrowings primarily used past three years pay dividends approximately billion company also invested approximately billion past three years capital expansion improve plant efficiency maintain superior research facilities past three years company repurchase common stock share repurchase program authorizes company purchase common stock time time open market private transactions market conditions permit program intended reduce increase shares outstanding option exercises obtain shares general corporate purposes dividends declared per common share december company declared quarterly dividend per common share indicated dividend full year per share dividend decisions made quarterly basis companys board directors companys financial condition liquidity could affected obligations make milestone onetime payments outcome pending litigations investigations including challenge plavix patent andor potential renewed additional generic competition plavix additional impairments investment portfolio information see item financial statementsnote alliances investments note cash cash equivalents marketable securities note shortterm borrowings longterm debt note legal proceedings contingencies table contents contractual obligations payments due period companys contractual obligations december follows obligations expiring period dollars millions total later years shortterm borrowings longterm debt operating leases purchase obligations standby letters creditperformance guarantees uncertain tax positions pension liabilities total current portion longterm debt obligations included shortterm borrowings companys consolidated balance sheet december balances approximate outstanding nominal longterm debt values contractual obligations table excludes interest payment obligations companys convertible debenture included due payment contains put call feature due uncertainty related timing reversal uncertain tax positions shortterm uncertain tax benefits provided table longterm amounts excluded table total million addition company committed make potential future milestone payments third parties part inlicensing development programs payments agreements generally become due payable upon achievement certain developmental regulatory andor commercial milestones specific timing predicted achievement milestones neither probable reasonably estimable contingencies recorded companys consolidated balance sheet discussion contractual obligations see item financial statementsnote shortterm borrowings longterm debt note financial instruments note leases note pension postretirement benefit plans sec consent order previously disclosed august company entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters settlement reached consent copy attached exhibit companys quarterly report form q period ended september terms consent company agreed subject certain defined exceptions limit sales products sold direct customers including wholesalers distributors hospitals retail outlets pharmacies government purchasers based expected demand amounts exceed approximately one month inventory hand without making timely public disclosure change practice company also agreed consent certain measures implemented including establishing formal review certification process annual quarterly reports filed sec b establishing business risk disclosure group c retaining outside consultant comprehensively study help reengineer companys accounting financial reporting processes publicly disclosing sales incentives offered direct customers purpose inducing purchase products excess expected demand e ensuring companys budget process gives appropriate weight inputs come bottom top come top bottom adequately documenting process company established companywide policy limit sales direct customers purpose complying consent policy includes adoption various procedures monitor limit sales direct customers accordance terms consent procedures include governance process escalate appropriate management levels potential questions concerns regarding compliance policy timely resolution questions concerns addition compliance policy monitored regular basisthe company maintains imas us pharmaceutical wholesalers account nearly total gross sales us pharmaceutical products current terms imas companys three largest wholesaler customers provide company weekly information respect months hand productlevel inventories amount outmovement products three wholesalers currently account approximately total gross sales us pharmaceuticals products inventory information received wholesalers together companys internal information used estimate months hand product level inventories wholesalers company estimates months hand product inventory levels us pharmaceutical businesss wholesaler customers three largest wholesalers extrapolating months hand calculated three largest wholesalers contrast companys pharmaceutical business outside us nutritionals convatec business units around world company significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly company relies variety methods estimate months hand product level inventories business units table contents company believes abovedescribed procedures provide reasonable basis ensure compliance consent previously disclosed june company entered dpa us attorneys office district new jersey resolving investigation usao company relating wholesaler inventory various accounting matters covered companys settlement sec pursuant dpa usao filed criminal complaint company alleging conspiracy commit securities fraud agreed defer prosecution company dismiss complaint two years company satisfied requirements dpa copy dpa filed exhibit form k filed company june incorporated reference hereto exhibit w fiscal year ended december terms dpa company agreed retain monitor monitor defined powers responsibilities dpa including oversee companys compliance terms dpa consent settlements derivative action federal securities class action powers responsibilities monitor ended april monitor filed final report usao june june dpa expired complaint dismissed company ongoing obligations dpa recently issued accounting standards december meeting financial accounting standards board fasb ratified consensus reached emerging issues task force eitf issue accounting collaborative arrangements related development commercialization intellectual property eitf concluded collaborative arrangement one participants actively involved exposed significant risks rewards depend ultimate commercial success endeavor revenues costs incurred third parties connection collaborative arrangements would presented gross net based criteria eitf reporting revenue gross principal versus net agent accounting literature payments collaborators would evaluated presented based nature arrangement terms nature entitys business whether payments within scope accounting literature nature purpose collaborative arrangements disclosed along accounting policies classification amounts significant financial statement amounts related arrangements activities arrangement conducted separate legal entity accounted accounting literature however required disclosure eitf applies entire collaborative agreement issue effective fiscal years beginning december applied retrospectively periods presented collaborative arrangements existing effective date company currently process evaluating impact adopting pronouncement december fasb issued sfas r business combinations replaces sfas business combinations requires acquirer recognize assets acquired liabilities assumed noncontrolling interest acquiree acquisition date measured fair values date limited exceptions statement also requires acquirer business combination achieved stages recognize identifiable assets liabilities well noncontrolling interest acquiree full amounts fair values sfas r makes various amendments authoritative literature intended provide additional guidance confirm guidance literature provided statement statement applies business combinations acquisition date fiscal years beginning december company currently process evaluating impact adopting pronouncement december fasb issued sfas noncontrolling interests consolidated financial statementsan amendment arb sfas establishes accounting reporting standards require ownership interests subsidiaries held parties parent clearly identified labeled presented consolidated statement financial position within equity separate parents equity statement also requires amount consolidated net income attributable parent noncontrolling interest clearly identified presented face consolidated statement income changes parents ownership interest parent retains controlling financial interest subsidiary must accounted consistently subsidiary deconsolidated retained noncontrolling equity investment former subsidiary must initially measured fair value gain loss deconsolidation subsidiary measured using fair value noncontrolling equity investment statement also requires entities provide sufficient disclosures clearly identify distinguish interests parent interests noncontrolling owners statement effective fiscal years beginning december company currently process evaluating impact adopting pronouncement june eitf reached consensus issue accounting nonrefundable advance payments goods services received used future research development activities nonrefundable advance payments goods services used rendered future research development activities deferred capitalized amounts recognized expense related goods delivered services performed goods services longer expected provided issue effective fiscal years beginning december earlier application permitted pronouncement expected material effect companys consolidated financial statements table contents february fasb issued sfas fair value option financial assets financial liabilitiesincluding amendment fasb statement permits entity measure certain financial assets financial liabilities fair value objective sfas improve financial reporting allowing entities mitigate volatility reported earnings caused measurement related assets liabilities using different attributes without apply complex hedge accounting provisions sfas entities elect fair value option instrument report unrealized gains losses earnings subsequent reporting date fair value option election irrevocable unless new election date occurs sfas establishes presentation disclosure requirements help financial statement users understand effect entitys election earnings eliminate disclosure requirements accounting standards assets liabilities measured fair value must displayed face balance sheet statement effective fiscal years beginning november company elect early adoption pronouncement permitted adoption accounting pronouncement expected material effect companys consolidated financial statements september fasb issued statement sfas employers accounting defined benefit pension postretirement plansan amendment fasb statements r pronouncement requires employer recognize overfunded underfunded status defined benefit postretirement plan multiemployer plan asset liability statement financial position recognize changes funded status year changes occur comprehensive income business entity pronouncement also requires employer measure funded status plan date yearend statement financial position limited exceptions pronouncement require prior periods restated reflect impact sfas company adopted sfas fiscal year ended december adoption accounting pronouncement resulted million reduction accumulated oci stockholders equity million reduction total assets million increase total liabilities adoption sfas impact companys results operations cash flows september fasb issued sfas fair value measurements pronouncement defines fair value establishes framework measuring fair value expands disclosures fair value measurements statement effective fiscal years beginning november november fasb agreed oneyear deferral implementation sfas nonfinancial assets liabilities adoption accounting pronouncement expected material effect companys consolidated financial statements financial assets liabilities assets liabilities carried fair value company currently process evaluating impact adopting pronouncement nonfinancial assets liabilities september sec issued staff accounting bulletin sab considering effects prior year misstatements quantifying misstatements current year financial statements expresses staffs views regarding process quantifying financial statement misstatements bulletin effective interim period first fiscal year ending november sab requires companies utilize dual approach assess quantitative effects financial statement misstatements dual approach includes income statement focus balance sheet focus assessment adoption bulletin effect companys consolidated financial statements july fasb issued fasb interpretation fin accounting uncertainty income taxes interpretation fasb statement case company effective january fin clarifies accounting uncertainty income taxes recognized enterprises financial statements accordance sfas accounting income taxes fin requires tax positions evaluated using recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return differences tax positions taken tax return amounts recognized financial statements recorded adjustments income taxes payable receivable adjustments deferred taxes fin also requires expanded disclosure end reporting period including tabular reconciliation unrecognized tax benefits company adopted fin january result adoption accounting pronouncement company recognized million previously unrecognized tax benefits accounted increase opening balance retained earnings may fasb issued fasb staff position fsp fin definition settlement fasb interpretation effective retroactively january fsp fin provides guidance determine whether tax position effectively settled purpose recognizing previously unrecognized tax benefits adoption fsp fin effect companys consolidated financial statements march fasb issued sfas accounting servicing financial assets amendment fasb statement pronouncement relates accounting separately recognized servicing assets servicing liabilities statement effective fiscal years beginning september adoption accounting pronouncement material effect companys consolidated financial statements table contents february fasb issued sfas accounting certain hybrid financial instruments amendment fasb statements pronouncement primarily resolves certain issues addressed implementation sfas accounting derivative instruments hedging activities concerning beneficial interests securitized financial assets statement effective financial instruments acquired issued subject remeasurement event occurring beginning fiscal year adoption accounting pronouncement material effect companys consolidated financial statements may fasb issued sfas accounting changes error correctionsa replacement apb opinion fasb statement pronouncement applies voluntary changes accounting principle revises requirements accounting reporting change accounting principle sfas requires retrospective application prior periods financial statements voluntary change accounting principle unless impracticable pronouncement also requires change method depreciation amortization depletion longlived nonfinancial assets accounted change accounting estimate affected change accounting principle sfas effective accounting changes corrections errors made fiscal years beginning december statement change transition provisions existing accounting pronouncements including transition phase effective date sfas adoption accounting pronouncement material effect companys consolidated financial statements march fasb issued fin accounting conditional asset retirement obligationsan interpretation fasb statement fin clarifies entity must record liability conditional asset retirement obligation fair value obligation reasonably estimated asset retirement obligations covered fin entity legal obligation perform asset retirement activity even timing method settling obligation conditional future event may may within control entity fin also clarifies entity would sufficient information reasonably estimate fair value asset retirement obligation interpretation effective later end fiscal years ending december company adopted provisions fin fiscal year ended december adoption accounting pronouncement material effect companys consolidated financial statements december fasb issued sfas revised sharebased payment sfas r requires measurement recognition compensation expense stockbased payment awards made employees directors based estimated fair values sfas r supersedes companys previous accounting apb accounting stock issued employees periods beginning january march sec issued sab sharebased payment relating sfas r company applied provisions sab adoption sfas r company adopted sfas r using modified prospective transition method requires application accounting standard january elected alternative method provided fsp r transition election related accounting tax effects sharebased payment awards determining companys pool excess tax benefits companys consolidated financial statements year ended december reflect impact sfas r accordance modified prospective transition method companys consolidated financial statements prior periods restated reflect include impact sfas r stockbased compensation expense recognized sfas r year ended december million million net tax per share corresponding amount recorded additional paidin capital within stockholders equity additionally million related performance awards reclassified liabilities stockholders equity connection adoption sfas r critical accounting policies company prepares financial statements conformity accounting principles generally accepted us preparation financial statements conformity us gaap requires use estimates assumptions affect reported amounts assets liabilities including disclosure contingent assets contingent liabilities date financial statements reported amounts revenue expenses reporting period companys critical accounting policies important companys financial condition results operations require difficult subjective complex judgments part management application often result need make estimates effect matters inherently uncertain uncertainty factors surrounding estimates judgments used preparation consolidated financial statements actual results may vary estimates company believes following discussion represents critical accounting policies management discussed companys critical accounting policies audit committee board directors table contents revenue recognition company recognizes revenue accordance sab revenue recognition financial statements amended sab revenue recognition companys accounting policy revenue recognition substantial impact reported results relies certain estimates require difficult subjective complex judgments part management company recognizes revenue net grosstonet sales adjustments discussed involve significant estimates judgments title substantially risks rewards ownership transferred customer generally occurs date shipment case new products product introduction extension existing line product company determines products similar therapeutic category company determines new product dissimilar characteristics existing products company reliably estimate expected returns new product company defers recognition revenue right return longer exists company developed sufficient historical experience estimate sales returns discussions revenue recognition see item financial statementsnote accounting policiesrevenue recognition sales rebate return accruals grosstonet sales adjustments company following significant categories grosstonet sales adjustments prime vendor chargebacks wic rebates managed health care rebates contract discounts medicaid rebates cash discounts sales returns adjustments involve significant estimates judgments require company use information external sources company accounts grosstonet sales adjustments accordance eitf issue accounting consideration given vendor customer including reseller vendors products sfas revenue recognition right return exists applicable see net sales section reconciliation companys gross sales net sales significant category grosstonet sales adjustment prime vendor chargebacks companys us businesses participate prime vendor programs government entities significant us department defense us department veterans affairs parties whereby pricing products extended wholesaler list price participating entities entities purchase products wholesalers lower prime vendor price wholesalers charge difference acquisition cost lower prime vendor price back company company accounts prime vendor chargebacks reducing accounts receivable amount equal companys estimate chargeback claims attributable sale company determines estimate prime vendor chargebacks primarily based historical experience regarding prime vendor chargebacks current contract prices prime vendor programs company considers prime vendor payments levels inventory distribution channel companys claim processing time lag adjusts reduction accounts receivable periodically throughout quarter reflect actual experience wic rebates companys us nutritionals business participates competitive bidding basis nutrition programs sponsored states tribal governments commonwealth puerto rico us territories wic programs company reimburses entities difference wholesaler list price contract price eligible products company accounts wic rebates establishing accrual amount equal companys estimate wic rebate claims attributable sale company determines estimate wic rebate accrual primarily based historical experience regarding wic rebates current contract prices wic programs company considers levels inventory distribution channel new wic contracts terminated wic contracts changes existing wic contracts wic participation adjusts accrual periodically throughout quarter reflect actual experience managed health care rebates contract discounts company offers rebates discounts managed health care organizations us manage prescription drug programs medicare advantage prescription drug plans covering medicare part drug benefit addition commercial plans well globally contract counterparties hospitals group purchasing organizations company accounts managed health care rebates contract discounts establishing accrual amount equal companys estimate managed health care rebates contract discounts attributable sale company determines table contents estimate managed health care rebates contract discounts accrual primarily based historical experience regarding rebates discounts current contract prices company considers sales performance products subject managed health care rebates contract discounts levels inventory distribution channel adjusts accrual periodically throughout quarter reflect actual experience medicaid rebates companys us businesses participate state governmentmanaged medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities discounts rebates provided latter programs included companys medicaid rebate accrual considered medicaid rebates purposes discussion company accounts medicaid rebates establishing accrual amount equal companys estimate medicaid rebate claims attributable sale company determines estimate medicaid rebates accrual primarily based historical experience regarding medicaid rebates well expansion prospective basis participation nonmandatory aspects qualifying federal state government programs legal interpretations applicable laws related medicaid qualifying federal state government programs new information regarding changes medicaid programs regulations guidelines would impact amount rebates company considers outstanding medicaid claims medicaid payments levels inventory distribution channel adjusts accrual periodically throughout quarter reflect actual experience cash discounts us certain countries company offers cash discounts approximating sales price incentive prompt payment company accounts cash discounts reducing accounts receivable full amount discounts company considers payment performance adjusts accrual reflect actual experience sales returns company accounts sales returns accordance sfas revenue recognition right return exists establishing accrual amount equal companys estimate sales recorded related products expected returned provision sales returns million million million respectively gross sales three years returns established products company determines estimate sales return accrual primarily based historical experience regarding sales returns also considers factors could impact sales returns factors include levels inventory distribution channel estimated shelf life product recalls product discontinuances price changes competitive products introductions generic products introductions competitive new products company considers factors adjusts accrual periodically throughout quarter reflect actual experience company considers level inventory distribution channel determines whether believes adjustment sales return accrual appropriate company adjusts sales return accrual based historical experience companys returned goods policy shelf life companys products life cycle product levels inventory distribution channel company considers introductions generic products factors impact sales returns calculation based historical experience companys returned goods policy event product recall product discontinuance company considers reasons impact actions adjusts sales return accrual appropriate taking account historical experience estimated levels inventory distribution channel product discontinuances estimates continuing demand sales returns accruals new products estimated primarily based historical sales returns experience similar products within line product within similar therapeutic category limited circumstances new product extension existing line product company historical experience products similar therapeutic category company reliably estimate expected returns new product company defers recognition revenue right return longer exists company developed sufficient historical experience estimate sales returns company also considers shelf life new products determines whether believes adjustment sales return accrual appropriate shelf life connection new products tends shorter shelf life established products company may still developing optimal manufacturing process new product would lengthen shelf life addition higher launch quantities may manufactured advance launch date ensure sufficient supply exists satisfy market demand cases company assesses reduced shelf life together estimated levels inventory distribution channel projected demand determines whether believes adjustment sales return accrual appropriate table contents adjustments addition grosstonet sales adjustments described company makes grosstonet sales adjustments example company offers sales discounts significantly nonus businesses also offers consumer coupons rebates significantly us nutritionals pharmaceuticals businesses addition number countries outside us including major european countries company provides rebates government entities company generally accounts grosstonet adjustments establishing accrual amount equal companys estimate adjustments attributable sale company generally determines estimates accruals grosstonet sales adjustments primarily based historical experience performance commitments government entities relevant factors including estimated levels inventory distribution channel adjusts accruals periodically throughout quarter reflect actual experience use information external sources company uses information external sources estimate grosstonet sales adjustments companys estimates inventory wholesalers deferred revenue consigned inventory based projected prescription demandbased sales products historical inventory experience well companys analysis thirdparty information including written oral information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data companys internal information inventory information received wholesalers product recordkeeping process excludes inventory held intermediaries sell retailers hospitals company receives information ims supplier market research pharmaceutical industry uses project prescription demandbased sales many us pharmaceutical products prior third quarter company historically reported estimated total us prescription growth estimated therapeutic category shares based data ims national prescription audit npa ims legacy national projection methodology ims made available subscription basis reported data based simple unweighted sum projected us prescriptions retail mail order channels third quarter company began disclosing npa prescription growth therapeutic category share data based version ims new revised ngps projection methodology consistency ngps version data used current comparative time periods properly account trend breaks new projection methodology coincident change reporting ims data ngps version basis company also began reporting retail mail prescription growth category shares weighted retailequivalent basis accounts significantly larger size average mail order prescription compared size average retail prescription retail equivalization calculations applied mail order volumes shares reported product time period ims refined improved ngps projection methodology fully rolled ngps version npa subscribers resulted newly revised volume estimates historic time periods therefore since first quarter company used new ims standard ngps version projection methodology applied ngps version data reporting prescription growth market shares periods presented annual report company also continued practice combining retail mail prescription volume retail equivalent basis company uses methodology internal demand forecasts company also uses information external sources identify prescription trends patient demand average selling prices companys estimates subject inherent limitations estimates rely thirdparty information certain thirdparty information form estimates reflect limitations including lags date thirdparty information generated date company receives thirdparty information retirement benefits companys pension plans postretirement benefit plans accounted using actuarial valuations required sfas employers accounting pensions sfas employers accounting postretirement benefits pensions company considers accounting retirement plans critical management required make significant subjective judgments number actuarial assumptions including discount rates salary growth longterm return plan assets retirement turnover health care cost trend rates mortality rates depending assumptions estimates used pension postretirement benefit expense could vary within range outcomes material effect reported earnings addition assumptions materially affect projected benefit obligations future cash funding company adopted sfas employers accounting defined benefit pension postretirement plansan amendment fasb statements r fiscal year ended december adoption accounting pronouncement resulted million reduction accumulated comprehensive income stockholders equity million reduction total assets million increase total liabilities adoption sfas impact companys results operations cash flows table contents plan description company certain subsidiaries defined benefit pension plans defined contribution plans termination indemnity plans regular full time employees principal defined benefit pension plan bristolmyers squibb retirement income plan principal defined contribution plan bristolmyers squibb savings investment program approximately total company defined benefit pension plan assets liabilities held us plans assets us plans held single trust common asset allocation unless specified otherwise references section total company plans ie us plans together international plans benefits companys defined benefit pension plans based primarily years credited service participants compensation assets companys defined benefit plans consist primarily equity fixedincome securities december fair market value plan assets companys defined benefit plans increased million million december us plans assets allocated equity securities compared end fixed income securities compared end private equity investments compared end bristolmyers squibb common stock represented less assets us plans end company provides comprehensive medical group life benefits substantially us retirees elect participate companys comprehensive medical group life plans asset allocation postretirement plans identical asset allocation described us defined benefit pension plans accrual accounting significant assumptions consistent requirements sfas company accounts pension benefits using accrual method recognizing pension expense payment benefits retirees accrual method accounting pension benefits necessarily requires actuarial assumptions concerning future events determine amount timing benefit payments companys key assumptions used calculating cost pension benefits discount rate rate compensation increase expected longterm rate return plan assets company consultation actuaries evaluates key actuarial assumptions assumptions used calculating cost pension benefits retirement turnover mortality rates based expectations actual experience appropriate determines assumptions december year calculate liability information date pension expense following year depending assumptions used pension expense could vary within range outcomes material effect reported earnings addition assumptions materially affect projected benefit obligations future cash funding actual results given year may differ estimated economic factors determining discount rate company uses yield high quality corporate bonds coincides cash flows plans estimated payouts citigroup median yield curve used determining discount rate us plans assumed rate compensation increase used company determining future pension obligations reflects estimate change actual future compensation levels due general price levels productivity seniority factors net pension expense companys defined benefit pension plans included earnings minority interest income taxes million compared million us plans pension expense determined using assumed discount rate assumed rate compensation increase present value benefit obligations december us plans determined using assumed discount rate assumed rate compensation increase assumed discount rate used determining us plans pension expense reduced expense would increased approximately million assumed rate compensation increase used determining us plans pension expense reduced expense would decreased approximately million assumed discount rate used determining accumulated benefit obligation december reduced accumulated benefit obligation would increased million us plans pension expense determined using expected longterm rate return plan assets expected longterm rate return plan assets used determining us plans pension expense reduced expense would increased million table contents actual rates return earned us plan assets last years follows year return year return december company increased assumed discount rate us plans maintained assumed rate compensation increase compensation assumed increase scale different rates different ages rate disclosed december single rate used age would produce present value benefit obligations company maintained expected rate return us plan assets company expects net pension expense defined benefit pension plans included earnings minority interest income taxes approximately million lower million reflecting primarily increase discount rate company used assumed discount rates expected longterm rates return plan assets calculating cost pension benefits cost postretirement benefits us plans except case discount rates december rates respectively used pension benefits versus respectively postretirement benefits reflect shorter duration postretirement liabilities december respectively us health care costs retiree population assumed increase trend expected increase per year actual costs higher assumed likely put significant upward pressure companys expense retiree health care effects medicare prescription drug improvement modernization act reflected net periodic postretirement benefit cost reduction million accumulated postretirement benefit obligation january reduction million recognition actuarial gains losses sfas required recognition actuarial gains losses component stockholders equity accumulated comprehensive income sfas provides delayed recognition years prior amounts arise changes estimated plan benefit obligations due changes assumed discount rate differences actual expected returns plan assets assumption changes net actuarial gain loss determined based marketrelated value plan assets differs fair market value calculated value recognizes changes fair value systematic rational manner five years amortized pension income expense year extent unrecognized net actuarial loss gain exceeds greater projected benefit obligation marketrelated value plan assets beginning year net gains losses recognized pension income expense prospectively period approximates average remaining service period active employees expected receive benefits plans approximately years extent offset losses gains subsequent years unrecognized net actuarial loss reflects large part steady reduction weightedaverage discount rate years unless offset future unrecognized gains higher discount rates higher expected returns plan assets amortization unrecognized loss expected increase pension expense million progressively lower amounts following nine years plan funding companys funding policy defined benefit plans contribute amounts provide current service fund past service liability company contributed million million defined benefit plans respectively discussions retirement benefits see item financial statementsnote pension postretirement benefit plans table contents acquired inprocess research development fair value inprocess research development acquired business combination determined based present value research projects projected cash flows income approach utilized consistent guidance practice aid issued american institute certified public accountants assets acquired business combination used research development activities focus software electronic devices pharmaceutical industries future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research projects underlying patent determining fair value research project expected revenues first adjusted technical risk completion resulting cash flows discounted rate approximating companys weightedaverage cost capital acquired inprocess research development expensed incurred underlying product received regulatory approval future alternative use addition costs nonrefundable related acquisition licensing products yet received regulatory approval marketed alternative future use charged earnings incurred discussions acquired inprocess research development see item financial statementsnote accounting policiesacquired inprocess research development impairment longlived assets accordance sfas accounting impairment disposal longlived assets company periodically evaluates whether current facts circumstances indicate carrying value depreciable assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows produced longlived asset appropriate grouping assets compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques including discounted value estimated future cash flows company reports asset disposed lower carrying value estimated net realizable value accordance sfas goodwill intangible assets goodwill tested least annually impairment using twostep process first step identify potential impairment second step measures amount impairment loss goodwill deemed impaired carrying amount reporting units goodwill exceeds estimated fair value sfas requires indefinitelived intangible assets tested impairment using onestep process consists comparison fair value carrying value intangible asset intangible assets deemed impaired net book value exceeds estimated fair value intangible assets evaluated impairment accordance sfas described estimates future cash flows based reasonable supportable assumptions projections require managements judgment changes key assumptions companys businesses prospects changes market conditions could result impairment charge discussions impairment longlived assets see item financial statementsnote accounting policiesimpairment longlived assets goodwill intangible assets equity investments company reviews equity investments impairment based determination whether decline market value investment companys carrying value temporary making determination company considers apb opinion equity method accounting investments common stock related interpretations set forth factors evaluated determining whether loss value recognized including companys ability hold investment market price market price fluctuations investments publicly traded shares inability investee sustain earnings capacity would justify carrying amount investment companys investment imclone subject accounting discussion companys investment imclone see item financial statementsnote alliances investments discussions equity investments see item financial statementsnote accounting policiesinvestments note alliances investments table contents marketable securities companys marketable securities december consisted us dollar denominated frs primarily aaaaaa rated frs long long term debt securities coupons reset periodically benchmark interest rate underlying assets companys frs consist primarily investment grade corporate bonds loans company accounts marketable securities accordance sfas accounting certain investments debt equity securities classifies available sale addition december company principal invested ars ars held company private placement securities longterm nominal maturities interest rates reset dutch auction month monthly auctions historically provided liquid market securities companys investments ars represent interests collateralized debt obligations supported pools residential commercial mortgages credit cards insurance securitizations structured credits including corporate bonds underlying collateral ars held company consists subprime mortgages due lack availability observable market quotes companys investment portfolio marketable securities ars company utilizes valuation models including based expected cash flow streams collateral values including assessments counterparty credit quality default risk underlying security discount rates overall capital market liquidity valuation companys investment portfolio subject uncertainties difficult predict factors may impact companys valuation include changes credit ratings securities well underlying assets supporting securities rates default underlying assets underlying collateral value discount rates counterparty risk ongoing strength quality market credit liquidity credit capital markets continued deteriorate uncertainties markets continue markets deteriorate company experiences additional ratings downgrades investments portfolio including ars company may incur additional impairments investment portfolio could negatively affect companys financial condition cash flow reported earnings discussions marketable securities see item financial statementsnote cash cash equivalents marketable securities restructuring streamline operations rationalize manufacturing facilities company periodically recorded restructuring charges result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place actual results could vary estimates adjustments million million million recorded respectively reflect changes estimates restructuring actions taken prior periods discussions restructuring see item financial statementsnote accounting policiesrestructuring note restructuring items contingencies normal course business company subject contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated estimates subject uncertainties difficult predict actual results could vary estimates discussions contingencies see item financial statementsnote accounting policiescontingencies note legal proceedings contingencies income taxes provision income taxes determined using asset liability approach accounting income taxes approach deferred taxes represent future tax consequences expected occur reported amounts assets liabilities recovered paid provision income taxes represents income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax bases companys assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recorded reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made december company net deferred tax assets million million respectively net valuation allowances million million respectively table contents company recorded significant deferred tax assets december related us foreign tax credit carryforwards approximately million us research tax credit carryforwards approximately million charitable contribution carryfowards million charitable contribution carryforwards expire varying amounts beginning foreign tax credit research tax credit carryforwards expire varying amounts beginning foreign tax credit research credit reduced due derecognition fin realization credits charitable contribution carryforwards dependent generating sufficient domestic taxable income prior expiration although realization assured management believes likely deferred tax assets realized company anticipates increasing level domestic profitability time undertaking actions pti increasing biologics manufacturing capacity us implementing tax planning strategies increasing domestic profitability likely cause companys effective tax rate increase also enhance companys ability utilize foreign tax credit research tax credit charitable contribution carryforwards company conducts business various countries throughout world subject tax numerous jurisdictions result business activities company files significant number tax returns subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported company may require several years resolve company establishes liabilities possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known company adopted fin january result adoption accounting pronouncement company recognized million previously unrecognized tax benefits accounted increase opening balance retained earnings previously reported upon adoption fin companys total amount uncertain tax benefits january net deferred income tax benefits excluding interest penalties million addition company derecognized adoption million unrecognized tax benefits tax rate impact settled gross unrecognized tax benefits january million total amount unrecognized tax benefits december excluding amounts recorded reductions deferred tax assets excluding interest penalties decreased million reduction primarily due tax benefits recognized favorable resolution uncertain tax positions partially offset additional uncertain tax benefits accrued additional information unrecognized tax benefits see item financial statementsnote income taxes december company approximately billion undistributed earnings foreign subsidiaries taxes provided company invested expects invest undistributed earnings permanently offshore future earnings repatriated us company determines earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided discussions income taxes see item financial statementsnote accounting policiesincome taxes note income taxes stockbased compensation expense company adopted sfas r sharebased payment requires measurement recognition compensation expense stockbased payment awards made employees directors based estimated fair values company uses modified prospective transition method requires application accounting standard january elected alternative method provided fsp r determining companys pool excess tax benefits companys consolidated financial statements years ended december reflect impact sfas r accordance modified prospective transition method companys consolidated financial statements prior periods restated reflect include impact sfas r stockbased compensation expense recognized sfas r years ended december million million respectively million million net tax respectively per share respectively corresponding amount recorded additional paidin capital within stockholders equity comparatively pro forma basis stockbased compensation expense million million net tax recognized year ended december apb additionally million related performance awards reclassified liabilities stockholders equity connection adoption sfas rthe company estimates fair value stockbased payment awards date grant using optionpricing model value portion award ultimately expected vest recognized expense requisite service periods companys consolidated statement earnings prior adoption sfas r company accounted stockbased awards employees directors using intrinsic value method related stock options accordance apb table contents allowed sfas accounting stockbased compensation intrinsic value method stockbased compensation expense recognized companys consolidated statement earnings exercise price companys stock options granted employees directors equaled fair market value underlying stock date grant stockbased compensation expense recognized period based value portion stockbased payment awards ultimately expected vest period stockbased compensation expense recognized companys consolidated statement earnings years ended december included compensation expense stockbased payment awards granted prior yet vested january based grant date fair value estimated accordance pro forma provisions sfas r compensation expense stockbased payment awards granted subsequent january based grant date fair value estimated accordance provisions sfas r conjunction adoption sfas r company changed method attributing value stockbased compensation expense accelerated multipleoption approach straightline single option method compensation expense stockbased payment awards granted prior continue recognized using accelerated multipleoption approach compensation expense stockbased payment awards service condition granted subsequent january recognized using straightline singleoption method stockbased payment awards granted subsequent january service market condition recognized using accelerated multipleoption approach required sfas r prior company applied apb opinion recognize compensation expense stock options granted plans exercise price option date grant equal fair market value date however grants restricted stock company recognized compensation expense straightline basis period restrictions expire fair value options granted estimated per common share per common share per common share respectively date grant using blackscholes optionpricing model assumptions used blackscholes optionpricing model follows expected volatility riskfree interest rate dividend yield expected life yrs yrs yrs company determines fair value certain stockbased payment awards date grant using optionpricing model model affected companys stock price well assumptions regarding number highly complex subjective variables variables include limited companys expected stock price volatility term awards actual projected employee stock option exercise behaviors respect accounting treatment retirement eligibility provisions employee stockbased compensation awards company historically followed nominal vesting period approach upon adoption sfas r company follows nonsubstantive vesting period approach recognizes compensation cost oneyear period awards granted retirementeligible employees period grant date date retirement eligibility achieved one year less vesting period impact applying nonsubstantive vesting period approach material companys consolidated financial statements stockbased compensation expense recognized consolidated statements earnings year ended december based awards ultimately expected vest reduced estimated forfeitures company estimates forfeitures time grant revises necessary subsequent periods actual forfeitures differ estimates companys pro forma information required sfas periods prior company accounted forfeitures occurredspecial note regarding forwardlooking statements annual report written oral statements company makes time time contain certain forwardlooking statements within meaning section securities act section e securities exchange act identify forwardlooking statements fact use words expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based table contents current expectations involve inherent risks uncertainties including factors could delay divert change could cause actual outcomes differ materially current expectations statements likely relate among things companys goals plans projections regarding financial position results operations cash flows market position product development product approvals sales efforts expenses performance results current anticipated products outcome contingencies legal proceedings financial results based current expectations involve inherent risks uncertainties including internal external factors could delay divert change next several years company included important factors cautionary statements included annual report particularly item risk factors company believes could cause actual results differ materially forwardlooking statement although company believes prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made company undertakes obligation release publicly revisions forwardlooking statements result new information future events otherwise table contents item quantitative qualitative disclosures market risk company exposed market risk due changes currency exchange rates interest rates deterioration credit capital markets reduce risk company enters certain derivative financial instruments available costeffective basis hedge underlying economic exposure instruments managed consolidated basis efficiently net exposures thus take advantage natural offsets derivative financial instruments used speculative purposes gains losses hedging transactions offset gains losses underlying exposures hedged ineffective portion hedges reported earnings occurs companys primary net foreign currency translation exposures euro canadian dollar japanese yen mexican peso chinese renminbi company utilizes foreign currency contracts hedge anticipated transactions primarily intercompany transactions certain foreign currencies designates derivative instruments foreign currency cash flow hedges appropriate table summarizes companys outstanding foreign exchange forward contracts december fair value foreign exchange forward contracts based yearend currency rates fair value foreign exchange forward contracts viewed relation fair value underlying hedged transactions overall reduction exposure adverse fluctuations foreign currency exchange rates weighted average strike fair value dollars millions except currency rates price notional amount assetliability maturity foreign exchange forwards cash flow hedges australian dollar british pound canadian dollar euro japanese yen mexican peso polish zloty swedish krona swiss franc total cash flow hedges nonqualifying hedges australian dollar british pound canadian dollar euro japanese yen polish zloty turkish lira total nonqualifying hedges total contracts nonqualifying hedges hedges qualify hedge accounting treatment prescribed sfas accounting derivative instruments hedging activities december company held foreign exchange option contracts buy sell japanese yen total notional fair market value buy contracts million million respectively fully offset total notional fair market value sell contracts million million respectively december company held foreign exchange forward contracts maturity dates notional amounts fair values expressed table dollars millions year maturity notional amount fair value december fair value companys foreign exchange forward contracts net liability million million recorded noncurrent asset million recorded current liability company estimates appreciation depreciation underlying currencies hedged levels dollar december variables held constant would decrease million increase million respectively fair value foreign exchange forward contracts held december table contents company obligated settle foreign exchange forward contracts based specified contract rates december balance deferred losses foreign exchange forward contracts included accumulated comprehensive income oci pretax basis million million net tax expected reclassified earnings within next months december fair value companys foreign exchange forward contracts net liability million million recorded noncurrent asset million recorded current liability years ended december impact hedge ineffectiveness earnings significant additionally years ended december impact discontinued hedges pretax loss million pretax loss million pretax gain million respectively furthermore company uses foreign exchange forward contracts offset exposure certain assets liabilities earnings denominated foreign currencies foreign exchange forward contracts designated hedges therefore changes fair value derivatives recognized earnings occur notional fair value amounts foreign exchange forward contracts december described table foreign exchange forward contracts type outstanding december impact foreign exchange forward contracts designated hedges pretax gain million amounts recognized earnings related foreign exchange forward contracts qualify hedge accounting treatment significant addition foreign exchange hedge contracts noted company utilizes forward contracts hedge foreign currencydenominated monetary assets liabilities primary objective forward contracts protect us dollar value foreign currencydenominated monetary assets liabilities effects volatility foreign exchange rates might occur prior receipt settlement us dollars foreign currency denominated monetary assets liabilities primarily denominated euro forward contracts designated hedges marked market expense net notional fair value amounts purchased foreign exchange forward contracts material december million million asset respectively december notional fair value amounts sold foreign exchange forward contracts december million million liability respectively december company uses nonus dollar borrowings primarily million notes due million notes due hedge foreign currency exposures companys net investment certain foreign affiliates nonus dollar borrowings designated hedges net investments effective portion foreign exchange gains losses hedges recorded part foreign currency translation component accumulated oci december million million losses respectively recorded foreign currency translation component accumulated oci company uses derivative instruments part interest rate risk management strategy derivative instruments used comprised principally fixed floating rate interest rate swaps subject fairvalue hedge accounting treatment november connection funding retirement fixed rate debt company executed several fixed floating interest rate swaps convert billion billion billion inception companys newly issued fixed rate debt paid variable rate debt total notional amount outstanding interest rate swaps billion billion billion december billion billion billion december accordance sfas accounting derivative instruments hedging activities company recognized net increase interest expense million million respectively net reduction interest expense million impact interest rate swaps table contents sfas requires revaluation fair value swap contracts well underlying debt hedged swap contracts underlying debt revalued resulting increase noncurrent assets million current liabilities million reduction longterm debt million december increase noncurrent assets million current liabilities million reduction longterm debt million december swap contracts generally held maturity intended create appropriate balance fixed floating rate debt company swap contracts qualify fair value hedges terminated prior maturity dates reported part carrying value underlying debt amortized earnings remaining life debt swap contracts qualify cash flow hedges terminated reported accumulated oci amortized earnings remaining life debt following tables summarize interest rate swaps outstanding december earnings impact terminated interest rate swap contracts interest rate swaps outstanding notional amount underlying variable rate year fair interest rate contracts debt received transaction maturity value dollars millions swaps associated notes due month us libor notes due month us libor million notes due month eur euribor million notes due month eur euribor notes due month us libor notes due month us libor earnings impact terminated interest rate swap contracts notional amount total pretax pretax incomeexpense recognized year underlying deferred termination debt gainloss interest rate contracts dollars millions interest rate swap lock associated notes due note due swaps associated notes due notes due notes due notes due underlying notes extinguished underlying notes extinguished underlying notes extinguished december company held interest rate swap contracts notional value billion billion billion fair value net liability million estimated increase decrease basis points shortterm longterm interest rates would material impact companys consolidated financial position results operations cash flows company million million longterm debt outstanding december respectively additional information see item financial statementsnote shortterm borrowings longterm debt note financial instrumentsthe companys marketable securities december consisted us dollar denominated floating rate securities frs primarily aaaaaa rated frs long longterm debt securities coupons reset periodically benchmark interest rate underlying assets companys frs consist primarily investment grade corporate bonds loans company accounts marketable securities accordance sfas accounting certain investments debt equity securities classifies available sale carrying value frs reduced million table contents million million december reflecting change fair market value company assessed decline fair market value temporary recorded pretax million reduction million net tax shareholders equity accumulated oci addition december company million principal invested auction rate securities ars ars held company private placement securities longterm nominal maturities interest rates reset dutch auction month monthly auctions historically provided liquid market securities companys investments ars represent interests collateralized debt obligations supported pools residential commercial mortgages credit cards insurance securitizations structured credits including corporate bonds underlying collateral ars held company consists subprime mortgages consistent companys investment policy guidelines ars investments held company aaaaaa credit ratings time purchase liquidity issues experienced global credit capital markets ars held company december experienced multiple failed auctions amount securities submitted sale exceeded amount purchase orders addition fourth quarter million principal invested ars held company downgraded others placed credit watch securities retain least one aaa rating december estimated market value companys ars holdings december million reflects million adjustment principal value million although ars continue pay interest according stated terms based thirdparty valuation models analysis thantemporary impairment factors company recorded pretax impairment charge million fourth quarter reflecting portion ars holdings company concluded otherthantemporary decline value addition company recorded unrealized loss million pre tax net tax accumulated oci reduction shareholders equity reflecting adjustments ars holdings company concluded temporary decline value million impairment charge material impact companys liquidity financial flexibility due lack availability observable market quotes companys investment portfolio marketable securities ars company utilizes valuation models including based expected cash flow streams collateral values including assessments counterparty credit quality default risk underlying security discount rates overall capital market liquidity valuation companys investment portfolio subject uncertainties difficult predict factors may impact companys valuation include changes credit ratings securities well underlying assets supporting securities rates default underlying assets underlying collateral value discount rates counterparty risk ongoing strength quality market credit liquidity credit capital markets continued deteriorate uncertainties markets continue markets deteriorate company experiences additional ratings downgrades investments portfolio including ars company may incur additional impairments investment portfolio could negatively affect companys financial condition cash flow reported earnings marketable securities december consisted us dollardenominated ars frs principal values ars frs million million respectively companys carrying value ars frs december principal value approximated fair value table contents bristolmyers squibb company consolidated statements earnings dollars shares millions except per share data item financial statements supplementary data year ended december earnings net sales costs products sold marketing selling administrative advertising product promotion research development acquired inprocess research development provision restructuring net litigation expense net gain sale product assets businesses equity net income affiliates expense net total expenses net earnings continuing operations minority interest income taxes provision income taxes minority interest net taxes net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings earnings per common share basic net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings per common share diluted net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings per common share average common shares outstanding basic diluted dividends declared per common share accompanying notes integral part financial statements table contents bristolmyers squibb company consolidated statements comprehensive income retained earnings dollars millions year ended december comprehensive income net earnings comprehensive incomeloss foreign currency translation tax effect net tax liability deferred gainslosses derivatives qualifying hedges net tax benefit net tax liability minimum pension liability adjustment net tax liability net tax benefit deferred gains pension postretirement benefits net tax liability deferred gainslosses available sale securities net tax benefit net tax liability net tax benefit total comprehensive income comprehensive income retained earnings retained earnings january cumulative effect adoption fin net earnings cash dividends declared retained earnings december accompanying notes integral part financial statements table contents bristolmyers squibb company consolidated balance sheets dollars millions except per share data december assets current assets cash cash equivalents marketable securities receivables net allowances inventories net deferred income taxes net valuation allowances prepaid expenses assets held sale total current assets property plant equipment net goodwill intangible assets net deferred income taxes net valuation allowances assets total assets liabilities current liabilities shortterm borrowings accounts payable accrued expenses deferred income accrued rebates returns us foreign income taxes payable dividends payable accrued litigation liabilities liabilities related assets held sale total current liabilities pension liabilities postretirement liabilities deferred income us foreign income taxes payable liabilities longterm debt total liabilities commitments contingencies note stockholders equity preferred stock convertible series authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares billion issued capital excess par value stock restricted stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares million total stockholders equity total liabilities stockholders equity accompanying notes integral part financial statements table contents bristolmyers squibb company consolidated statements cash flows dollars millions year ended december cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities depreciation amortization deferred income tax benefits litigation settlement expense net recoveries stockbased compensation expense provision restructuring gain sale product asset businesses deferred income recognized acquired inprocess research development impairment charges asset writeoffs loss disposal property plant equipment investment companies deferred expenses extinguishment longterm debt underover distribution earnings affiliates unfunded pension expense changes operating assets liabilities receivables inventories prepaid expenses assets litigation settlement payments net insurance recoveries accounts payable accrued expenses product liability us foreign income taxes payable deferred income liabilities net cash provided operating activities cash flows investing activities proceeds marketable securities purchases marketable securities additions property plant equipment capitalized software proceeds disposal property plant equipment investment companies proceeds sale product assets businesses proceeds sale leaseback properties milestone payments purchase adnexus therapeutics net cash acquired purchases investments net cash used inprovided investing activities cash flows financing activities shortterm repaymentsborrowings longterm borrowings longterm debt repayments charges extinguishment longterm debt issuances common stock stock plans excess tax benefits sharebased payment arrangements dividends paid net cash used financing activities effect exchange rates cash cash equivalents decrease cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period consolidated statements cash flows include activities medical imaging business accompanying notes integral part financial statements table contents note accounting policies basis consolidation consolidated financial statements prepared conformity united states us generally accepted accounting principles gaap include accounts bristolmyers squibb company bms company bristolmyers squibb controlled majorityowned subsidiaries intercompany balances transactions eliminated certain prior year amounts reclassified conform current year presentation use estimates preparation financial statements requires use estimates assumptions based complex judgments considered reasonable affect reported amounts assets liabilities disclosure contingent assets contingent liabilities date financial statements reported amounts revenues expenses reporting period significant assumptions employed estimates used determining values intangible assets restructuring charges accruals sales rebate return accruals legal contingencies tax assets tax liabilities stockbased compensation costs retirement postretirement benefits including actuarial assumptions financial instruments observable market quotes well estimates used applying revenue recognition policy actual results may may differ estimated results revenue recognition company recognizes revenue accordance staff accounting bulletin sab revenue recognition financial statements amended sab revenue recognition title substantially risks rewards ownership transferred customer generally revenue recognized time shipment however case certain sales made nutritionals convatec segments certain nonus businesses within pharmaceuticals segment revenue recognized date receipt purchaser accordance statements financial accounting standards sfas revenue recognition right return exists revenues reduced time recognition reflect expected returns estimated based historical experience business trends additionally accordance emerging issues task force eitf issue accounting consideration given vendor customer including reseller vendors products provisions made time revenue recognition discounts rebates estimated sales allowances based historical experience updated changes facts circumstances appropriate provisions recorded reduction revenue case new products product introduction extension existing line product company determines products similar therapeutic category company determines new product dissimilar characteristics existing products company reliably estimate expected returns new product company defers recognition revenue right return longer exists company developed sufficient historical experience estimate sales returns sales rebate return accruals medicaid rebate accruals million million december respectively women infants children wic rebate accruals million million december respectively sales return accruals million million december respectively managed health care rebate contractual discount accruals million million december respectively rebate accruals established period related revenue recognized resulting reduction sales establishment liability included accrued liabilities accrual recorded based estimate proportion recorded revenue result rebate return prime vendor chargeback accruals established similar manner recorded reduction accounts receivable million million december respectivelyincome taxes provision income taxes determined using asset liability approach accounting income taxes approach deferred taxes represent future tax consequences expected occur reported amounts assets liabilities recovered paid provision income taxes represents income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax bases companys assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recorded reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made december company net deferred tax assets million million respectively net valuation allowances million million respectively table contents note accounting policies continued company recorded significant deferred tax assets december related us foreign tax credit carryforwards approximately million us research tax credit carryforwards approximately million charitable contribution carryforwards million charitable contribution carryforwards expire varying amounts beginning foreign tax credit research tax credit carryforwards expire varying amounts beginning foreign tax credit research credit reduced due derecognition financial accounting standards board fasb interpretation fin accounting uncertainty income taxes interpretation fasb statement realization credits charitable contribution carryforwards dependent generating sufficient domestic taxable income prior expiration although realization assured management believes likely deferred tax assets realized company anticipates increasing level domestic profitability time undertaking actions productivity transformation initiative pti increasing biologics manufacturing capacity us implementing tax planning strategies increasing domestic profitability likely cause companys effective tax rate increase also enhance companys ability utilize foreign tax credit research tax credit charitable contribution carryforwards company conducts business various countries throughout world subject tax numerous jurisdictions result business activities company files significant number tax returns subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported company may require several years resolve company establishes liabilities possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known effect changes estimates related contingent tax liabilities included effective tax rate reconciliation note income taxes july fasb issued fin case company effective january fin clarifies accounting uncertainty income taxes recognized enterprises financial statements accordance sfas accounting income taxes fin requires tax positions evaluated using recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return differences tax positions taken tax return amounts recognized financial statements recorded adjustments income taxes payable receivable adjustments deferred taxes fin also requires expanded disclosure end reporting period including tabular reconciliation unrecognized tax benefits company adopted fin january result adoption accounting pronouncement company recognized million previously unrecognized tax benefits accounted increase opening balance retained earnings may fasb issued fasb staff position fsp fin definition settlement fasb interpretation effective retroactively january fsp fin provides guidance determine whether tax position effectively settled purpose recognizing previously unrecognized tax benefits adoption fsp fin effect companys consolidated financial statements previously reported upon adoption fin companys total amount uncertain tax benefits january net deferred income tax benefits excluding interest penalties million addition company derecognized adoption million unrecognized tax benefits tax rate impact settled gross unrecognized tax benefits january million december company approximately billion undistributed earnings foreign subsidiaries taxes provided company invested expects invest undistributed earnings permanently offshore future earnings repatriated us company determines earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided cash cash equivalents cash cash equivalents primarily consist bank deposits time deposits money market funds cash equivalents primarily highly liquid investments original maturities three months less time purchase recorded cost approximates fair value company maintains cash cash equivalent balances us dollars foreign currencies subject currency rate risk marketable securities company accounts marketable securities accordance sfas accounting certain investments debt equity securities company determined appropriate classification marketable securities availableforsale time purchase december companys investments marketable securities reported fair value fair value determined based observable market quotes valuation models using assessments table contents note accounting policies continued counterparty credit worthiness credit default risk underlying security overall capital market liquidity declines fair value considered temporary charged earnings considered temporary reported component accumulated comprehensive income oci stockholders equity company uses average cost method determining cost basis computing realized gains losses sale available forsale securities realized gains losses included income expense inventory valuation inventories generally stated average cost excess market capital assets depreciation expenditures additions renewals improvements capitalized cost depreciation generally computed straightline method based estimated useful lives related assets estimated useful lives major classes depreciable assets years buildings years machinery equipment fixtures company periodically evaluates whether current events circumstances indicate carrying value depreciable assets may recoverable impairment longlived assets company periodically evaluates whether current facts circumstances indicate carrying value depreciable assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows produced longlived asset appropriate grouping assets compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques including discounted value estimated future cash flows company reports asset disposed lower carrying value estimated net realizable value capitalized software certain costs obtain internal use software significant systems projects capitalized amortized estimated useful life software ranges years costs obtain software projects significant expensed incurred capitalized software net accumulated amortization included intangible assets million million december respectively amortization expense million million million years ended december respectively investments company accounts lessowned companies ability exercise significant influence using equity method accounting otherwise cost method used companys share net income losses equity investments included equity net income affiliates consolidated statement earnings losses recognized income expense decline market value deemed temporary company reviews equity investments impairment based determination whether decline market value investment companys carrying value temporary making determination company considers accounting principles board apb opinion equity method accounting investments common stock related interpretations set forth factors evaluated determining whether loss value recognized including companys ability hold investment market price market price fluctuations investments publicly traded shares inability investee sustain earnings capacity would justify carrying amount investment goodwill intangible assets accordance sfas goodwill intangible assets goodwill tested impairment annually using twostep process first step identify potential impairment second step measures amount impairment loss goodwill deemed impaired carrying amount reporting units goodwill exceeds estimated fair value company completed annual goodwill impairment assessment first quarter monitored potential impairment remaining quarters neither indicated impairment goodwillother intangible assets consisting patents trademarks technology licenses capitalized software amortized straightline basis useful lives ranging years intangible assets capitalized software deemed impaired net carrying value exceeds estimated fair value capitalized software evaluated impairment described impairment longlived assets table contents note accounting policies continued restructuring streamline operations rationalize manufacturing facilities company periodically recorded restructuring charges result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place actual results may vary estimates product liability accruals product liability including associated legal costs recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information accruals adjusted periodically assessment efforts progress additional information becomes available receivables related insurance thirdparty recoveries product liabilities recorded undiscounted basis probable recovery realized classified reduction litigation charges consolidated statement earnings contingencies normal course business company subject loss contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability tax matters accordance sfas accounting contingencies company records accruals loss contingencies probable liability incurred amount loss reasonably estimated company accordance sfas recognize gain contingencies realized discussion contingencies see note income taxes note legal proceedings contingencies derivative financial instruments derivative financial instruments used company principally management interest rate foreign currency exposures company hold issue derivative financial instruments speculative purposes company records derivative instruments balance sheet fair value changes derivatives fair value recognized earnings unless specific hedge criteria met derivative designated fair value hedge changes fair value derivative hedged item attributable hedged risk recognized consolidated statement earnings derivative designated cash flow hedge effective portions changes fair value derivative recorded oci subsequently recognized consolidated statement earnings hedged item affects earnings cash flows classified consistent underlying hedged item purchased foreign currency options entire change fair value included measurement hedge effectiveness cash flow hedges ineffective portions changes fair value cash flow hedges recognized charge credit earnings company designates assigns derivatives hedges forecasted transactions specific assets specific liabilities hedged assets liabilities sold extinguished forecasted transactions hedged longer expected occur company immediately recognizes gain loss designated hedging financial instruments consolidated statement earnings shipping handling costs company typically charge customers shipping handling costs therefore shipping handling costs included marketing selling administrative expenses million million million advertising costs advertising costs expensed incurred advertising expense million million million respectively table contents note accounting policies continued research development research development costs expensed incurred company time time enter strategic alliances third parties give company rights develop manufacture market andor sell pharmaceutical products rights owned third parties result alliances company may obligated make payments alliance partners connection research development contingent upon achievement certain predetermined criteria milestones achieved prior regulatory approval product payments expensed research development milestone payments made connection regulatory approvals including nonus regulatory approvals additional indications capitalized amortized cost products sold remaining useful life asset capitalized milestone payments tested recoverability periodically whenever events changes circumstances indicate carrying amounts may recoverable company records research development net reimbursements connection collaboration agreements acquired inprocess research development fair value inprocess research development acquired business combination determined based present value research projects projected cash flows income approach utilized consistent guidance practice aid issued american institute certified public accountants assets acquired business combinations used research development activities focus software electronic devices pharmaceutical industries future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research projects underlying patent determining fair value research project expected revenues first adjusted technical risk completion resulting cash flows discounted rate approximating companys weightedaverage cost capital acquired inprocess research development expensed incurred underlying product received regulatory approval future alternative use addition costs nonrefundable related acquisition licensing products yet received regulatory approval marketed alternative future use charged earnings incurred earnings per share basic earnings per common share computed using weightedaverage number shares outstanding year diluted earnings per common share computed using weightedaverage number shares outstanding year plus incremental shares outstanding assuming exercise dilutive stock options restricted stock convertible instruments foreign currency translation statements earnings companys foreign subsidiaries translated us dollars using average exchange rates net assets companys foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation adjustment account included accumulated oci recently issued accounting standards december meeting fasb ratified consensus reached eitf issue accounting collaborative arrangements related development commercialization intellectual property eitf concluded collaborative arrangement one participants actively involved exposed significant risks rewards depend ultimate commercial success endeavor revenues costs incurred third parties connection collaborative arrangements would presented gross net based criteria eitf reporting revenue gross principal versus net agent accounting literature payments collaborators would evaluated presented based nature arrangement terms nature entitys business whether payments within scope accounting literature nature purpose collaborative arrangements disclosed along accounting policies classification amounts significant financial statement amounts related arrangements activities arrangement conducted separate legal entity accounted accounting literature however required disclosure eitf applies entire collaborative agreement issue effective fiscal years beginning december applied retrospectively periods presented collaborative arrangements existing effective date company currently process evaluating impact adopting pronouncementin december fasb issued sfas r business combinations replaces sfas business combinations requires acquirer recognize assets acquired liabilities assumed noncontrolling interest acquiree acquisition date measured fair values date limited exceptions statement also requires table contents note accounting policies continued acquirer business combination achieved stages recognize identifiable assets liabilities well noncontrolling interest acquiree full amounts fair values sfas r makes various amendments authoritative literature intended provide additional guidance confirm guidance literature provided statement statement applies business combinations acquisition date december company currently process evaluating impact adopting pronouncement december fasb issued sfas noncontrolling interests consolidated financial statementsan amendment arb sfas establishes accounting reporting standards require ownership interests subsidiaries held parties parent clearly identified labeled presented consolidated statement financial position within equity separate parents equity statement also requires amount consolidated net income attributable parent noncontrolling interest clearly identified presented face consolidated statement income changes parents ownership interest parent retains controlling financial interest subsidiary must accounted consistently subsidiary deconsolidated retained noncontrolling equity investment former subsidiary must initially measured fair value gain loss deconsolidation subsidiary measured using fair value noncontrolling equity investment statement also requires entities provide sufficient disclosures clearly identify distinguish interests parent interests noncontrolling owners statement effective fiscal years beginning december company currently process evaluating impact adopting pronouncement june eitf reached consensus issue accounting nonrefundable advance payments goods services received used future research development activities nonrefundable advance payments goods services used rendered future research development activities deferred capitalized amounts recognized expense related goods delivered services performed goods services longer expected provided issue effective fiscal years beginning december earlier application permitted pronouncement expected material effect companys consolidated financial statements february fasb issued sfas fair value option financial assets financial liabilitiesincluding amendment fasb statement permits entity measure certain financial assets financial liabilities fair value objective sfas improve financial reporting allowing entities mitigate volatility reported earnings caused measurement related assets liabilities using different attributes without apply complex hedge accounting provisions sfas entities elect fair value option instrument report unrealized gains losses earnings subsequent reporting date fair value option election irrevocable unless new election date occurs sfas establishes presentation disclosure requirements help financial statement users understand effect entitys election earnings eliminate disclosure requirements accounting standards assets liabilities measured fair value must displayed face balance sheet statement effective fiscal years beginning november company elect early adoption pronouncement permitted adoption accounting pronouncement expected material effect companys consolidated financial statements september fasb issued statement sfas employers accounting defined benefit pension postretirement plansan amendment fasb statements r pronouncement requires employer recognize overfunded underfunded status defined benefit postretirement plan multiemployer plan asset liability statement financial position recognize changes funded status year changes occur comprehensive income business entity pronouncement also requires employer measure funded status plan date yearend statement financial position limited exceptions pronouncement require prior periods restated reflect impact sfas company adopted sfas fiscal year ended december adoption accounting pronouncement resulted million reduction accumulated oci stockholders equity million reduction total assets million increase total liabilities adoption sfas impact companys results operations cash flows september fasb issued sfas fair value measurements pronouncement defines fair value establishes framework measuring fair value expands disclosures fair value measurements statement effective fiscal years beginning november november fasb agreed oneyear deferral implementation sfas nonfinancial assets liabilities adoption accounting pronouncement expected material effect companys consolidated financial statements financial assets liabilities assets liabilities carried fair value company currently process evaluating impact adopting pronouncement nonfinancial assets liabilities table contents note accounting policies continued september us securities exchange commission sec issued sab considering effects prior year misstatements quantifying misstatements current year financial statements expresses staffs views regarding process quantifying financial statement misstatements bulletin effective interim period first fiscal year ending november sab requires companies utilize dual approach assess quantitative effects financial statement misstatements dual approach includes income statement focus balance sheet focus assessment adoption bulletin effect companys consolidated financial statements july fasb issued fasb interpretation fin accounting uncertainty income taxes interpretation fasb statement case company effective january fin clarifies accounting uncertainty income taxes recognized enterprises financial statements accordance sfas accounting income taxes fin requires tax positions evaluated using recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return differences tax positions taken tax return amounts recognized financial statements recorded adjustments income taxes payable receivable adjustments deferred taxes fin also requires expanded disclosure end reporting period including tabular reconciliation unrecognized tax benefits company adopted fin january result adoption accounting pronouncement company recognized million previously unrecognized tax benefits accounted increase opening balance retained earnings may fasb issued fsp fin definition settlement fasb interpretation effective retroactively january fsp fin provides guidance determine whether tax position effectively settled purpose recognizing previously unrecognized tax benefits adoption fsp fin effect companys consolidated financial statements march fasb issued sfas accounting servicing financial assets amendment fasb statement pronouncement relates accounting separately recognized servicing assets servicing liabilities statement effective fiscal years beginning september adoption accounting pronouncement material effect companys consolidated financial statements february fasb issued sfas accounting certain hybrid financial instruments amendment fasb statements pronouncement primarily resolves certain issues addressed implementation sfas accounting derivative instruments hedging activities concerning beneficial interests securitized financial assets statement effective financial instruments acquired issued subject remeasurement event occurring beginning fiscal year adoption accounting pronouncement material effect companys consolidated financial statements may fasb issued sfas accounting changes error correctionsa replacement apb opinion fasb statement pronouncement applies voluntary changes accounting principle revises requirements accounting reporting change accounting principle sfas requires retrospective application prior periods financial statements voluntary change accounting principle unless impracticable pronouncement also requires change method depreciation amortization depletion longlived nonfinancial assets accounted change accounting estimate effected change accounting principle sfas effective accounting changes corrections errors made fiscal years beginning december statement change transition provisions existing accounting pronouncements including transition phase effective date sfas adoption accounting pronouncement material effect companys consolidated financial statements march fasb issued fin accounting conditional asset retirement obligationsan interpretation fasb statement fin clarifies entity must record liability conditional asset retirement obligation fair value obligation reasonably estimated asset retirement obligations covered fin entity legal obligation perform asset retirement activity even timing method settling obligation conditional future event may may within control entity fin also clarifies entity would sufficient information reasonably estimate fair value asset retirement obligation interpretation effective later end fiscal years ending december company adopted provisions fin fiscal year ended december adoption accounting pronouncement material effect companys consolidated financial statementsin december fasb issued sfas revised sharebased payment sfas r requires measurement recognition compensation expense stockbased payment awards made employees directors based estimated fair values sfas r supersedes companys previous accounting apb accounting stock issued employees periods beginning january march sec issued sab sharebased table contents note accounting policies continued payment relating sfas r company applied provisions sab adoption sfas r company adopted sfas r using modified prospective transition method requires application accounting standard january elected alternative method provided fsp r transition election related accounting tax effects sharebased payment awards determining companys pool excess tax benefits companys consolidated financial statements year ended december reflect impact sfas r accordance modified prospective transition method companys consolidated financial statements prior periods restated reflect include impact sfas r stockbased compensation expense recognized sfas r year ended december million million net tax per share corresponding amount recorded additional paidin capital within stockholders equity additionally million related performance awards reclassified liabilities stockholders equity connection adoption sfas r note alliances investments sanofiaventis company agreements sanofiaventis sanofi codevelopment cocommercialization avaproavalide irbesartan angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy plavix clopidogrel platelet aggregation inhibitor worldwide alliance operates framework two geographic territories one americas principally us canada puerto rico latin american countries australia europe asia accordingly two territory partnerships formed manage central expenses marketing research development royalties supply finished product individual countries general country level agreements either copromote whereby partnership formed parties sell brand comarket whereby parties operate sell brands independently place agreements expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patents exclusivity rights applicable territory company acts operating partner territory covering americas australia owns majority controlling interest territory sanofis ownership interest territory company consolidates country partnership results territory records sanofis share results minority interest net taxes million million million company recorded sales territory comarketing countries territory covering europe asia million million million cash flows operating activities partnerships territory covering americas australia recorded operating activities within companys consolidated statement cash flows distributions partnership profits sanofi sanofis funding ongoing partnership operations occur routine basis also recorded within operating activities companys consolidated statement cash flows sanofi acts operating partner territory covering europe asia owns majority financial controlling interest within territory companys ownership interest partnerships within territory company accounts investment partnership entities territory equity method records share results equity net income affiliates consolidated statement earnings companys share net income partnership entities taxes million million million company routinely receives distributions profits provides funding ongoing operations partnerships territory covering europe asia transactions recorded operating activities within companys consolidated statement cash flows company sanofi companies formed alliance copromotion irbesartan part company contributed irbesartan distribution rights us sanofi paid company total million two years ended december company accounted transaction sale interest license million deferred amortized income expected useful life license approximately years formation irbesartan copromotion alliance company recognized income million million million respectively unamortized portion deferred income recorded liabilities section consolidated balance sheet million million december respectively table contents note alliances investments continued following summarized financial information companys equity investments partnership sanofi territory covering europe asia dollars millions revenues gross profit net income current assets current liabilities otsuka company worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote otsuka abilify aripiprazole treatment schizophrenia related psychiatric disorders except japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt product currently copromoted otsuka united kingdom uk germany france spain us germany spain product invoiced thirdparty customers company behalf otsuka company records alliance revenue contractual share thirdparty net sales records expenses related product company recognizes alliance revenue abilify shipped risks rewards ownership transferred thirdparty customers uk france italy company presently exclusive distributor product company records net sales related cost products sold expenses company also exclusive right sell abilify countries europe americas number countries asia countries company records net sales related cost products sold terms agreement company purchases product otsuka performs finish manufacturing sale company otsuka thirdparty customers agreement expires november us entire european union agreement expires june country company exclusive right sell abilify agreement expires later th anniversary first commercial sale country expiration applicable patent country company recorded total revenue abilify million million million total milestone payments made otsuka agreement december million million expensed acquired inprocess research development remaining million capitalized intangible assets amortized cost products sold remaining life agreement us ranging years company amortized cost products sold million unamortized capitalized payment balance million million december respectively imclone company commercialization agreement expiring september imclone systems incorporated imclone biopharmaceutical company focused developing targeted cancer treatments codevelopment copromotion erbitux us us food drug administration fda approved biologics license application erbitux use combination irinotecan treatment patients epidermal growth factor receptor egfrexpressing metastatic colorectal cancer mcrc refractory irinotecanbased chemotherapy use single agent treatment patients egfrexpressing mcrc intolerant irinotecanbased chemotherapy march fda approved erbitux use treatment squamous cell carcinoma head neck combination radiation monotherapy company paid million milestone payment imclone fda approvals agreement imclone receives distribution fee based flat rate net sales north america october company imclone amended codevelopment agreement merck kgaa provide cocommercialization erbitux japan expires imclone ability terminate agreement determine commercially unreasonable continue erbitux yet marketed japan although application submitted japanese pharmaceuticals medical devices agency use erbitux treating patients advanced colorectal cancer company accounts million total approval milestones paid license acquisitions amortizes payments cost products sold remaining term agreement ends company amortized cost products sold million million million respectively unamortized portion approval payments recorded intangible assets million million december respectively table contents note alliances investments continued company accounts investment imclone equity method records share results equity net income affiliates consolidated statement earnings companys recorded investment market value holdings imclone common stock million approximately million december respectively million approximately million december respectively company holds million shares imclone stock representing approximately imclones shares outstanding december per share basis carrying value imclone investment closing market price imclone shares december respectively compared respectively december company determines equity share imclones net income loss eliminating imclones results milestone revenue imclone recognizes million preapproval milestone payments made company company recorded million preapproval milestone payments equity investment expensed remaining million acquired inprocess research development period milestone revenue recognized imclone excess million eliminated company determining equity share imclones results share imclones results operations company recorded net income million net income million net loss million company recorded net sales erbitux million million million gilead company gilead sciences inc gilead entered joint venture develop commercialize fixeddose combination companys sustiva efavirenz gileads truvada emtricitabine tenofovir disoproxil fumarate us july fda granted approval atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg treatment human immunodeficiency virus infection adults september companies amended agreements commercialize atripla canada atripla approved health canada october european commission december commercialization countries eu well norway iceland gilead records atripla revenues consolidates results joint venture operating results company records revenue bulk efavirenz component atripla upon sales product joint venture gilead thirdparty customers companys revenue efavirenz component determined applying percentage atripla revenue approximates revenue sustiva brand company recorded efavirenz revenues million million respectively related atripla sales company accounts participation joint venture equity method accounting records share joint venture results equity net income affiliates consolidated statement earnings company recorded equity loss joint venture gilead million million million astrazeneca january company entered two worldwide except japan codevelopment cocommercialization agreements astrazeneca plc astrazeneca one codevelopment cocommercialization saxagliptin dppiv inhibitor saxagliptin agreement one codevelopment cocommercialization dapagliflozin sodiumglucose contransporter sglt inhibitor sglt agreement compounds studied treatment diabetes discovered company terms agreements company received astrazeneca upfront payment million january deferred recognized useful life products income company amortized income million upfront payments unamortized portion upfront payment million december milestone payments expected received company upon successful achievement various development regulatory events well salesrelated milestones saxagliptin agreement company could receive million development regulatory milestones met additional million salesbased milestones met sglt agreement company could receive million development regulatory milestones met additional million salesbased milestones met agreement company astrazeneca also share development commercialization costs majority development costs initial development plans paid astrazeneca additional development costs generally shared equally company records development costs related saxagliptin dapagliflozin net astrazenecas share research development expenses agreement two companies jointly develop clinical marketing strategy share commercialization expenses profitslosses equally global basis excluding japan company manufacture productspfizer april company pfizer inc pfizer entered worldwide codevelopment cocommercialization agreement apixaban anticoagulant discovered company studied prevention treatment broad range venous arterial thrombotic conditions accordance terms agreement pfizer made upfront payment table contents note alliances investments continued million company may deferred recognized life agreement income december company pfizer agreed include japan worldwide agreement connection japan agreement pfizer made additional upfront payment million december deferred recognized useful life product income company amortized income million two upfront payments unamortized portion upfront payment million december pfizer fund development costs effective january going forward company fund company records apixaban development costs net pfizers share research development expenses company may also receive additional payments million pfizer based development regulatory milestones companies jointly develop clinical marketing strategy share commercialization expenses profitslosses equally global basis manufacture product arrangement note restructuring activities december company announced threeyear plan fundamentally change way runs business meet challenges changing business environment take advantage diverse opportunities marketplace company transformed nextgeneration biopharmaceutical company previously announced pti company aims achieve culture continuous improvement enhance efficiency effectiveness competitiveness substantially improve cost base company recorded pretax charges million relating termination benefits related costs workforce reductions approximately manufacturing selling administrative personnel across geographic regions charges offset million adjustments reflecting changes estimates restructuring actions taken prior periods following table presents detail charges segment type company expects substantially complete activities end termination dollars millions benefits exit costs total pharmaceuticals nutritionals convatec corporateother subtotal changes estimates provision restructuring net activities company recorded pretax charges million relating termination benefits related costs workforce reductions approximately selling operating administrative personnel primarily north america europe asia latin america charges decreased million adjustments reflecting changes estimates restructuring actions taken prior periods following table presents detail charges segment type company expects substantially complete activities termination benefits exit costs total dollars millions pharmaceuticals nutritionals convatec subtotal changes estimates provision restructuring net table contents note restructuring continued activities company recorded pretax charges million relating termination benefits related costs workforce reductions approximately selling administrative personnel primarily north america latin america europe africa asia charge includes restructuring us cardiovascularmetabolics primary care sales organization charges offset million adjustments reflecting changes estimates restructuring actions taken prior periods following table presents detail charges segment type company substantially completed restructuring activities termination dollars millions benefits exit costs total pharmaceuticals nutritionals convatec subtotal changes estimates provision restructuring net restructuring charges spending liabilities associated prior current actions follows employee termination exit cost dollars millions liability liability total balance january charges spending changes estimates balance december charges spending changes estimates balance december charges spending changes estimates balance december addition charges company recorded million million million accelerated depreciation fixed asset impairment charges primarily related rationalization manufacturing network respectively charges primarily recorded cost products sold consolidated statement operations primarily related pharmaceuticals segment note acquisitions divestitures october company completed acquisition adnexus therapeutics inc adnexus developer new therapeutic class biologics called adnectins net purchase price million addition event certain future development regulatory milestones achieved company obligated terms agreement pay former stockholders adnexus additional million net purchase price acquisition preliminarily allocated tangible identifiable intangible assets acquired liabilities assumed based estimated fair values acquisition date million million allocated acquired inprocess research development immediately expensed million assigned identifiable intangible assets predominantly related existing process technology used future discovery excess purchase price associated transaction costs estimated fair values net assets acquired recorded goodwill acquisition accounted purchase method accordingly results operations included accompanying consolidated financial statements date acquisition pro forma supplemental financial information included impact business combination material july company completed sale bufferin excedrin brands japan asia excluding china taiwan certain oceanic countries lion corporation japan million cash result transaction company recognized pretax gain million million net tax third quarter january company completed sale inventory trademark patent intellectual property rights us related dovonex treatment psoriasis warner chilcott company inc million cash addition company received royalty based net sales dovonex end result transaction company recognized pretax gain million million net tax first quarter table contents note acquisitions divestitures continued third quarter company completed sale us canadian consumer medicines consumer medicines business related assets novartis ag novartis terms agreement novartis acquired trademarks patents intellectual property rights consumer medicines million cash including impact working capital adjustment million attributable postclosing supply arrangement company novartis related assets include rights us consumer medicines brands latin america europe middle east africa results operations consumer medicines included companys consolidated statement earnings date disposal result transaction company recorded pretax gain million million net tax third quarter note discontinued operations assets held sale december company entered definitive agreement avista capital partners lp avista sale medical imaging business purchase price approximately million cash subject customary postclosing adjustments closing transaction completed january company expects recognize pretax gain approximately million million million million loss net tax first quarter subject postclosing adjustments results medical imaging business previously included former health care operating segment included incomeloss discontinued operations net tax periods presented net assets associated medical imaging business totaling approximately million well assets totaling million reclassified assets held sale december period time company continue generate cash flows report income statement activity incomeloss discontinued operations net tax associated medical imaging business activities give rise cash flows income statement activities transitional nature generally result agreements ensure facilitate orderly transfer business operations agreements include services accounting customer service distribution manufacturing activities expected material companys results operations cash flows agreements extend periods generally less months majority ranging months following assets liabilities segregated classified assets held sale liabilities related assets held sale appropriate consolidated balance sheet december assets liabilities relate medical imaging business described totaling million well assets totaling million balances december reclassified amounts presented adjusted exclude cash intercompany receivables payables business held sale company excluded divestiture addition goodwill december million excluded following summary net assets held sale considered determining gain sale dollars millions december assets receivables net allowances inventories net assets property plant equipment net intangible assets net total assets held sale liabilities accounts payable accrued liabilities total liabilities related assets held sale net assets held sale may company completed sale oncology therapeutics network otn one equity partners llc cash proceeds million including impact preliminary working capital adjustment company recorded pretax gain million million net tax presented gain sale discontinued operations consolidated statement earnings otn previously presented separate segment table contents note discontinued operations assets held sale continued following summarized financial information related medical imaging otn businesses segregated continuing operations reported discontinued operations date disposition reflect costs certain services provided medical imaging otn company costs allocated company medical imaging otn services included legal counsel insurance external audit fees payroll processing certain human resource services information technology systems support year ended december dollars millions net sales earnings incomes taxes provision income taxes net earnings discontinued operations consolidated statement cash flows includes medical imaging otn businesses date disposition company uses centralized approach cash management financing operations accordingly debt allocated business table contents note earnings per share numerator basic earnings per share net earnings available common stockholders numerator diluted earnings per share net earnings available common stockholders interest expense added back assumed conversion convertible debt common stock denominator basic earnings per share weightedaverage number common stock outstanding period denominator diluted earnings per share weightedaverage shares outstanding adjusted effect dilutive stock options assumed conversion convertible debt common stock computations basic diluted earnings per common share follows year ended december amounts millions except per share data basic net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings basic earnings per share average common shares outstanding basic net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings per common share diluted net earnings continuing operations interest expense conversion convertible debt net taxes net earnings continued operations used diluted earnings per common share calculation discontinued operations earnings net taxes gain disposal net taxes net earnings diluted earnings per share average common shares outstanding conversion convertible debt incremental shares outstanding assuming exercisevesting dilutive stock optionsrestricted stock average common shares outstanding diluted net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings per common share weightedaverage shares issuable upon exercise stock options included diluted earnings per share calculation antidilutive million million million respectively million weightedaverage shares issuable well million million respectively interest expense net tax assumed conversion convertible debt included diluted earnings per share calculation antidilutive table contents note expense net components expense net follows year ended december dollars millions interest expense interest income foreign exchange transaction losses net expense net interest expense increased net interest swap losses million interest expense increased net interest swap losses million interest expense reduced net interest swap gains million net includes income thirdparty contract manufacturing royalty income expense debt retirement costs impairment marketable securities gains losses disposal property plant equipment gains losses sale marketable securities insurance recoveries deferred income recognized certain litigation matters see item financial statementsnote financial instruments additional discussion terminated swap contracts note income taxes components earnings loss continuing operations minority interest income taxes follows year ended december dollars millions us nonus amounts categorized based location taxing authorities provisionbenefit income taxes attributable continuing operations consisted year ended december dollars millions current us nonus deferred us nonus table contents note income taxes continued effective tax rate companys provision income taxes different amount computed applying statutory us federal income tax rate earnings continuing operations minority interest income taxes result following earnings minority interest income taxes dollars millions earnings continuing operations minority interest income taxes us statutory rate foreign tax effect operations ireland puerto rico switzerland state local taxes net valuation allowance us federal foreign contingent tax matters dividend repatriation ajca us federal research tax credit acquired inprocess research development expense impairment auction rate securities us federal foreign valuation allowance foreign effective income tax rate earnings continuing operations minority interest income taxes compared tax rate unfavorably impacted impairment companys investment certain auction rate securities ars tax benefit nondeductible writeoff acquired inprocess research development expenses related acquisition adnexus partially offset tax benefit million first quarter due favorable resolution certain tax matters us internal revenues service irs related deductibility litigation settlement expenses impact foreign tax credits effective tax rate unfavorably impacted elimination tax benefits section internal revenue code treatment provisions portion certain litigation reserves nondeductible partially offset favorable us tax legislation enacted related tax treatment certain intercompany transactions amongst companys foreign subsidiaries implementation tax planning strategies related utilization certain charitable contributions increase effective tax rate primarily due aforementioned section benefit elimination treatment provisions portion certain litigation reserves nondeductible tax benefits associated settlement irs examination favorable adjustment taxes special dividends american jobs creation act partially offset favorable us tax legislation enacted related tax treatment certain intercompany transactions amongst companys foreign subsidiaries implementation tax planning strategies related utilization certain charitable contributions table contents note income taxes continued deferred taxes valuation allowance components current noncurrent deferred income tax assets liabilities follows december dollars millions acquired inprocess research development intercompany profit inventory items us federal foreign tax credit carryforward deferred income us federal research development tax credit carryforward us federal charitable contribution carryforward state net operating loss carryforwards foreign net operating loss carryforwards foreign deferred tax assets pension postretirement benefits depreciation share based compensation repatriation foreign earnings legal settlements net valuation allowance deferred tax assets net recognized deferred income taxes current deferred income taxes noncurrent us foreign income taxes payable liabilities noncurrent total company recorded significant deferred tax assets december related us foreign tax credit carryforwards approximately million us research tax credit carryforwards approximately million charitable contribution carryforwards million charitable contribution carryforwards expire varying amounts beginning foreign tax credit research tax credit carryforwards expire varying amounts beginning foreign tax credit research tax credit reduced due derecognition fin realization credits charitable contribution carryforwards dependent generating sufficient domestic taxable income prior expiration although realization assured management believes likely deferred tax assets realized company anticipates increasing level domestic profitability time undertaking actions pti increasing biologics manufacturing capacity us implementing tax planning strategies increasing domestic profitability likely cause companys effective tax rate increase also enhance companys ability utilize foreign tax credit research tax credit charitable contribution carryforwards company also recorded deferred tax assets related foreign net operating loss carryforwards million december increase million compared million december primarily due international reorganization two companys foreign affiliates operating loss carryforwards related international reorganization fully offset establishment valuation allowance million reflecting companys view loss carryfowards expected realized valuation allowance million december relates million state deferred tax assets million foreign net operating loss tax credit carryforwards million state net operating loss tax credit carryforwards company believes likely realized million state deferred tax assets related adnexus acquisition offset goodwill income taxes paid year million million million respectivelyin october company filed refund claim irs years carry back foreign tax credits recover taxes paid principal amount refund claim approximately million fourth quarter company accrued interest income refund claim approximately million net federal benefit reflected provision income taxes table contents note income taxes continued current tax benefit realized upon exercise stock options credited capital excess par value stock amounted million million million respectively december company approximately billion undistributed earnings foreign subsidiaries taxes provided company invested expects invest undistributed earnings permanently offshore future earnings repatriated us company determines earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided company conducts business various countries throughout world subject tax numerous jurisdictions result business activities company files significant number tax returns subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported company may require several years resolve company establishes liabilities possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known effect changes estimates related contingent tax liabilities included effective tax rate reconciliation company adopted provisions fin january resulting recognition million previously unrecognized tax benefits accounted increase opening balance retained earnings reconciliation companys changes uncertain tax positions january december follows unrecognized unrecognized unrecognized income tax benefits federal state income tax benefits deferred including interest penalties foreign including income tax net deferred income dollars millions tax benefits interest penalties interest penalties benefits tax benefits total uncertain tax positions recognized would impact effective tax rate january add tax attributable deferred tax items january balance gross uncertain tax positions january gross additions tax positions related current year gross reductions tax positions related current year gross additions tax positions related prior years gross reductions tax positions related prior years settlements reductions tax positions related lapse statute cumulative translation adjustment balance gross uncertain tax positions december less tax attributable deferred tax items december total uncertain tax positions recognized would impact effective tax rate december uncertain tax benefits december recorded companys deferred tax assets extent uncertainty directly related asset otherwise recorded either current noncurrent income tax payableas previously reported upon adoption fin companys total amount uncertain tax benefits january net deferred income tax benefits excluding interest penalties million addition company derecognized upon adoption million unrecognized tax benefits tax rate impact settled gross unrecognized tax benefits january million table contents note income taxes continued included balance unrecognized tax benefits million uncertain tax positions january million december ultimate deductibility highly certain uncertainty timing deductibility impact deferred tax accounting interest penalties applicable disallowance shorter deductibility period would affect annual effective tax rate would accelerate payment cash taxing authority utilization tax attributes earlier period amounts unrecognized tax benefits recognized would impact effective tax rate million january million december company classifies interest penalties related unrecognized tax benefits income tax expense amounts reflected separately reconciliation total amount interest penalties related uncertain tax positions recognized statement earnings million interest million penalties total amount interest penalties related uncertain tax positions recognized balance sheet december million interest million penalties company currently examination number tax authorities including major tax jurisdictions listed table proposed adjustments tax issues transfer pricing certain tax credits deductibility certain expenses company estimates reasonably possible balance unrecognized tax benefits december decrease range approximately million million next twelve months result anticipated effective settlement certain tax audits jurisdictions listed settlements involve payment additional taxes adjustment certain deferred taxes andor recognition tax benefits company also anticipates reasonably possible new issues raised tax authorities may require increases balance unrecognized tax benefits however estimate increases made company believes adequately provided open tax years tax jurisdiction fin company files income tax returns us federal jurisdiction various state foreign jurisdictions exceptions company subject us federal state local nonus income tax examinations tax authorities following summary major tax jurisdictions tax authorities may assert additional taxes company based upon tax years currently audit subsequent years likely audited us canada france germany italy mexico table contents note cash cash equivalents marketable securities cash cash equivalents december primarily consisted bank deposits time deposits money market funds cash equivalents primarily highly liquid investments original maturities three months less time purchase recorded cost approximates fair value company maintains cash cash equivalent balances us dollars foreign currencies subject currency rate risk marketable securities december consisted us dollardenominated floating rate securities frs primarily aaaaaa rated frs longterm debt securities coupons reset periodically benchmark interest rate underlying assets companys frs consist primarily investment grade corporate bonds loans company accounts marketable securities accordance sfas accounting certain investments debt equity securities classifies available sale carrying value frs reduced million million million december reflecting change fair market value company assessed decline fair market value temporary recorded pretax million reduction million net tax shareholders equity accumulated oci addition december company million principal invested ars ars held company private placement securities longterm nominal maturities interest rates reset dutch auction month monthly auctions historically provided liquid market securities companys investments ars represent interests collateralized debt obligations supported pools residential commercial mortgages credit cards insurance securitizations structured credits including corporate bonds underlying collateral ars held company consists subprime mortgages consistent companys investment policy guidelines ars investments held company aaaaaa credit ratings time purchase liquidity issues experienced global credit capital markets ars held company december experienced multiple failed auctions amount securities submitted sale exceeded amount purchase orders addition fourth quarter million principal invested ars held company downgraded others placed credit watch securities retained least one aaa rating december estimated market value companys ars holdings december million reflects million adjustment principal value million although ars continue pay interest according stated terms based valuation models analysis otherthantemporary impairment factors company recorded pretax impairment charge million fourth quarter reflecting portion ars holdings company concluded otherthantemporary decline value addition company recorded unrealized loss million pretax net tax accumulated oci reduction shareholders equity reflecting adjustments ars holdings company concluded temporary decline value million impairment charge material impact companys liquidity financial flexibility ars classified prior periods current assets marketable securities given failed auctions companys ars illiquid successful auction accordingly entire amount remaining ars reclassified marketable securities noncurrent assets marketable securities december consisted us dollardenominated ars frs principal values ars frs million million respectively companys carrying value ars frs december principal value approximates fair value following tables summarize companys available sale debt securities december december unrealized loss accumulated december cost fair value carrying value oci dollars millions shortterm floating rate securities total shortterm longterm available sale auction rate securitiesa total longterm company recorded pretax otherthantemporary impairment charge million earnings december related securities table contents note cash cash equivalents marketable securities continued unrealized loss december cost fair value carrying value accumulated oci dollars millions shortterm auction rate securities floating rate securities total shortterm contractual maturities carrying value availableforsale debt securities december follow dollars millions within year years years years total available sale debt securities floating rate securities auction rate securities total debt securities company purchased billion billion billion debt securities respectively sold billion billion billion debt securities respectively purchase sale value debt securities approximated principal value security note receivables major categories receivables follows december dollars millions trade receivables miscellaneous receivables less allowances receivables net miscellaneous receivables include million million respectively receivables alliance partners miscellaneous receivables also included million income tax refund claims additional information companys alliance partners see note alliances investments note inventories major categories inventories follows december dollars millions finished goods work process raw packaging materials inventories net table contents note property plant equipment major categories property plant equipment follows december dollars millions land buildings machinery equipment fixtures construction progress less accumulated depreciation property plant equipment net capitalized interest million million million years ended december respectively included categories property plant equipment shown note goodwill changes carrying amount goodwill years ended december follows pharmaceuticals nutritionals convatec discontinued dollars millions segment segment segment operations total balance january adjustments reduction due sale business purchase price allocation adjustments balance december adjustments purchase price adjustments balance december goodwill million recorded pharmaceuticals segment result acquisition adnexus medical imaging goodwill million reported discontinued operations written part pretax gain disposal discussion acquisitions see note acquisitions divestitures note intangible assets december intangible assets consisted following december dollars millions patentstrademarks less accumulated amortization patentstrademarks net licenses less accumulated amortization licenses net technology less accumulated amortization technology net capitalized software less accumulated amortization capitalized software net total intangible assets net table contents note intangible assets continued included decrease patentstrademarks technology million reclassification medical imaging assets held sale amortization expense intangible assets years ended december million million million respectively includes million million million amortization expense related medical imaging discontinued operations years ended december respectively expected amortization expense related current net carrying amount intangible assets follows years ending december dollars millions later years note shortterm borrowings longterm debt shortterm borrowings end billion million respectively longterm debt billion december compared billion december company reclassified longterm debt shortterm borrowings million yen notes due million yen notes due million notes due associated unamortized discount interest rate swap valuation billion floating rate convertible debentures due putcall september company repaid billion remaining balance fiveyear tranche floating rate bank term facility due fourth quarter company restructured longterm debt retiring outstanding billion notes due cash tender offer subsequent redemption issuing million million inception aggregate principal amount notes due million million inception aggregate principal amount notes due well billion aggregate principal amount notes due resulted million pretax expense comprised items discussed premium paid debt tender make whole million million respectively addition company recognized earnings million unamortized discount debt issuance costs associated debt incurred pretax loss million related termination remaining billion notional amount fixedtofloating interest rate swap agreements recognized earnings pretax unamortized portion million aforementioned loss incurred termination million notional amount fixedtofloating interest rate swaps occurred june furthermore november company recognized earnings accumulated oci pretax unamortized portion million million net tax loss incurred settlement interest rate lock contracts used manage exposure changes interest rates anticipated issuance longterm fixed rate debt december company replaced prior billion revolving credit facility new billion fiveyear revolving credit facility syndicate lenders extendable anniversary date consent lenders facility contains customary terms conditions substantially similar prior facility including financial covenant whereby ratio consolidated debt consolidated capital exceed end quarter company compliance covenant since inception new facility borrowings outstanding revolving credit facility december company unused shortterm lines credit available trade finance facilities foreign banks million million december respectively table contents note shortterm borrowings longterm debt continued components longterm debt follows december dollars millions floating rate bank term facility due notes due floating rate convertible debentures due euro notes due euro notes due notes due notes due debentures due debentures due debentures due yen notes due industrial revenue bonds due yen notes due yen notes due variable rate industrial revenue bonds due companys outstanding billion convertible debentures pay interest quarterly annual rate equal threemonth libor reset quarterly minus yield never less zero final maturity september debentures callable par time september issuer holders also redeem debentures par september fundamental change ownership company occurs bond initial conversion price conversion rate shares adjustable depending average closing prices applicable period maximum conversion rate shares company entered fixed floating interest rate swaps billion us dollar value december longterm debt conjunction new issuance billion notes due billion notes billion inception company executed several fixed floating interest rate swaps convert new fixed rate debt paid variable rate debt years ended december company realized net increases interest expense million million respectively result higher floating rates obtained swap agreements november connection early retirement outstanding billion notes due company terminated remaining billion notional amount fixed floating interest rate swap agreements incurred pretax loss million april connection early redemption billion notes due company terminated billion notional amount fixedtofloating interest rate swap agreements incurred pretax loss million june company terminated million notional amount fixedtofloating interest rate swap agreements related billion notes due incurred pretax loss million loss amortized interest expense million million recognized respectively remaining loss million together million loss incurred unwind billion swap fully recognized september company terminated million notional amount fixedtofloating interest rate swap agreements related million debentures due pretax gain million gain recognized interest expense remaining life debentures due approximately million pretax recognized cash payments interest including payments due interest rate swaps million million million respectively companys cash receipts interest rate swaps million million million respectively excluded cash payments interest payments due period later dollars millions total years longterm debt obligations included shortterm borrowings companys consolidated balance sheet december balances approximate outstanding nominal longterm debt values companys convertible debenture included due payment contains put call feature described table contents note shortterm borrowings longterm debt continued december company provided total million financial guarantees form standby letters credit performance bonds standby letters credit insurance companies support thirdparty liability programs performance bonds issued support range ongoing operating activities including sale company products hospitals foreign ministries health bonds customs duties value added tax guarantees related miscellaneous legal actions significant majority companys outstanding financial guarantees expire within year expected funded note stockholders equity changes common shares treasury stock capital excess par value stock restricted stock follows cost capital excess common shares treasury treasury par value restricted dollars shares millions issued shares stock stock stock balance january issued pursuant stock plans options amortization restricted stock lapses forfeitures restricted stock balance december issued pursuant stock plans options amortization restricted stock lapses forfeitures restricted stock balance december issued pursuant stock plans options amortization restricted stock lapses forfeitures restricted stock balance december share companys preferred stock convertible shares common stock callable companys option reductions number issued shares preferred stock due conversions shares common stock dividends declared per common share accumulated balances related component oci net taxes follows deferred charges minimum pension accumulated foreign deferred pension currency incomeloss liability postretirement available comprehensive dollars millions translation effective hedges adjustment benefits sale securities incomeloss balance january comprehensive incomeloss balance december comprehensive incomeloss adjustments adoption sfas balance december comprehensive incomeloss balance december table contents note employee stock benefit plans employee stock plans may stockholders approved companys stock award incentive plan plan plan replaced stock incentive plan plan expired may plan provides million new shares common stock reserved delivery participants plus shares remaining available new grants plan shares recaptured outstanding awards plan number shares actually delivered participants connection award restrictions lapsed counted number shares reserved shares tendered prior year pay purchase price options number shares previously utilized satisfy withholding tax obligations upon exercise continue available reserved december million shares common stock reserved issuance pursuant stock plans options conversions preferred stock million million shares available granted active plans december respectively adjusted combination plans companys plan plan executive officers key employees may granted options purchase companys common stock less market price date option granted options generally become exercisable installments per year first fourth anniversaries grant date maximum term years generally company issues shares stock option exercise treasury stock additionally plan provides granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price plan plan provide granting common stock key employees subject restrictions continuous employment restrictions generally expire fouryear period date grant compensation expense recognized restricted period first quarter company began granting restricted stock units instead restricted stock plan plan also incorporate companys longterm performance awards awards delivered form target number performance shares threeyear cycle awards annual goals set beginning performance period based earnings per share sales maximum performance result maximum payout goals awards set threeyear period based cumulative earnings per share cumulative sales ultimate payout modified companys total stockholder return versus companies proxy peer group maximum performance three measures result maximum payout target threshold targets met performance period payment made plan teamshare stock option plan terminated january fulltime employees excluding key executives granted options purchase companys common stock market price date options granted company authorized million shares issuance plan individual grants generally became exercisable evenly third fourth fifth anniversary grant date maximum term years options million shares exercised plan december companys results operations years ended december reflect impact sfas r includes impact expensing stock options company elected alternative method provided fsp r determining companys pool excess tax benefits results operations year ended december restated reflect impact expensing stock options prepared accordance apb following table summarizes stockbased compensation expense net tax related employee stock options restricted stock longterm performance awards years ended december years ended december dollars millions cost products sold marketing selling administrative research development total stockbased compensation expense deferred tax benefit stockbased compensation net tax table contents note employee stock benefit plans continued table reflects pro forma net income diluted net income per share year ended december year ended december dollars millions except per share data net earnings reported total stockbased employee compensation expense included reported net earnings net related tax effects total stockbased employee compensation expense determined fair valuebased method awards net related tax effects pro forma basic earnings per share reported pro forma diluted earnings per share reported pro forma stock options summary option activities follows shares common weightedaverage stock issued exercise price shares millions plan shares balance january granted exercised expired forfeited balance december granted exercised expired forfeited balance december granted exercised expired forfeited balance december table contents note employee stock benefit plans continued information related stock option grants exercises plan plan summarized follows years ending december amounts millions except per share data available stock option awards stock options granted weightedaverage grantdate fair value per share total intrinsic value stock options exercised cash proceeds exercise stock options december million total unrecognized compensation cost related stock options expected recognized weightedaverage period years following tables summarize information concerning companys stock compensation plans currently outstanding exercisable options number securities remaining available future number securities issued weightedaverage exercise issuance equity upon exercise outstanding price outstanding compensation plans excluding shares millions options rights options rights securities reflected column b c plan category equity compensation plans approved security holders equity compensation plans approved security holders shares plan longer issued following table summarizes significant ranges outstanding exercisable options december amounts millions except per share data options outstanding options exercisable weighted weighted average weighted average weighted remaining average aggregate remaining average aggregate contractual exercise intrinsic contractual exercise intrinsic number life price per value number life price per value range exercise prices outstanding years share millions exercisable years share millions vested expected vest aggregate intrinsic value preceding table represents total pretax intrinsic value based companys closing stock price december would received option holders option holders exercised options date total number inthe money options exercisable december million december million outstanding options exercisable weighted average exercise price table contents note employee stock benefit plans continued fair value employee stock options granted estimated date grant prior january estimated using weightedaverage estimated per option value granted using blackscholes option pricing model following assumptions expected volatility riskfree interest rate dividend yield expected life yrs yrs yrs company derived expected volatility assumption required blackscholes model calculating year historical volatility weighting equally derived implied volatility consistent sfas r sab prior company used historical stock price volatility accordance sfas purposes pro forma information selection blended historical implied volatility approach based companys assessment calculation expected volatility representative future stock price trends using historical volatility riskfree interest rate assumption based upon us treasury yield curve effect time grant dividend yield assumption based companys history expectation dividend payouts expected life employee stock options represents weightedaverage period stock options expected remain outstanding derived output latticebinomial model expected life employee stock options impacted underlying assumptions calibration companys model latticebinomial model assumes employees exercise behavior function options remaining vested life extent option inthemoney latticebinomial model estimates probability exercise function two variables based entire history exercises cancellations past option grants made company prior company used optionpricing model indirectly estimate expected life stock options expected life expected volatility stock options based upon historical economic data trended future forfeitures employee stock options accounted incurred basis stockbased compensation expense recognized consolidated statement earnings months ended december based awards ultimately expected vest reduced estimated forfeitures sfas r requires forfeitures estimated time grant revised necessary subsequent periods actual forfeitures differ estimates forfeitures estimated based historical experience companys pro forma information required sfas periods prior company accounted forfeitures occurred company acquired adnexus october part acquisition agreement company assumed million shares adnexus incentive stock options isos replaced million shares company isos converted options retain original vesting schedules including vesting commencement date well expiration date blackscholes model used determine expected term individual isos valuations result weightedaverage expected term years weightedaverage fair value october table contents note employee stock benefit plans continued restricted stock awards restricted stock units fair value nonvested shares companys common stock determined based average trading price companys common stock grant date restricted share activities follows weightedaverage shares thousands number shares grantdate fair value nonvested shares january granted vested forfeited nonvested shares december granted vested forfeited nonvested shares december granted vested forfeited nonvested shares december expected vest december million million respectively total unrecognized compensation cost related nonvested restricted stock restricted stock units cost expected recognized weightedaverage period years balance december years balance december total cost nonvested shares share units granted recognized compensation expense twelve months ended december million million million respectively total fair value shares share units vested months ended december million million million respectively performance awards prior adoption sfas r compensation expense related performance awards determined based market price companys stock time award applied expected number shares contingently issuable amortized threeyear performance cycle since adoption sfas r fair value performance award estimated date grant using monte carlo simulation model due market condition monte carlo simulation model utilizes multiple input variables determine probability satisfying market condition stipulated award grant calculates fair market value longterm performance awards performance award award contain market condition fair value based closing trading price companys common stock grant date valuation model award used following assumptions weightedaverage expected riskfree grant year grant date expected volatility dividend yield interest rate weightedaverage expected volatility based threeyear historical volatility levels companys common stock expected dividend yield based historical dividend payments riskfree interest rate reflects yield fiveyear zero coupon us treasury bonds based performance shares contractual term fair value performance awards amortized performance period award table contents note employee stock benefit plans continued information related performance awards plan plan summarized follows shares thousands performance cycle weightedaverage performance shares outstanding grant date measurement date shares granted grant date fair value december december annually annually total outstanding december million million respectively total unrecognized compensation cost related performance share plan expected recognized weightedaverage period years years respectively accuracy fair value estimates companys determination fair value stockbased payment awards date grant using optionpricing model affected companys stock price well assumptions regarding number highly complex subjective variables variables include limited companys expected stock price volatility term awards actual projected employee stock option exercise behaviors optionpricing models developed use estimating value traded options vesting hedging restrictions fully transferable companys employee stock options certain characteristics significantly different traded options changes subjective assumptions materially affect estimated value managements opinion existing valuation models may provide accurate measure fair value companys employee stock options although fair value employee stock options determined accordance sfas r sab using optionpricing model value may indicative fair value observed willing buyerwilling seller market transaction company adopted sfas r requires measurement recognition compensation expense stockbased payment awards made employees directors based estimated fair values sfas r supersedes companys previous accounting apb periods beginning january march sec issued sab relating sfas r company applied provisions sab adoption sfas r company adopted sfas r using modified prospective transition method requires application accounting standard january elected alternative method provided fsp r determining companys pool excess tax benefits companys consolidated financial statements year ended december reflect impact sfas r accordance modified prospective transition method companys consolidated financial statements prior periods restated reflect include impact sfas r stockbased compensation expense recognized sfas r years ended december million million respectively million million net tax respectively per share per share respectively corresponding amount recorded additional paidin capital within stockholders equity additionally million related performance awards reclassified liabilities stockholders equity connection adoption sfas r table contents note financial instruments company exposed market risk due changes currency exchange rates interest rates reduce risk company enters certain derivative financial instruments available costeffective basis hedge underlying economic exposure instruments managed consolidated basis efficiently net exposures thus take advantage natural offsets derivative financial instruments used speculative purposes companys primary net foreign currency translation exposures euro canadian dollar japanese yen mexican peso chinese renminbi company utilizes foreign currency contracts hedge anticipated transactions primarily intercompany transactions certain foreign currencies designates derivative instruments foreign currency cash flow hedges appropriate notional amounts companys foreign exchange derivative contracts december million million respectively derivatives majority qualify hedges future anticipated cash flows effective portion changes fair value temporarily deferred accumulated oci recognized earnings hedged item affects earnings table summarizes companys outstanding foreign exchange forward contracts december fair value foreign exchange forward contracts based yearend currency rates fair value foreign exchange forward contracts viewed relation fair value underlying hedged transactions overall reduction exposure adverse fluctuations foreign currency exchange rates weightedaverage fair value dollars millions except currency rates strike price notional amount assetliability maturity foreign exchange forwards cash flow hedges australian dollar british pound canadian dollar euro japanese yen mexican peso polish zloty swedish krona swiss franc total cash flow hedges nonqualifying hedges australian dollar british pound canadian dollar euro japanese yen polish zloty turkish lira total nonqualifying hedges total contracts nonqualifying hedges hedges qualify hedge accounting treatment prescribed sfas accounting derivative instruments hedging activities december company held foreign exchange option contracts buy sell japanese yen total notional fair market value buy contracts million million respectively fully offset total notional fair market value sell contracts million million respectively company reclassified pretax deferred losses million million million respectively accumulated oci earnings majority classified cost products sold december balance deferred losses foreign exchange forward contracts included accumulated oci pretax basis million million net tax expected reclassified earnings within next months table contents note financial instruments continued sfas requires company perform periodic assessments hedge effectiveness assessments determine whether derivatives designated qualifying hedges continue highly effective offsetting changes cash flows hedged items ineffective portion fair value longer deferred accumulated oci included current period earnings years ended december impact hedge ineffectiveness earnings significant additionally years ended december impact discontinued hedges pretax loss million pretax loss million respectively furthermore company uses foreign exchange forward contracts offset exposure certain currency assets liabilities earnings denominated certain foreign currencies foreign exchange forward contracts designated hedges therefore changes fair value derivatives recognized earnings income net occur notional fair value amounts foreign exchange forward contracts december described table foreign exchange forward contracts type outstanding december impact foreign exchange forward contracts designated hedges pretax gain million amounts recognized earnings related types foreign exchange forward contracts qualify hedge accounting treatment significant fair value forward contracts net liability million december million recorded noncurrent asset million recorded current liability fair value forward contracts net liability million december million recorded noncurrent asset million recorded current liability fair value foreign exchange contracts based yearend currency rates blackscholes model case option contracts addition foreign exchange hedge contracts noted company utilizes forward contracts hedge foreign currencydenominated monetary assets liabilities primary objective forward contracts protect us dollar value foreign currencydenominated monetary assets liabilities effects volatility foreign exchange rates might occur prior receipt settlement us dollars foreign currency denominated monetary assets liabilities primarily denominated euro forward contracts designated hedges marked market expense net notional fair value amount purchased foreign exchange forward contracts material december million million asset respectively december notional fair value amounts sold foreign exchange forward contracts december million million liability respectively december company also uses nonus dollar borrowings primarily million notes due million notes due hedge foreign currency exposures companys net investment certain foreign affiliates nonus dollar borrowings designated hedges net investments effective portion foreign exchange gains losses hedges recorded part foreign currency translation component accumulated oci december million million losses respectively recorded foreign currency translation component accumulated oci company unhedged exposures net foreign currencydenominated assets liabilities approximately billion billion december respectively primarily mexico japan uk china australia canada company uses derivative instruments part interest rate risk management strategy derivative instruments used comprised principally fixed floating rate interest rate swaps subject fairvalue hedge accounting treatment november connection funding retirement fixed rate debt company executed several fixed floating interest rate swaps convert billion billion billion inception companys newlyissued fixed rate debt paid variable rate debt total notional amounts outstanding interest rate swaps billion billion billion december billion billion billion december accordance sfas accounting derivative instruments hedging activities company recognized net increase interest expense million million respectively net reduction interest expense million impact interest rate swaps swap contracts well underlying debt hedged recorded fair value resulted increase noncurrent assets million current liabilities million reduction longterm debt million december increase noncurrent assets million current liabilities million reduction longterm debt million december swap contracts generally held maturity intended create appropriate balance fixed floating rate debt company swap contracts qualify fair value hedges terminated prior maturity dates reported part carrying value underlying debt amortized earnings remaining life debt swap contracts qualify cash flow hedges terminated reported accumulated oci amortized earnings remaining life debt following tables summarize interest rate swaps outstanding december earnings impact terminated interest rate swap contracts table contents note financial instruments continued interest rate swaps outstanding notional amount underlying variable rate year fair interest rate contracts debt received transaction maturity value dollars millions swaps associated notes due month us libor notes due month us libor million notes due month eur euribor million notes due month eur euribor notes due month us libor notes due month us libor earnings impact terminated interest rate swap contracts notional pretax incomeexpense amount total pretax recognized year underlying deferred termination debt gainloss interest rate contracts dollars millions interest rate swap lock associated notes due note due swaps associated notes due notes due notes due notes due underlying notes extinguished underlying notes extinguished underlying notes extinguished carrying amount companys financial instruments includes cash cash equivalents accounts receivable accounts payable approximates fair value december discussion cash cash equivalents marketable securities see note cash cash equivalents marketable securities longterm debt difference fair value carrying value material note segment information company organized three reportable segmentspharmaceuticals nutritionals convatec pharmaceuticals segment comprised global pharmaceutical international consumer medicines businesses nutritionals segment consists mead johnson primarily infant formula business childrens nutritional business convatec segment consists ostomy wound skin care business december company entered definitive agreement avista sale medical imaging business closing transaction completed january results medical imaging business previously included former health care operating segment included income discontinued operations net tax periods net assets associated medical imaging business totaling approximately million well assets totaling million reclassified assets held sale december included corporateother may company completed sale otn one equity partners llc results otn previously presented separate operating segment included income discontinued operations net tax year ended december results medical imaging business otn included tables third quarter company completed sale consumer medicines business included pharmaceuticals operating segment additional information sale consumer medicines see note acquisitions divestitures table contents note segment information continued companys products sold principally wholesale retail trade nationally internationally certain products also sold drug manufacturers hospitals clinics government agencies medical profession three wholesalers accounted approximately respectively companys total net sales sales wholesalers accounted approximately respectively companys total net sales three wholesalers accounted respectively companys total net sales sales concentrated pharmaceuticals segment earnings continuing operations net sales minority interest income taxes yearend assets dollars millions pharmaceuticals nutritionals convatec health care group total segments corporateother total net sales companys key products follows sales products dollars millions pharmaceuticals plavix avaproavalide pravachol coumadin reyataz sustiva franchise total revenue baraclude erbitux taxol paclitaxel sprycel ixempra abilify total revenue pharmaceuticals total pharmaceuticals nutritionals enfamil enfagrow nutritionals total nutritionals convatec ostomy wound therapeutics convatec total convatec total corporateother consists principally interest income interest expense certain administrative expenses allocations business segments certain corporate programs litigation expense impairment auction rate securities debt retirement costs gain sale businesses product assets deferred income recognized collaboration agreement restructuring charges corporateother assets include cash cash equivalents marketable securities assets discontinued operations certain assets table contents note segment information continued capital expenditures depreciation dollars millions pharmaceuticals nutritionals convatec health care group total segments corporateothera total corporateother amounts include activities medical imaging business including capital expenditures million million million respectively depreciation expense million million million respectively geographic areas net sales yearend assets dollars millions united states europe middle east africa western hemisphere pacific total table contents note leases minimum rental commitments noncancelable operating leases primarily real estate motor vehicles effect december follows years ending december dollars millions later years total minimum payments less total minimum sublease rentals net minimum rental commitments operating lease rental expense net sublease rental income million million million million million million december company completed sale leaseback several administrative facilities new jersey million resulted pretax gain transaction million million deferred reduce future lease rental costs lease periods ranging years note pension postretirement benefit plans company certain subsidiaries defined benefit pension plans defined contribution plans termination indemnity plans regular full time employees principal pension plan bristolmyers squibb retirement income plan us funding policy contribute amounts provide current service fund past service liability plan benefits based primarily participants years credited service compensation plan assets consist principally equity fixedincome securities company also provides comprehensive medical group life benefits substantially us retirees elect participate comprehensive medical group life plans medical plan contributory contributions adjusted periodically vary date retirement original retiring company life insurance plan noncontributory plan assets consist principally equity fixedincome securities similar plans exist employees certain countries outside us net periodic benefit cost companys defined benefit pension postretirement benefit plans included following components pension benefits benefitsa dollars millions service cost benefits earned year interest cost projected benefit obligation expected return plan assets amortization prior service costbenefit amortization loss amortization transitional obligation net periodic benefit cost curtailments settlements total net periodic benefit cost company recognized impact medicare prescription drug improvement modernization act accordance fsp accounting disclosure requirements related medicare prescription drug improvement modernization act recorded million respectively reduction net periodic benefit costs table contents note pension postretirement benefit plans continued net actuarial loss prior service costbenefit amortized accumulated oci net periodic benefit costs million million respectively pension benefits million benefit million respectively benefits estimated net actuarial loss prior service cost amortized accumulated oci net periodic benefit cost dollars millions pension benefits benefits amortization net actuarial loss amortization prior service costbenefit changes benefit obligations plan assets funded status amounts recognized balance sheet years ended december companys defined benefit postretirement benefit plans follows pension benefits benefitsb dollars millions benefit obligation beginning year service costbenefits earned year interest cost projected benefit obligation plan participants contributions curtailments settlements actuarial lossesgains plan amendments retiree drug subsidy received benefits paid special termination benefit exchange rate gainslosses benefit obligation end year fair value plan assets beginning year actual return plan assets employer contribution plan participants contributions settlements retiree drug subsidy received benefits paid exchange rate lossesgains fair value plan assets end year funded status amounts recognized balance sheet consist assets accrued expenses pension postretirement liabilities accrued benefit cost net amount recognized amounts recognized accumulated comprehensive loss net actuarial loss net obligation adoption prior service cost b company recognized impact medicare prescription drug improvement modernization act accordance fsp recorded million million respectively reduction accumulated postretirement benefit obligation several plans underfunded accrued benefit obligations exceeded accrued benefit liabilities december additional minimum liabilities established increase accrued benefit liabilities values underfunded accrued benefit obligations additional minimum liabilities totaled million december prior adoption sfas us unfunded benefit equalization plan several international plans liabilities reversed accumulated oci upon adoption sfas table contents note pension postretirement benefit plans continued accumulated benefit obligation defined benefit pension plans million million december respectively information related companys pension plans december follows december dollars millions pension plans projected benefit obligations excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligation excess plan assets accumulated benefit obligation fair value plan assets attributable primarily unfunded us benefit equalization plan several plans international markets unfunded us benefit equalization plan provides pension benefits employees compensation irs limits funded taxadvantaged manner additional information pertaining companys pension postretirement plans follows pension benefits benefits dollars millions decreaseincrease minimum liability including impact foreign currency fluctuations included comprehensive income weightedaverage assumptions used determine benefit obligations december follows pension benefits benefits discount rate rate compensation increase weightedaverage actuarial assumptions used determine net periodic benefit cost years ended december follows pension benefits benefits discount rate expected longterm return plan assets rate compensation increase december companys expected longterm rate return us pension plan assets target asset allocation public equity us international private equity fixed income approximated applying expected returns public equity private equity fixed income target allocation actual historical returns also relevant annualized returns periods ended december years years years us pension plan assets represented approximately total company pension plan assets december disclosed total company expected return assets us pension plans due impact international pension plans typically employ less aggressive asset allocation expected return disclosed benefits relevant assets invested manner us pension plan assets international plan assets table contents note pension postretirement benefit plans continued assumed health care cost trend rates december follows health care cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend rate year rate reaches ultimate trend rate assumed health care cost trend rates effect amounts reported health care plans onepercentagepoint change assumed health care cost trend rates would following effects percentage percentage dollars millions point increase point decrease effect total service interest cost effect postretirement benefit obligation companys asset allocation pension postretirement benefits december follows pension benefits benefits public equity securities debt securities including cash private equity total companys investment strategy emphasizes equities order achieve high expected returns long run low expense low required cash contributions us pension plans target asset allocation public equity us international private equity fixed income maintained cash flow ie cash contributions benefit payments used rebalance back targets necessary investments well diversified within three major asset categories us equity passively managed otherwise investments actively managed investment strategies international pension plans typically similar although asset allocations usually conservative bristolmyers squibb company common stock represents less plan assets december assets postretirement benefits commingled us pension plan assets therefore investment strategy identical described us pension plans contributions although minimum contributions required company made cash contributions us pension plans million million million respectively company also plans make cash contribution us pension plans contributions made us pension plans company may make taxdeductible contributions h account retiree medical benefits equal portion pension normal cost contributions international pension plans million million million respectively contributions international plans expected range million million table contents note pension postretirement benefit plans continued estimated future benefit payments following benefit payments mainly us pension plans reflect expected future service appropriate expected paid benefits dollars millions pension benefits gross medicare subsidy net years adoption sfas company adopted sfas fiscal year ended december resulting million reduction accumulated oci stockholders equity million reduction total assets million increase total liabilities impact adoption summarized follows sfas adjustments dollars millions presfas pretax tax net postsfas current assets deferred income taxes noncurrent assets deferred income taxes prepaid pension assets current liabilities accrued expenses us foreign income taxes payable noncurrent liabilities liabilities stockholders equity accumulated comprehensive loss savings plan principal defined contribution plan bristolmyers squibb savings investment program companys contribution based employee contributions level company match companys contributions plan million million million termination indemnity plans company operates certain jurisdictions primarily europe require recording statutory termination obligations obligations assessed accordance eitf issue determination vested benefit obligation defined benefit pension plan total pension liability recorded obligations million december million december table contents note legal proceedings contingencies various lawsuits claims proceedings investigations pending involving company certain subsidiaries accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated matters involve antitrust securities patent infringement pricing sales marketing practices environmental health safety matters consumer fraud employment matters product liability insurance coverage significant matters described assurance increase scope pending matters future lawsuits claims proceedings investigations material intellectual property plavix litigation plavix currently companys largest product ranked net sales net sales plavix approximately billion year ended december billion year ended december billion year ended december us net sales plavix billion billion billion plavix patents subject number challenges us including litigation apotex inc apotex corp apotex described less significant markets product possible reasonably estimate impact lawsuits company however loss market exclusivity plavix sustained generic competition would material companys sales plavix results operations cash flows could material companys financial condition liquidity company product partner sanofi companies intend vigorously pursue enforcement patent rights plavix plavix litigation united states patent infringement litigation apotex related matters previously disclosed companys us territory partnership alliance sanofi plaintiff pending patent infringement lawsuit instituted us district court southern district new york district court entitled sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v apotex suit based us patent patent composition matter patent discloses claims among things hydrogen sulfate salt clopidogrel medicine made available us companies plavix plaintiffs infringement position based apotexs filing abbreviated new drug application anda fda seeking approval sell generic clopidogrel bisulfate prior expiration composition matter patent apotex alleged patent invalid andor unenforceable previously disclosed march company sanofi announced executed proposed settlement agreement march agreement apotex settle pending patent infringement lawsuit response concerns expressed federal trade commission ftc state attorneys general parties modified march agreement modified agreement may july companies announced modified agreement failed receive required antitrust clearance state attorneys general august apotex launched generic version clopidogrel bisulfate august district court issued preliminary injunction ordering apotex halt sales generic clopidogrel bisulfate recall product customers june district court issued opinion order upholding validity enforceability patent maintaining main patent protection plavix us november district court also ruled apotexs generic clopidogrel bisulfate product infringed patent permanently enjoined apotex engaging activity infringes patent including marketing generic product us patent expires amount damages set later time apotexs appeal district courts decision pending us court appeals federal circuit hearing scheduled march district court stayed certain antitrust counterclaims brought apotex pending outcome appeal activities relating damages phase litigation continuing also previously disclosed companys us territory partnership alliance sanofi also plaintiff three additional pending patent infringement lawsuits dr reddys laboratories inc dr reddys laboratories ltd dr reddys teva pharmaceuticals usa inc teva cobalt pharmaceuticals inc cobalt related patent trial date action dr reddys set january dr reddys received final approval anda january court entered order requires dr reddys give company business days notice intent launch patent infringement actions teva cobalt stayed pending resolution apotex litigation parties actions agreed bound outcome litigation apotex although teva cobalt appeal outcome litigation table contents note legal proceedings contingencies continued consequently july district court entered judgments cobalt teva permanently enjoined cobalt teva engaging activity infringes patent patent expires cobalt teva filed appeal dr reddys teva cobalt filed anda fda exclusivity periods statutory stay periods hatchwaxman act expired accordingly final approval fda would provide company authorization distribute generic clopidogrel bisulfate product us subject various legal remedies companies may apply including injunctive relief damages previously disclosed march company served civil investigative demand ftc requesting documents information related proposed settlement addition previously disclosed april company received subpoena new york state attorney generals office antitrust bureau documents related proposed settlement company cooperating fully investigations possible time reasonably assess outcomes investigations impact company also previously disclosed companys us territory partnership alliance sanofi plaintiff another pending patent infringement lawsuit instituted us district court district new jersey entitled sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v watson pharmaceuticals inc watson laboratories inc watson suit filed october based us patent patent discloses claims particular crystalline polymorph form hydrogen sulfate salt clopidogrel marketed plavix case discovery phase december court permitted watson pursue declaratory judgment counterclaim respect us patent january court approved parties stipulation stay case pending outcome trial apotex matter april pharmastar filed request inter partes reexamination patent us patent trademark office granted request july thus patent currently reexamination possible time reasonably assess outcomes appeal apotex district courts decision plavix patent litigations timing renewed generic competition plavix apotex additional generic competition plavix thirdparty generic pharmaceutical companies however apotex prevail appeal patent litigation company would expect face renewed generic competition plavix apotex promptly thereafter loss market exclusivity plavix andor sustained generic competition would material companys sales plavix results operations cash flows could material companys financial condition liquidity additionally possible time reasonably assess amount damages could recovered company apotexs ability pay damages event company prevails apotexs appeal district court decision see antitrust litigation shareholder derivative actions securities litigation discussion certain us litigations relating plavix plavix litigation international plavix canada apotex inc previously disclosed sanofisynthelabo sanofisynthelabo canada inc instituted prohibition action federal court canada apotex inc minister health response notice allegation noa apotex directed canadian patent patent covering clopidogrel bisulfate apotexs noa indicated filed abbreviated new drug submission ands clopidogrel bisulfate tablets sought approval notice compliance ands expiration patent scheduled august apotexs noa alleged patent invalid infringed march canadian federal court ottawa rejected apotexs challenge canadian plavix patent held asserted claims novel obvious infringed granted sanofis application order prohibition minister health apotex order prohibition precludes approval apotexs ands patent expires unless federal courts decision reversed appeal apotex filed appeal canadian federal court appeal heard december december federal court appeal dismissed apotexs appeal upheld federal courts issuance order prohibition february apotex filed leave appeal decision supreme court canada july supreme court canada granted apotex leave appeal decision canadian federal court appeal biotecanada canadian generic pharmaceutical association canadas researchbased pharmaceutical companies granted leave intervene oral hearing scheduled april also previously disclosed april apotex filed lawsuit canada ontario superior court justice entitled apotex inc apotex corp v sanofiaventis sanofisynthelabo inc bristolmyers squibb company bristolmyers squibb sanofi pharmaceuticals holding partnership seeking payment million plus interest related breakup proposed settlement agreement defendants filed motions dismiss grounds forum non conveniens subject matter jurisdiction motions granted january table contents note legal proceedings contingencies continued plavix canada cobalt previously disclosed sanofi sanofisynthelabo canada instituted prohibition action federal court canada cobalt minister health response noa cobalt directed patent canadian patent patent cobalts noa indicated filed ands clopidogrel bisulfate tablets sought notice compliance ands expiration patents cobalt alleged patent invalid patent invalid infringed case stayed pending outcome apotex appeal plavix korea previously disclosed june korean intellectual property tribunal kipt invalidated claims sanofis korean patent including claims directed clopidogrel pharmaceutically acceptable salts clopidogrel bisulfate sanofi appealed january patent court affirmed kipt decision company sanofi considering options including appeal sanofi also commenced infringement actions generic pharmaceutical companies several launched generic clopidogrel bisulfate product korea possible time reasonably assess outcome lawsuits impact company plavix australia previously disclosed sanofi notified august genrx proprietary limited genrx obtained regulatory approval application clopidogrel bisulfate mg tablets australia august genrx filed application federal court australia seeking revocation sanofis australian patent case nsd sanofi filed counterclaims infringement sought injunction september australian court granted sanofis injunction scheduled trial date april intellectual property litigation abilify previously disclosed otsuka filed patent infringement actions teva barr pharmaceuticals inc barr sandoz inc sandoz synthon laboratories inc synthon sun pharmaceuticals sun apotex relating us patent covers aripiprazole expires october aripiprazole comarketed company otsuka us abilify lawsuits currently pending us district court district new jersey possible time reasonably assess outcome lawsuits impact company erbitux yeda litigation october yeda research development company ltd yeda filed suit imclone aventis pharmaceuticals inc federal court claiming three individuals associated yeda named inventors us patent patent covers therapeutic combination egfrspecific monoclonal antibody antineoplastic agents chemotherapeutic agents use treatment cancer september following trial court issued opinion order held three researchers yeda sole inventors subject matter patent giving complete ownership patent yeda imclone appealed imclone also filed declaratory judgment action district court complaint alleged yeda researchers remain sole inventors patent patent invalid commercial agreement imclone company pays royalty imclone sales erbitux impacted courts decision pursuant settlement agreement executed imclone sanofi yeda announced december end worldwide litigation related patent yeda sanofi granted imclone worldwide license patent parties agreed yeda sole owner patent us yeda sanofi coowners patent foreign counterparts settlement agreement change imclones worldwide royalty rate erbitux sales commercial agreement imclone company pays royalty imclone sales erbitux impacted settlement agreement table contents note legal proceedings contingencies continued yeda also right license patent others yedas license patent third parties could result product competition erbitux might otherwise occur early assess whether extent competitive impact occur quantify impact however yeda licensed patent amgen inc amgen amgen received fda approval market egfr product competes erbitux abbott laboratories previously disclosed february abbott laboratories abbott filed suit imclone us district court district massachusetts alleging imclones manufacture sale erbitux infringe us patent patent seeking damages alleged infringement pursuant settlement sublicensing agreements executed imclone repligen corporation repligen announced september repligen granted imclone royaltyfree irrevocable worldwide sublicense future use patented technology including patent owned abbott licensed repligen agreement abbott repligen companys commercial agreements imclone include provisions pursuant certain financial consequences company resulting settlement sublicensing agreements would responsibility imclone settlement sublicensing agreements however end lawsuit possible time assess outcome lawsuit potential impact company orencia january repligen regents university michigan filed complaint company us district court eastern district texas marshall division orencia launched february complaint alleges companys thenanticipated sales orencia infringe us patent repligen since amended complaint include ongoing future sales orencia courtordered mediation scheduled march trial scheduled commence april august zymogenetics inc filed complaint company us district court district delaware complaint alleges companys manufacture sales orencia infringe us patents nos trial expected commence pravachol december lek dd lek slovenian generic company whollyowned novartis filed suit company watson us district court eastern district texas marshall texas leks complaint alleges companys sale pravachol watsons sale authorized generic pravachol infringe two patents lek patents us patents nos issued may issued july company filed answer complaint june company believes strong defense suit intends defend vigorously trial scheduled commence august possible time reasonably assess outcome lawsuits impact company general commercial litigation clayworth litigation previously disclosed company together number pharmaceutical manufacturers named defendant action filed california state superior court oakland james clayworth et al v bristolmyers squibb company et al alleging defendants conspired fix prices pharmaceuticals agreeing charge drugs us charge outside us particularly canada asserting claims californias cartwright act unfair competition law plaintiffs sought trebled monetary damages injunctive relief relief december court granted company manufacturers motion summary judgment based passon defense judgment entered favor defendants january notice appeal respect judgment filed remains pending possible time reasonably assess outcome lawsuit impact company event plaintiffs successful appeal table contents note legal proceedings contingencies continued rxusa wholesale litigation previously disclosed july complaint filed drug wholesaler rxusa wholesale inc us district court eastern district new york company drug manufacturers five drug wholesalers two officers defendant mckesson wholesale distribution industry trade group rxusa wholesale inc v alcon labs inc et al complaint alleges violations federal new york antitrust laws well various laws plaintiff claims defendants allegedly engaged anticompetitive acts resulted exclusion plaintiff relevant market seeks million damages trebling relief company together manufacturer defendants filed motion dismiss case november motion remains pending court possible time reasonably estimate outcome lawsuit impact company antitrust litigation previously disclosed lawsuits comprised individual suits purported class actions filed company us district court southern district ohio western division various plaintiffs including pharmacy chains individually assignees whole part certain wholesalers various health welfare benefit plansfunds individual residents various states lawsuits allege among things purported settlement apotex patent infringement litigation violated sherman act related laws plaintiffs seeking among things permanent injunctive relief barring apotex settlement andor monetary damages class actions filed behalf direct purchasers consolidated caption plavix direct purchaser antitrust litigation class actions filed behalf indirect purchasers consolidated caption plavix indirect purchaser antitrust litigation amended complaints filed october defendants filed consolidated motion dismiss december possible time reasonably assess outcome lawsuits impact company shareholder derivative actions july certain members board directors current former officers company named two derivative actions filed new york state supreme court john frank v peter dolan et al donald beebout v peter dolan et al one derivative action filed federal district court steven w sampson v james robinson iii et al cv complaints allege breaches fiduciary duties allegedly failing disclose material information relating efforts settle plavix patent infringement litigation apotex plaintiffs seek monetary damages behalf company contribution indemnification decision filed december state court granted motions dismiss complaints frank beebout relating certain members board directors dismiss complaints former officers company filed motion dismiss federal district court action sampson pending securities litigation bristolmyers squibb co securities litigation previously disclosed june july two putative class action complaints minneapolis firefighters relief assoc v bristolmyers squibb co et al cv jean lai v bristolmyers squibb company et al filed us district southern district new york company companys former chief executive officer peter dolan current chief financial officer andrew bonfield complaints allege violations securities laws allegedly failing disclose material information relating efforts settle plavix patent infringement litigation apotex september court dismissed lai case without prejudice changed caption case bristolmyers squibb co securities litigation appointed ontario teachers pension plan board lead plaintiff october ontario teachers pension plan board filed amended complaint making similar allegations earlier filed complaints longer naming andrew bonfield defendant motions dismiss filed company intends defend vigorously litigation possible time reasonably assess outcome lawsuits potential impact company table contents note legal proceedings contingencies continued pricing sales promotional practices litigation investigations previously disclosed company together number defendants defendant number private civil matters relating pricing practices addition company together number pharmaceutical manufacturers received subpoenas document requests various government agencies seeking records relating pricing sales marketing practices best price reporting september company department justice doj office us attorney district massachusetts finalized previously disclosed agreement principle settle several investigations involving companys drug pricing sales marketing activities settlement agreement provides civil resolution resolves matters actively investigated discussed doj us attorney district massachusetts number years including matters relating pricing certain products sold several years ago subsidiary reimbursed governmental health care programs financial relationships subsidiary certain customers entities certain consulting programs promotion abilify unapproved indications calculation certain medicaid rebates serzone nefazodone hydrochloride pricing certain companys products reimbursed governmental health care programs criminal charges company respect matters pursuant agreement company agreed pay million plus interest resolve federal state claims resulting total amount approximately million settlement date company paid federal portion global settlement approximately million plus interest state portion global settlement approximately million plus interest disbursed unless states approve settlement assurances states approve settlement connection settlement company entered fiveyear corporate integrity agreement office inspector general department health human services settlement covers matters outlined doj us attorney district massachusetts states indicated may pursue matters outside scope settlement event matters could result assertion civil andor criminal claims also previously disclosed result agreement principle company recorded aggregate reserves amount million plus interest matters payment federal portion global settlement made remaining reserve december million plus interest certain states choose participate amount reserved may reflect eventual losses possible time reasonably assess outcome additional matters doj office us attorney district massachusetts may pursue potential impact company litigation previously disclosed company together number pharmaceutical manufacturers defendant private class actions well suits brought attorneys general numerous states many new york counties city new york actions plaintiffs allege defendants caused average wholesale prices awps products inflated thereby injuring government programs entities persons reimbursed prescription drugs based awps twelve state attorneys general suits pending federal state courts around country case alabama state court scheduled first proceed trial february one set class actions suit arizona attorney general several suits filed new york counties city new york consolidated us district court district massachusetts awp mdl court awp mdl certified three classes persons entities paid reimbursed seven companys physicianadministered drugs june nonjury trial awp mdl court found company liable violations massachusetts consumer protection laws respect certain oncology drugs certain years awarded damages amount thousand class private thirdparty payors instructed parties apply courts opinion determine damages class medigap insurers august court found damages thousand class company appealed june decision us court appeals first circuit previously disclosed june company settled principle claims class medicare part b beneficiaries nationwide million plus half costs class notice maximum payment million parties finalizing terms settlement hearing scheduled thereafter preliminary approval class settlement company recorded reserves million matters accordance gaap reserve reflects companys estimate probable loss respect matters assuming settlement finalized settlement finalized amount reserved may reflect eventual losses possible time reasonably assess outcome litigation matters described potential impact company table contents note legal proceedings contingencies continued product liability litigation company party various product liability lawsuits addition lawsuits company also faces unfiled claims involving products time company believe ongoing matters potential unfiled claims aware potential result material effect companys financial results operations environmental proceedings previously reported company party several environmental proceedings matters responsible various state federal foreign laws including comprehensive environmental response compensation liability act cercla certain costs investigating andor remediating contamination resulting past industrial activity companys current former sites waste disposal reprocessing facilities operated third parties cercla matters respect cercla matters company responsible various state federal foreign laws company typically estimates potential costs based information obtained us environmental protection agency epa counterpart state agency andor studies prepared independent consultants including total estimated costs site expected costsharing potentially responsible parties company accrues liabilities probable reasonably estimable december company estimated share total future costs sites approximately million recorded liabilities represents sum best estimates simple estimate reasonably made estimates minimal probable amount among range costs without taking account potential recoveries parties currently expected puerto rico air emissions civil litigation previously disclosed company one several defendants class action suit filed superior court puerto rico relating air emissions governmentowned operated wastewater treatment facility court certified class august august parties executed global settlement agreement resolving claims litigation hearing approve settlement held october terms settlement certain measures including capital improvements implemented wastewater treatment facility minimize potential future odor emissions companys share payment plaintiffs approximately thousand november court entered final judgment approving settlement concludes companys involvement litigation except companys payment share cost capital improvements finalized early passaic river nj remediation natural resource damages claims previously disclosed september new jersey department environmental protection njdep issued administrative enforcement directive requiring company companies perform assessment natural resource damages implement unspecified interim remedial measures restore conditions lower passaic river lpr directive named company due releases nearby bulk chemical reprocessing facility operated predecessor mckesson corp subsequently epa issued notice letter numerous parties company requesting performance remedial investigationfeasibility study rifs conditions lpr consent agreement epa group parties committed pay roughly half million estimated rifs epa time epa thereafter substantially increased estimate scope cost rifs result epa agreed allow group perform remaining rifs tasks groups estimate total costs complete rifs related tasks exceed million group negotiated amended consent agreement epa conduct remaining rifs work became effective may part deal company mckesson bought remaining rifs tasks separately company agreed pay approximately thousand towards rifs tasks previously funded mckesson work cooperatively going forward addition mid epa announced plans seek implementation earlyaction remedial measures address highlycontaminated portions lpr rifs completed epa indicated expects select actions early also group federal natural resource trustee agencies proposed private party group enter agreement assess natural resource damages lpr group expects discuss proposal trustees near future extent liability company may face related requirements yet determined table contents note legal proceedings contingencies continued north brunswick township board education previously disclosed october company contacted counsel representing north brunswick nj board education boe regarding site waste materials er squibb sons may disposed fill material containing industrial waste heavy metals excess residential standards discovered expansion project north brunswick township high school well number neighboring residential properties adjacent public park areas january njdep sent company others information request letter possible waste disposal site company responded march boe township current owners school property park conducting jointly financing soil remediation work ground water investigation work work plan approved njdep asked company contribute cost due financial constraints late boe asked company contribute funds interim basis assure uninterrupted performance necessary site work company continues actively monitor cleanup project including costs date neither school board township asserted claim company instead company local entities negotiated agreement attempt resolve matter mediation central component anticipated agreement provision company interim funding help defray cleanup costs agreement executed parties company transmitted initial interim funding payment january parties recently commenced work prepare mediation expected conclude mid ods regulatory compliance previously disclosed epa investigating industrial commercial facilities throughout us use refrigeration equipment containing ozone depleting substances ods enforcing compliance regulations governing prevention service repair leaks ods requirements company performed voluntary corporatewide audit facilities us puerto rico use odscontaining refrigeration equipment company submitted audit report epa november identifying potential violations ods requirements several facilities addition matters covered companys audit report letter epa epa previously sent companys whollyowned subsidiary mead johnson request information regarding compliance ods requirements facility evansville indiana company responded request june result identified potential violations evansville facility company currently discussions epa resolve potential violations discovered audit identified result epa request information evansville facility epa determines evansville facility facilities violation applicable ods requirements company could subject penalties andor required convert replace refrigeration equipment use nonods approved substitutes mact compliancepuerto rico facilities barceloneta humacao previously disclosed march company commenced voluntary environmental audit barceloneta humacao puerto rico facilities determine compliance epas regulations regarding maximum achievable control technology requirements emissions hazardous air pollutants pharmaceuticals production pharmaceutical mact company submitted epa audit report humacao facility june barceloneta facility july disclosed potential violations pharmaceutical mact requirements facilities company epa currently discussions regarding resolution matter wage hour litigation previously disclosed two putative class action complaints filed company former sales representatives kin fung et al v bristolmyers squibb company et al case number rg filed june superior court state california county alameda plaintiff alleges company violated california wage hour laws among things paying overtime compensation putative class similarly situated sales employees plaintiff filed amended complaint september add cause action penalties california labor code private attorney general act california labor code allows plaintiff collect civil penalties violations provision california labor code collected labor workforce development agency california labor code oneyear statute limitations allows recovery penalty outstanding violation per pay period could interpreted require penalty per employee per pay period january court dismissed kin fung matter entirety due mr fungs assertion wish participate plaintiff matter beth amendola v bristolmyers squibb company et al docket cv filed june district court plaintiff alleges company violated federal fair labor standards act among things paying overtime compensation putative class similarly situated sales employees parties currently engaged preliminary discovery amendola matter table contents note legal proceedings contingencies continued company intends vigorously defend lawsuits matters early stages litigation possible time reasonably assess outcome litigation matters described expected outcome would material companys results operations cash flows material financial condition liquidity proceedings sec germany investigation previously disclosed october sec notified company conducting informal inquiry activities certain companys german pharmaceutical subsidiaries employees andor agents october sec informed company inquiry formal secs inquiry encompasses matters currently investigation german prosecutor munich germany company understands inquiry investigation concern potential violations foreign corrupt practices act german law respectively company cooperating sec german authorities company established accrual represents minimum expected probable losses respect investigation german prosecutor possible time reasonably assess outcome investigations impact company bari italy investigation previously disclosed january company notified prosecutor bari region italy bari prosecutor company investigation result activities two employees region investigation also involved number doctors pharmacists pharmaceutical companies sales representatives main allegation parties engaged plan defraud national health service companies lacked appropriate compliance controls andor processes procedures control activities sales representatives february company bari prosecutor reached agreement principle settle matter agreement requires final approval civil court final hearing matter occur company paid administrative fine amount material company convatec italy investigation italian competition authorities investigated complaint lodged hospital ferrara region italy relating allegation four medical device companies including convatec boycotted tenders ferrara tenders convatec responded allegations earlier year may convatec received statement objections italian competition authorities whereby authorities alleged four medical device companies including convatec acted concerted manner regard ferrara tenders tenders pricing discussions three regions acted way prevent competition throughout italy hearing matter held july august competition authorities issued decision found four medical device companies infringed italian antitrust law participating ferrara tenders imposed fine convatec convatec division bms italy fine imposed bms italy fine based convatecs market share turnover companies also fined amounts smaller convatec appealed decision administrative court hearing appeal expected early mid decision likely issue soon thereafter note subsequent events december company entered definitive agreement avista sale medical imaging business purchase price approximately million cash subject customary postclosing adjustments closing transaction completed january company expects recognize pretax gain approximately million million million million loss net tax first quarter subject post closing adjustments february company completed sale leaseback administrative facility paris france approximately million company expects record gain majority deferred reduce future lease rental costs lease period table contents note selected quarterly financial data unaudited dollars millions except per share data first quarter second quarter third quarter fourth quarter year net sales gross margin net earningsloss continuing operations net earnings discontinued operations net net earningsloss earnings per common share basic net earningsloss continuing operations net earnings discontinued operations net net earningsloss per common share diluted net earningsloss continuing operations net earnings discontinued operations net net earningsloss per common share dividends declared per common share cash cash equivalents marketable securities net sales gross margin net earningsloss continuing operations net earnings discontinued operations net net earningsloss earnings per common share basic net earningsloss continuing operations net earnings discontinued operations net net earningsloss per common share diluted net earningsloss continuing operations net earnings discontinued operations net net earningsloss per common share dividends declared per common share cash cash equivalents marketable securities earnings per share quarters may add amounts year period computed discrete basis common equivalent shares excluded computation diluted earnings per share effect would antidilutive follows millions first second third fourth quarter quarter quarter quarter year three months ended december result net loss basic diluted loss per share equal million weightedaverage shares issuable well million million interest expense net tax conversion convertible debt included diluted earnings per share calculation antidilutive table contents note selected quarterly financial data unaudited continued company recorded following items affected comparability results first second third fourth dollars millions quarter quarter quarter quarter year productivity transformation initiative downsizing streamlining worldwide operations accelerated depreciation asset impairment process standardization implementation costs litigation settlement insurance recovery product liability upfront milestone payments acquired inprocess research development auction rate securities impairment downsizing streamlining worldwide operations accelerated depreciation asset impairment contract termination gain sale properties product assets income taxes items change estimate taxes prior year item increasedecrease net earnings continuing operations first second third fourth quarter quarter quarter quarter year litigation matters pharmaceutical pricing sales litigation product liability claim damages commercial litigations insurance recovery debt retirement costs accelerated depreciation asset impairment contract termination upfront milestone payments downsizing streamlining worldwide operations gain sale product asset income taxes items minority interest net taxes change estimate taxes prior year items increasedecrease net earnings continuing operations financial information reflects medical imaging business discontinued operations see note discontinued operations assets held sale table contents report independent registered public accounting firm board directors stockholders bristolmyers squibb company audited accompanying consolidated balance sheets bristolmyers squibb company subsidiaries company december related consolidated statements earnings comprehensive income retained earnings cash flows years ended audits also included financial statement schedule years ended december listed index item financial statements financial statement schedule responsibility companys management responsibility express opinion financial statements financial statement schedule based audits consolidated financial statements company year ended december effects retrospective adjustments discontinued operations bristolmyers squibb medical imaging mi business discussed note consolidated financial statements audited auditors whose report dated march expressed unqualified opinion statements conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidated financial statements present fairly material respects financial position company december results operations cash flows years ended conformity accounting principles generally accepted united states america also opinion financial statement schedule years ended december considered relation basic consolidated financial statements taken whole presents fairly material respects information set forth therein also audited retrospective adjustments consolidated financial statements operations mi discontinued discussed note consolidated financial statements procedures included obtaining companys underlying accounting analysis prepared management retrospective adjustments discontinued operations comparing retrospectively adjusted amounts per consolidated financial statements analysis comparing previously reported amounts previously issued consolidated financial statements year testing mathematical accuracy accounting analysis comparing adjustments retrospectively adjust consolidated financial statements discontinued operations companys supporting documentation opinion retrospective adjustments appropriate properly applied however engaged audit review apply procedures consolidated financial statements company respect retrospective adjustments accordingly express opinion form assurance consolidated financial statements taken whole discussed notes consolidated financial statements company adopted financial accounting standards board interpretation fin accounting uncertainty income taxes interpretation fasb statement effective january statement financial accounting standards sfas r sharebased payment effective january sfas employers accounting defined benefit pension postretirement plans amendment fasb statements r effective december also audited accordance standards public company accounting oversight board united states companys internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion companys internal control financial reporting deloitte touche llp deloitte touche llp parsippany new jersey february table contents report independent registered public accounting firm board directors stockholders bristolmyers squibb company opinion consolidated statements earnings comprehensive income retained earnings cash flows year ended december effects adjustments retrospectively reflect discontinued operations described note present fairly material respects results operations cash flows bristolmyers squibb company subsidiaries year ended december conformity accounting principles generally accepted united states america consolidated financial statements effects adjustments discussed note presented herein addition opinion financial statement schedule year ended december effects adjustments retrospectively reflect discontinued operations described note financial statement schedule presents fairly material respects information set forth therein read conjunction related consolidated financial statements referred financial statement schedule year ended december effects adjustments discussed note financial statement schedule presented herein financial statements financial statement schedule responsibility companys management responsibility express opinion financial statements financial statement schedule based audit conducted audit effects adjustments described statements accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audit provides reasonable basis opinion engaged audit review apply procedures adjustments retrospectively reflect discontinued operations described note financial statements note financial statement schedule accordingly express opinion form assurance whether adjustments appropriate properly applied adjustments audited auditors pricewaterhousecoopers llp pricewaterhousecoopers llp philadelphia pa march table contents item changes disagreements accountants accounting financial disclosure none item controls procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure controls procedures term defined exchange act rule e based evaluation management concluded december disclosure controls procedures effective managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included report form k issued report effectiveness companys internal control financial reporting december included herein changes internal control financial reporting changes companys internal control financial reporting quarter ended december materially affected reasonably likely materially affect companys internal control financial reporting item b information none table contents report independent registered public accounting firm board directors stockholders bristolmyers squibb company audited internal control financial reporting bristolmyers squibb company subsidiaries company december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed supervision companys principal executive principal financial officers persons performing similar functions effected companys board directors management personnel provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting including possibility collusion improper management override controls material misstatements due error fraud may prevented detected timely basis also projections evaluation effectiveness internal control financial reporting future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission also audited accordance standards public company accounting oversight board united states consolidated financial statements financial statement schedule year ended december company report dated february expressed unqualified opinion financial statements financial statement schedule included explanatory paragraph regarding companys adoption financial accounting standards board interpretation fin accounting uncertainty income taxes interpretation fasb statement effective january deloitte touche llp deloitte touche llp parsippany new jersey february table contents part iii item directors executive officers registrant reference made proxy statement filed march respect directors registrant incorporated herein reference made part hereof response information required item b information required item respect executive officers registrant included part ia reliance general instruction g instruction item b regulation sk item executive compensation reference made proxy statement filed march respect executive compensation incorporated herein reference made part hereof response information required item item security ownership certain beneficial owners management related stockholder matters reference made proxy statement filed march respect security ownership certain beneficial owners management incorporated herein reference made part hereof response information required item item certain relationships related transactions reference made proxy statement filed march respect certain relationships related transactions incorporated herein reference made part hereof response information required item item auditor fees reference made proxy statement filed march respect auditor fees incorporated herein reference made part hereof response information required item table contents part iv item